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Abstract 
Digestion of proteins takes place mainly in the small intestine followed by the 
absorption of amino acids and peptides by enterocytes. The absorption surface area in the 
intestine is drastically increased by finger-like protrusions along the small intestinal 
lumen (called villi) and invaginations (called crypts). Enterocytes develop from stem cells 
in the crypt and differentiate into mature enterocytes while moving along the crypt–villus 
axis. The Slc6a19 mRNA and its resulting B0AT1 protein show a striking increase of 
expression towards the tip of the villi and are virtually absent in the crypts. 
In my PhD research, I investigated transcription factors and epigenetic modulators 
that regulate Slc6a19 expression. The Slc6a19 gene encodes the neutral amino acid 
transporter B0AT1, which provides the main mechanism of neutral amino acid absorption 
in the intestine. My experiments demonstrate that epigenetic modifications and 
transcription factor distribution orchestrate B0AT1 expression along the crypt–villus axis. 
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Chapter 1      Introduction 
 
1.1 Amino acid transport systems 
Proteins are an essential part of nutrition and are required for normal functioning 
and maintenance of the human body. Once ingested, various gastrointestinal digestive 
enzymes break down the proteins into amino acids and peptides. Amino acids and 
peptides are then absorbed by epithelial cells (enterocytes) lining the small intestine. 
Amino acid absorption into enterocytes is mediated by many different amino acid 
transport systems (Silk et al., 1985). 
After absorption, amino acids are delivered to all the organs and to the kidneys by 
the circulatory system. To prevent their loss into the urine, they are reabsorbed in 
proximal tubules by amino acid transporters after filtration by the kidney glomerulus. 
Different types of amino acid transport systems function to absorb amino acids and 
peptides across the enterocyte cell membrane, and in the proximal tubule including parts 
of the renal glomerulus. Renal amino acid transport systems are similar to the intestinal 
transporters (Young and Freedman, 1971). 
The pioneering amino acid transport studies conducted in the 1960s (Oxender and 
Christensen, 1963) established that distinct amino acid transport systems accept different 
groups of amino acids, and that these systems may exhibit overlapping substrate 
specificities. Distinct transport systems for neutral, cationic and anionic amino acids were 
subsequently identified (Oxender and Christensen, 1963). Later, intestinal transporters 
for neutral amino acids, cationic amino acids, anionic amino acids, glycine, proline and 
hydroxyproline were described and characterised in the 1980s (Munck, 1980, Stevens and 
Wright, 1987).  
Several amino acid transport systems have been characterised in epithelial cells. 
System b0,+ transports cationic and neutral amino acids. It is Na+-independent (Chillarón 
et al., 2001).  A heterodimer formed by SLC3A1 and SLC7A9 was identified as the 
molecular correlate of this system (Feliubadaló et al., 1999). System B0 is a Na+-
dependent transporter that carries all neutral amino acids, but  has limited activity for 
glycine or proline (Stevens et al., 1982). The molecular correlate of the system B0 is 
B0AT1 (SLC6A19) which is the major neutral amino acid transporter (Bröer et al., 2004). 
The Na+-dependent IMINO system preferentially transports glycine and proline (Stevens 
and Wright, 1987). The molecular correlate of this system is apical transporter SLC6A20 
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(Kowalczuk et al., 2005). Anionic amino acids are taken up by system X–AG. It is a Na
+-
dependent aspartate/glutamate transporter. It has been showed that EAAT3 the molecular 
correlate of this transporter (Kanai and Hediger, 2003). Proline and glycine are 
transported by the IMINO system (Stevens and Wright, 1985). The molecular correlate 
of this system has been identified as the proton amino acid transporter PAT1 (Anderson, 
2003). 
 
1.2 The small intestine  
The gastrointestinal tract originates from three embryonic germ layers: the 
endoderm, mesoderm and ectoderm. Anatomically, the gut has been divided into two 
parts: the small intestine and the large intestine. The small intestine comprises the 
duodenum, the jejunum, and the ileum (Barker et al., 2008). Histologically, the wall of 
the small intestine consists of the following layers: mucosa, submucosa, muscularis 
propria, and serosa. The mucosal layer contains cuboidal epithelial cells, the connective 
tissue, and the muscular layers. The submucosa layer contains the connective tissue that 
supports the mucosa and the muscular layer; the latter is responsible for peristaltic 
movements throughout the gastrointestinal tract (Sancho et al., 2004).  
 
1.2.1 Crypt–villus functional unit 
Proteins are digested mainly in the small intestine, and the resultant protein-derived 
nutrients are absorbed by epithelial cells (van der Flier and Clevers, 2009). The intestinal 
absorptive surface area is highly expanded by finger-like microscopic protrusions into the 
small intestinal lumen, called villi, and by invaginations, called crypts (Heath, 2010). The 
bottom of an intestinal crypt houses five or six stem cells; these cells divide every 24 h 
(Barker et al., 2007). Such a high growth rate is necessary to replace the epithelial cells 
which slough off at the tip of a villus every 24 h (Sato et al., 2009). In addition to 
progenitor cells, there are 25-42 clonogenic stem cells which can regenerate progenitor 
cells if necessary (Booth and Potten 2000). The newly generated cells differentiate into 
four different cell types: enterocytes, goblet cells, enteroendocrine cells, and Paneth cells 
(Huet et al., 1987). Enterocytes (in this thesis the term enterocytes refers to the absorptive 
cells of the differentiated epithelium, not including goblet, enteroendocrine or Paneth 
cells) are the most numerous cell type of the mature intestinal epithelium and they absorb 
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most nutrients from the lumen. Enterocytes are crucial for the final step of protein 
digestion. Peptides of 2-10 residues length, are generated by the action of gastric and 
pancreatic proteases. These are further digested into individual amino acids, di- and 
tripeptides by brush-border peptidases located on enterocytes (Erickson and Kim, 1990). 
Goblet cells secrete the intestinal mucus into the lumen for lubrication and protection of 
the epithelium. The enteroendocrine cells secrete hormones which regulate 
gastrointestinal functions and communicate with the rest of the body. The Paneth cells 
secrete lysozymes, antimicrobials, and defensins all of which have important functions in 
antibacterial protection and innate immunity. The first three cell types migrate towards 
the villus tip; the Paneth and stem cells are the only cells that reside at the crypt bottom 
(Figure 1.1) (Clatworthy and Subramanian, 2001).  
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Figure 1.1: The intestinal crypt–villus structure 
The stem cells residing in the crypt renew the epithelial cells on the villus. Arrows 
indicate migration of the differentiated cells along the crypt–villus axis. Epithelial cells 
migrate towards the villus tip, where they slough off into the intestinal lumen. The Paneth 
cells and stem cells reside within the crypt niche. From (Crosnier et al., 2006). 
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1.3 Homeostatic regulation of intestinal development 
Different mechanisms regulate maturation of the intestinal cells from the progenitor 
cells in the crypt to mature cells in the villus. Here, I briefly describe the important 
signalling pathways and the transcription factors that are involved in intestinal 
development. 
 
1.3.1 The Wnt signalling is involved in intestinal development 
Wnt signalling is involved in many aspects of development, including proliferation 
and differentiation of the intestinal epithelium (van de Wetering et al., 2002). Proteins 
involved in Wnt signalling are conserved in animals (Cadigan and Nusse, 1997). Wnt 
signalling is conveyed through three different intracellular signalling cascades: the first 
is the canonical Wnt pathway (Wnt/β-catenin signalling) which controls β-catenin 
stability. β-Catenin has an important function in cell adhesion. The second is the Wnt/Ca2+ 
pathway (non-canonical Wnt pathway) that activates the calcium/calmodulin-dependent 
protein-kinase complex in the cytoplasm. Lastly, another non-canonical Wnt pathway 
(the planar cell-polarity pathway) interacts with the Rho family of GTPases, ultimately 
controlling cytoskeletal dynamics. These pathways are initiated by the Wnt protein, 
which is produced by mesenchymal cells underlying the epithelial cell layer and 
surrounding the intestinal crypt. The Wnt protein binds to the Frizzled cell-surface 
receptor (Lewis, 2007). 
When Wnt signalling is inactive, the cytoplasmic β-catenin is captured by a 
destruction complex which is composed of at least four proteins: the scaffolding protein 
axin, the tumour suppressor adenomatous polyposis coli (APC), casein kinase I, and 
glycogen synthase kinase 3 (GSK3). This complex phosphorylates cytoplasmic β-catenin 
which is then ubiquitinated and degraded in the proteasome (Figure 1.2) (Scoville et al., 
2008, Lewis, 2007, Sokol, 2007). 
In the presence of Wnt, activated cell’s surface Frizzled receptor inhibits the 
destruction complex, causing β-catenin translocation from the cytoplasm into the nucleus. 
In the nucleus, β-catenin interacts with the T-cell-factor (TCF) to activate transcription of 
Wnt target genes (Figure 1.2) (Logan and Nusse, 2004). 
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Figure 1.2: The canonical Wnt pathway 
(Left panel) In the absence of Wnt stimulation, the β-catenin is degraded by the 
destruction complex, which includes adenomatosis polyposis coli (APC), axin, glycogen 
synthase kinase 3 (GSK3), and casein kinase I (CKI). (Right panel) The binding of Wnt 
ligand to its receptor Frizzled (Fz) and the LRP co-receptor, inactivates the destruction 
complex in the cytoplasm. Non-phosphorylated β-catenin translocates to the nucleus and 
binds the T-cell factor (TCF) to activate the transcription of target genes. From (Clevers, 
2006). 
 
1.3.1.1 Wnt/β-catenin signalling in the intestine 
The Wnt signalling pathway is important in the intestinal homeostasis, by 
regulating stem cell populations (Clevers, 2006).  
Mutations of various members of this tightly regulated pathway lead to serious 
intestinal pathologies. For example, deletion of the mouse intestinal Tcf4 gene causes loss 
of progenitor cells in the proliferative niche of the intestine (Korinek et al., 1998). Thus, 
the Wnt pathway is fundamental to the maintenance of the proliferative cells. In 
agreement with this notion, mutations of Apc, (a tumour suppressor gene which 
negatively regulates the Wnt pathway), causes crypt enlargement and interruption of cell 
migration from the crypt to the villus (Sansom et al., 2004). Apc mutations were also 
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found to be associated with intestinal cancers in humans (Morin et al., 1997). In addition, 
the Wnt pathway stimulates maturation of the Paneth cells in the intestinal crypt (van Es 
et al., 2005). 
 
1.3.2 Transcription factors (TFs) involved in intestinal development 
Many transcription factors have been implicated in enterocyte maturation. Here, the 
most important candidates are introduced. 
 
1.3.2.1 SOX9 
The SOX (Sry-related HMG box) family of transcription factors contain the HMG 
(high-mobility group) DNA-binding domain. SOX and Sry (sex determining region Y) 
proteins share ~50% identity in their HMG domain. SOX factors are well-conserved 
proteins amongst vertebrates (Dong et al., 2004). At least 20 different human and murine 
SOX proteins exist, and these are subdivided into eight subgroups (Bowles et al., 2000). 
SOX proteins are mainly involved in organ development and tissue maturation, but 
mutated SOX proteins are also associated with malignancies (Kiefer, 2007). 
SOX9 is an important SOX protein involved in crypt–villus development (Kormish 
et al., 2010). The main function of SOX9 in the intestine is enterocyte maturation and 
crypt formation (Bastide et al., 2007). SOX9 is also essential for the development of male 
gonads, the neural crest, and cartilages (Morais da Silva et al., 1996, Zhao et al., 1997, 
Cheung and Briscoe, 2003). In the mouse, SOX9 is expressed in many different organs; 
Sox9 mRNA and protein can be detected in the lower third of the intestinal crypts, in 
colon crypts, the Paneth cells (Blache et al., 2004), and in the epithelium of pancreatic 
and biliary ducts (Figure 1.3) (Furuyama et al., 2011). TCF proteins, which function in 
Wnt-targeted gene regulation, also have the same DNA-binding domain as SOX does 
(van Beest et al., 2000). 
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Figure 1.3: The SOX9 expression profile in the gastrointestinal system 
SOX9 is significantly expressed in the extrahepatic biliary tract, pancreatic duct cells and 
intestinal crypts. From (Furuyama et al., 2011). 
 
1.3.2.2 Interaction between SOX9 and Wnt/β-catenin 
The Wnt pathway and SOX expression are important in the development of 
different organs. The interaction between SOX9 and β-catenin has been shown to be 
essential for cartilage development. β-catenin deletion, and inversely, SOX9 
overexpression can interrupt chondrocyte differentiation (Akiyama et al., 2004). In the 
female gonad, activated SOX9 can repress Wnt/β-catenin pathway, and this leads to a 
male sex determination during development (Bernard et al., 2008). In the intestines, Wnt 
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signalling orchestrates crypt formation and promotes stem cell proliferation. SOX9, by 
contrast, inhibits the Wnt pathway and promotes differentiation of the stem cells into 
mature intestinal cell types. Therefore, interaction between SOX9 and Wnt is essential 
for the cell proliferation–maturation balance (Kormish et al., 2010).  
SOX9 mutations have been shown to cause loss of the Paneth cells in the crypts 
(Bastide et al., 2007, Mori-Akiyama et al., 2007). Cdx2 and Muc2 proteins are highly 
expressed in the mature enterocytes in the villi and known as differentiation markers; 
however, in the crypts, they are transcriptionally repressed by SOX9 (Blache et al., 2004). 
As a result, SOX9 is thought to be a key transcription factor to repress the proliferation 
programs in the progenitor cells in the crypts.  
In summary, these studies indicate that SOX9 down-regulates the Wnt pathway, 
and that, together with the Wnt/β-catenin pathway, it plays an important role in the 
homeostasis of intestinal development. 
 
1.3.2.3 HNF1a  
Hepatocyte nuclear factors (HNFs) encode a family of transcription factors. These 
were first identified as transcription factors that regulate hepatocyte specific genes. This 
family includes five transcription factors; HNF1, HNF4, HNF6, C/EBP 
(CCAAT/enhancer binding protein), and FOXA2 (fork-head box A2) (Costa et al., 2003). 
Studies in mice revealed that Hepatocyte nuclear factor 1 alpha (HNF1a) is 
expressed in kidney, pancreas, intestine and stomach (Blumenfeld et al., 1991). In the 
kidney, it is exclusively expressed in the proximal tubules but not throughout the entire 
nephron (Pontoglio et al., 1996). HNF1a-deficient mice die around weaning time due to 
hepatomegaly. Also, these mice show signs of aminoaciduria (Lee et al., 1998, Pontoglio 
et al., 1996). The HNF4a-knockout mice show the renal Fanconi syndrome because of 
dysfunction of the proximal renal tubules. The renal Fanconi syndrome is characterised 
by diabetes, glycosuria, and aminoaciduria, indicating loss of renal and pancreatic 
functions (Pontoglio et al., 1996). It has been shown that HNF1a-knockout mice excrete 
three times more of the neutral amino acid proline in urine than wildtype mice (Bonzo et 
al., 2010). 
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Within the gastrointestinal system, HNF1a mRNA can be detected from the 
stomach down to the colon, and the gene is expressed along the crypt–villus axis in the 
intestine (Boudreau et al., 2002, Serfas and Tyner, 1993). A study showed that in the 
intestine of HNF1a-null mice, epithelial barrier function, Paneth cell differentiation, and 
crypt cell proliferation were disrupted (Lussier et al., 2010). HNF1a is also essential for 
pancreatic islets development (Pontoglio et al., 1996, Shih et al., 2001, Tronche et al., 
1997). Mutations in the HNF1a gene are the most common reason for maturity onset 
diabetes of the young (MODY) (Yamagata et al., 1996b). 
 
1.3.2.4 HNF4a 
HNF4a (hepatocyte nuclear factor 4 alpha) is a member of the nuclear receptor 
super family (Sladek et al., 1990), and is highly conserved in vertebrates (Ryffel, 2001). 
In mice, the HNF4a gene is located on chromosome 2 and it consists of 11 exons. The 
tissue expression profile of HNF4a is similar to that of HNF1a, and it was initially 
identified as a transcriptional regulator of hepatic genes such as the fibrinogen, albumin, 
and α1-antitrypsin (Cereghini et al., 1987). HNF4a is expressed in differentiated adult 
cells located in the liver, pancreas, stomach, intestine, skin and kidney (Taraviras et al., 
1994). HNF4a is highly expressed in blastocysts at day 4.5 and in the visceral endoderm 
at day 5.5. It is also expressed in the embryonic liver and gut (Duncan et al., 1994). The 
HNF4a knockout is embryonically lethal, demonstrating its crucial role as a transcription 
factor in early development (Duncan et al., 1994). Certain HNF4a gene mutations cause 
maturity onset diabetes of the young (Yamagata et al., 1996a). Additional studies 
demonstrated that HNF4a is a key regulator of crypt formation and goblet-cell maturation 
(Garrison et al., 2006). 
Interestingly, not only do HNF4a and HNF1a share similar expression patterns, but 
they also appear to be regulating each other’s transcription, being linked through a 
transcriptional feedback loop (Shih et al., 2001). 
 
1.3.2.5 Other TFs 
A variety of TFs are involved in intestinal cell differentiation. The transcription 
factor CDX2 is necessary for intestinal development (Lorentz et al., 1997) and together 
with HNF1a, regulates sucrose-isomaltase and lactase-phlorizin hydrolase gene 
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expression along the crypt-villus axis (Mitchelmore et al., 2000). GATA4 is another 
crucial TF which is required for activation of intestinal genes involved in nutrient 
absorption (Bosse et al., 2007). CDX2 and GATA4 appear to be sufficient to activate 
many of the enterocyte-specific genes in the mammals (Benoit et al., 2010). SPDEF and 
FOXA2 TFs are exclusively expressed in cells residing in crypts (Besnard et al., 2004).  
SPDEF is required for maturation of intestinal Paneth and goblet cells (Gregorieff et al., 
2009), while FOXA2 regulates goblet cell differentiation via activation of Muc2, which 
induces expression of mucin secreted by the goblet cells (Ye and Kaestner, 2009). 
 
1.4 B0AT1 protein 
System B0 is a Na+-dependent, low-affinity transport system that takes up neutral 
amino acids. It was initially described as neutral brush border system (NBB) by a study 
of rabbit intestinal brush border membrane vesicles (Stevens et al., 1982) and afterwards, 
it was renamed as system B0, to designate broad neutral amino acids (Maenz and Patience, 
1992).  
In 2004, the molecular correlate of this transport system was identified in mouse 
and named B0AT1 (B0-like amino acid transporter 1). B0AT1 was found to be highly 
expressed on the apical membrane of intestinal brush borders and kidney proximal tubules 
(Bröer et al., 2004). It is a member of the solute carrier (SLC) family 6, also known as the 
neurotransmitter transporter family. Unlike other members of the solute carrier (SLC) 
family 6, the B0AT1 transport function is Cl–-independent (Bohmer et al., 2005). 
 
1.4.1 Structure of B0AT1 protein 
Structure of the SLC6 transporters is similar to the crystal structure of the bacterial 
leucine transporter (LeuT). The LeuT transporter of the bacterium Aquifex aeolicus is a 
structural homolog of the mammalian B0AT1 protein (Yamashita et al., 2005). LeuT has 
12 transmembrane α-helices. Particularly, the first and sixth helix of both proteins show 
high similarity, containing residues that are important for substrate and ion binding. Both 
proteins mediate Na+-dependent, Cl–-independent transport of a broad range of neutral 
amino acids (Broer, 2006). 
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According to the LeuT-based homology model, the B0AT1 structure is 
characterized by 12 transmembrane helices and intracellular N- and C- termini. Helices 1 
and 6 are crucial for substrate translocation in the protein. Additionally, helix 8 has a role 
in substrate binding (Figure 1.4) (Broer, 2006). 
 
Figure 1.4: Homology model of B0AT1 based on the structure of LeuT 
The B0AT1 model was generated based on the crystal structure of the bacterial leucine 
transporter, LeuT. Helix 1 (yellow) and helix 6 (blue) are indicated among other helices 
(pink). From (Broer, 2008). 
 
1.4.2 Tissue distribution and cellular localization of B0AT1 
The B0AT1 protein is mainly present in the kidney and the intestine. In the kidney, 
B0AT1 is highly expressed in the cells of the S1 and S2 segments of the proximal tubule 
(Romeo et al., 2006). Here, B0AT1 protein expression is limited to the brush border 
membrane of the proximal tubules (Kleta et al., 2004). B0AT1 expression in the digestive 
system is evident predominantly in the duodenum, the jejunum and the ileum (Terada et 
al., 2005). In the intestine, B0AT1 is highly expressed in the villus tip, but not at the crypt 
bottom (Bröer et al., 2004). B0AT1 is also expressed, to some extent, in the colon, 
pancreas, and prostate (Kleta et al., 2004). 
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1.4.3 Interaction of B0AT1 with other proteins 
Intracellular trafficking of B0AT1 to the cell membrane is an important step 
required for its proper functioning. To date, two trafficking proteins have been found in 
the kidney and the intestine, namely collectrin (TMEM27) and angiotensin-converting 
enzyme 2 (ACE2), respectively. 
Collectrin was named according to its presumed location in the cells of the renal 
collecting ducts. Collectrin expression was later confirmed in the pancreas, stomach, 
jejunum, ileum, heart, lung, spleen, and liver (Akpinar et al., 2005, Danilczyk et al., 2006). 
In 2006, Danilczyk and colleagues showed that in collectrin-deficient mice, neutral amino 
acids were excreted into the urine. Further analysis revealed that expression of collectrin 
was similar to B0AT1 expression in the kidney tubules (Danilczyk et al., 2006, 
Malakauskas et al., 2007). B0AT1 cell surface expression in the proximal tubule was 
significantly reduced in collectrin-null mice.  
However, collectrin is not expressed in the intestinal brush border where B0AT1 is 
highly expressed (Kowalczuk et al., 2008). In the intestine, B0AT1 requires a different 
cofactor to transport it to the enterocyte apical membrane. Studies in Xenopus laevis 
oocytes showed that co-expression of the brush-border peptidase ACE2, which shows 
homology with the transmembrane domain of collectrin (Zhang et al., 2001), and B0AT1 
increased the uptake of neutral amino acids due to increased B0AT1 surface expression 
(Kowalczuk et al., 2008, Camargo et al., 2009). ACE2 also has an important regulatory 
role in the renin-angiotensin system, which is crucial for renal and cardiovascular 
functions (Burrell et al., 2004). ACE2 is associated with diseases of the cardiovascular 
system (Crackower et al., 2002)  
In collectrin-deficient mice, B0AT1 was almost absent in the luminal membrane of 
the renal proximal tubules, thereby causing neutral aminoaciduria (Danilczyk et al., 2006). 
By contrast, amino acid composition in the urine of ACE2-deficient mice was not affected 
(Camargo et al., 2009). The B0AT1 (Slc6a19)-null mice show aminoaciduria similar to 
collectrin-null mice but in addition have reduced body size and body weight and also 
show weak insulin responses in the pancreas (Broer et al., 2011). 
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1.4.3.1 Hartnup disorder 
Hartnup disorder is an autosomal recessive inherited disorder which is 
characterized by aminoaciduria, and a photosensitive pellagra-like skin rash. 
Occasionally cerebellar ataxia, nystagmus and tremor are observed. It was first described 
in 1956 (Baron et al., 1956). Intestinal absorption and renal absorption of most neutral 
amino acids were reduced in this disorder. Nowadays, protein-rich diets appear to 
compensate for deficient neutral amino acid uptake; therefore, in developed countries, 
Hartnup patients are usually asymptomatic (Broer, 2009). Newborn screening programs 
in Australia and North America showed an incidence of about 1 case per 30,000 newborns 
(Levy 2001). 
Neutral aminoaciduria is the diagnostic hallmark of Hartnup disorder. 
Aminoaciduria is caused by the renal defect, whereas other symptoms are likely caused 
by the lack of intestinal neutral amino acid uptake. The pellagra-like symptoms may result 
from a lack of tryptophan. Pellagra is typically caused by Niacin deficiency, the vitamin 
involved in NAD(P)H biosynthesis. However, the body can, to some extent, produce 
NAD(P)H, using the essential neutral amino acid tryptophan, the uptake of which is 
reduced in Hartnup disorder. NADPH among other roles is necessary for fatty acid 
biosynthesis and glutathione reduction. Typical manifestations of Pellagra are bilateral, 
symmetric and photosensitive dermatitis, dementia, and diarrhoea (Broer, 2009). 
Homozygosity mapping performed by a Japanese group established that Hartnup 
disorder is linked to chromosome band 5p15 (Nozaki et al., 2001). Subsequently, Kleta 
et al. (Kleta et al., 2004) and Seow et al., (Seow et al., 2004) found that SLC6A19 gene 
mutations cause Hartnup Disorder. So far, 21 different mutations associated with Hartnup 
disorder have been identified, including missense and nonsense deletions, splicing and 
small deletions (Broer, 2009). Functionally, all of these mutations cause loss of neutral 
amino acid transportation (Broer and Palacin, 2011). Among these mutations, the most 
frequent in caucasians is 517 G→A causing a D173N replacement in the protein 
(Azmanov et al., 2008). While many mutations were not informative with regard to 
protein function, B0AT1(R240Q) results in loss of transport function only when auxiliary 
proteins are co-expressed with B0AT1. No defect was observed when it is expressed 
without auxiliary proteins (Kowalczuk et al., 2008). Subsequently, it was demonstrated 
that the collectrin binding site is in close proximity to residue R240 (Fairweather et al., 
2015). 
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1.5 SLC6A19 gene structure 
The SLC6A19 gene encodes for B0AT1. SLC6A19 is located on the chromosomal 
region 5p15.33 in humans; in the mouse, it is located on chromosome 13 and maps to 
region 13C1. The gene has 12 exons and encodes a protein of 634 amino acids in both 
species (Figure 1.5) (Broer, 2006). 
 
 
Figure 1.5: Chromosomal locations of Slc6a19 in human and mouse 
Location of human and mouse Slc6a19 genes using the UCSC Genome Browser 
(http://genome.ucsc.edu). 1) The human Slc6a19 is located at chr5p15. 2) The mouse 
Slc6a19 is located at chr13qC1.  
  
1.6 Transcriptional regulation 
Almost every cell has an identical copy of the entire genomic material, yet each cell 
type expresses its unique complement of proteins (Russell, 2002). Activation of specific 
network of genes during differentiation and development is the basis of existence of many 
different cell types. Gene expression can be regulated at multiple points (Figure 1.6), the 
most important of which occurs at the initiation of transcription (Alberts, 2004). 
(1) 
(2
) 
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Well-orchestrated interactions between DNA regulatory elements (which include 
promoter-binding elements), RNA polymerase enzymes, and histones ensure timely and 
well-coordinated transcription of different genes. Accessibility of transcription factors to 
DNA is regulated by chromatin modifications, thereby constituting an additional level of 
transcriptional regulation. 
 
1.6.1 Promoter recognition 
To initiate the transcriptional process, RNA polymerases must be positioned 
upstream of the first exon of the target gene in the promoter region. Formation of a 
transcription preinitiation complex, which incorporates a polymerase and several general 
transcription factors, is necessary for RNA polymerase to bind to its correct site with 
correct orientation (Wolpert, 2007).  
 
DNA 
RNA 
Transcript Protein 
 
 
 Nucleus    Cytosol 
Transcriptional  
Regulation 
Post-transcriptional  
Regulation 
Post-translational  
Regulation 
   
Figure 1.6: The central dogma of gene regulation  
The control points during gene expression and protein synthesis are shown. Control of 
transcription and translation occurs at three major checkpoints: transcriptional, post-
transcriptional, and post-translational regulation.  
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1.6.1.1 Promoter elements 
In eukaryotes, different promoter elements are defined according to their positions. 
These elements are the core promoter elements, proximal promoter elements, and distal 
promoter elements (enhancers). 
 
1.6.1.1.1 Core promoter elements 
A core promoter element is the minimum DNA sequence required to initiate proper 
transcription by the transcription initiation complex. This region spans ~40 base pairs (bp) 
upstream of the transcription start site (TSS). The main core promoter elements identified 
across a wide range of promoters are BRE (TFIIB recognition element), TATA (TATA 
box), Inr (initiator element), and DPE (downstream promoter element). Importantly, it is 
not necessary for all these elements to be found in each promoter region. Rather, they 
appear in different combinations, usually depending on the particular regulatory 
requirements of a specific gene (Figure 1.7) (Latchman, 2008). 
 
 
Figure 1.7: An eukaryotic promoter region and its regulatory elements  
Graph shows specific DNA regulatory components and regions, including the TATA box, 
proximal (core) promoter elements, and the enhancer. From (Lodish, 2003). 
 
In most TATA box-containing eukaryotic promoters, the core promoter element is 
located 25–35 bp upstream of the TSS. This sequence is recognized by the TATA-binding 
protein to initiate transcription. Except for housekeeping genes, most genes require this 
sequence in their promoter regions for activating transcription. 
Core promoter Distal promoter 
Exon Intron 
TATA 
Proximal promoter 
elements Enhancer 
+
1 
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1.6.1.1.2 Proximal promoter elements 
Proximal promoter elements are located ~50–200 bp upstream of the TSS. Two 
frequently identified elements within this region are the GC box and CCAAT box. These 
DNA sequences can be recognized by transcription factor Sp1 and CCAAT-binding 
transcription factor (CTF), respectively (Lodish, 2003).  
 
1.6.1.2 Enhancers 
Enhancers are position-independent, positive regulatory elements that are present 
in eukaryotic cells, but usually absent in prokaryotic cells. The activity of enhancers does 
not depend on their exact location or distance from the promoter. They can be found 
thousands of base pairs away from the TSS, either downstream or upstream of its target 
gene promoter (Lodish, 2003).  
 
1.6.1.3 Other elements 
Silencers are regulatory DNA elements that have an opposite function to enhancers, 
i.e. they act to decrease gene transcription. There are two types: position-dependent and 
position-independent silencers. Their position is variable in mammalian genomes. 
Another regulatory element is the insulators (boundary elements) which are located up to 
3 kb from TSS and mainly prevent the interactions between the enhancers and the 
promoters (Lodish, 2003). 
 
1.6.2 Transcription factors 
Transcription factors are regulatory proteins that non-covalently interact with 
specific DNA sequences via relevant DNA-binding domains. TFs can positively or 
negatively control the rate of gene expression. This regulation is often tissue-specific or 
elicited by appropriate signals. The human genome contains ~2000 transcription factor 
genes, amounting to roughly 10% of the genome (Wolpert, 2007).  
The activity of TFs is based on two major domains. These domains are the DNA-
binding domain and the activation domain. The DNA-binding domain recognises specific 
DNA sequences within regulatory regions of genes, whereas the activation domain 
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interacts with other protein complexes comprising the transcriptional machinery (Lewin, 
2004).  
In eukaryotes, many different types of DNA-binding motifs have been identified. 
The most commonly observed motifs are helix-turn-helix, zinc-finger, leucine zipper, and 
helix-loop-helix motifs. The most studied motif is the helix-turn-helix motif, which is 
found in the homeodomain family, for instance, HNF1a. This motif has two helices that 
are linked to each other by a short turn. The C-terminal helix of this motif fits into the 
major groove of the DNA helix and binds a specific DNA sequence. It is, therefore, called 
the recognition helix. The N-terminus helps to position the C-terminal helix (Strachan 
and Read, 2004). 
Another DNA-binding domain is the zinc finger. This domain includes a zinc 
molecule inside the helical structure of the recognition helix. HNF4a contains an example 
of this group. Some TFs have more than one zinc-finger domain. 
In leucine zipper TFs, the α-helix has regular leucine repeats, which are necessary 
for dimerization. This motif contains two α-helical proteins forming homodimers or 
heterodimers, which bind to a specific DNA region, with both helices (Watson, 2003).  
The helix-loop-helix motif has a short and a longer α-helix, which are bound 
together by a loop. The dimer gains flexibility with the loop structure. Together with 
another helix-loop-helix protein, they can form a homodimeric or heterodimeric structure 
(Watson, 2003).  
The second characteristic domain of TFs is the transcription activation domain 
(TAD), which is essential for transcription initiation via interaction with the transcription 
initiation complex. In contrast to DNA-binding domains, TADs do not interact with DNA 
structures. These domains mostly interact with general TFs to recruit the RNA 
polymerase II to the promoter (Tjian and Maniatis, 1994). General TFs such as TFIIB, 
TFIID, and TFIIF can interact with different activation domains (Blau et al., 1996). For 
instance, AF2 is the activation domain of the HNF4 protein, and it binds to TFIIB, and 
this interaction recruits the preinitiation complex (Malik and Karathanasis, 1996).  
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1.6.2.1 Regulation of TFs 
Almost all cell types express a set of housekeeping genes, which are necessary for 
basic cell functions. In contrast, the tissue-specific genes are expressed in the specific cell 
types only. Therefore, regulation of TFs is an important mechanism underlying 
development and differentiation in organisms. This process is achieved by different steps 
in TF expression and activation. 
TFs themselves are controlled by external signalling. Gene expression can be 
triggered by extracellular signals such as growth factors, hormones, chemokines, 
cytokines and apoptosis factors. Each of them shows its effects via different intracellular 
pathways and TFs. The STAT pathway, for instance, is activated by cytokines and growth 
factors. The activated cytokine receptor triggers STAT phosphorylation in the cytoplasm 
and promotes dimerization of phosphorylated STAT. The activated dimers can then enter 
the nucleus to start transcription of target genes (Lodish, 2003). 
 
1.6.3 Epigenetics 
Epigenetic factors can modify transcriptional regulation without affecting the DNA 
code. Intriguingly, these changes can be inherited through mitosis (Nussbaum et al., 
2007). Epigenetics alter gene expression by modulating DNA methylation or histone 
modifications. Epigenetic modifications have been studied extensively over the last 
several decades (Razin and Riggs, 1980, Holliday, 1996). 
 
1.6.4 Chromatin modifications 
In eukaryotes, genetic information is compacted as chromatin. This compaction 
prevents TFs from binding to regulatory DNA regions (see Section 1.6.1.1). Therefore, 
chromatin unpacking is a prerequisite of transcriptional regulation. It is now established 
that chromatin not only plays a role in packaging the genomic material, but also plays a 
central role in transcriptional regulation (Turner, 2002). 
Chromatin packing is regulated by histones, protein components of chromatin that 
compact the DNA (see Section 1.6.4.1). Inactive genes are in a highly condensed state, 
inaccessible to transcription factors. Chromatin remodelling and histone modifications 
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can reversibly unpack the compacted DNA to let activators access their corresponding 
binding sites (Fischle et al., 2003). 
 
1.6.4.1 Histone modifications 
Histones are positively charged proteins, which associate with DNA. Five different 
histone subtypes exist in eukaryotic cells, namely H1, H2A, H2B, H3, and H4. A histone 
octamer contains two H2A–H2B and two H3–H4 dimers. Approximately 150 bp of DNA 
wrap around each octamer of core histones to form a complex called the nucleosome 
(Kornberg and Lorch, 1999). 
Histones N-terminal tails (Figure 1.8) bind DNA and stabilise the chromatin 
structure. Post-translational modifications in histone tails, such as methylation, 
acetylation, phosphorylation, and ubiquitination, regulate chromatin stability and, 
therefore, transcriptional regulation (Kouzarides, 2007). 
 
 
Figure 1.8: Structure of histone tails  
The DNA double helix wraps around histone octamers containing the H2A, H2B, H3, 
and H4 subunits. N-terminal tails of each histone are chemically modified to regulate 
nucleosome DNA accessibility. From (Watson, 2003). 
 
Histone acetyl transferases (HATs) catalyse addition of acetyl groups to lysine 
residues on the N-terminal tails of histones. This causes loss of their positive charges, 
which in turn weakens their binding to negatively charged DNA. As a result, DNA 
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becomes accessible, and the transcription initiation complex can bind the promoter region 
to start transcription. The acetylation reaction is reversible; histone deacetylases (HDAC) 
remove the acetyl groups from lysine residues and thereby reduce the accessibility to the 
nucleosomal DNA (Richards and Elgin, 2002).  
Similarly, methylation of histone H3 tails by histone methyl transferases (HMTs) 
can control gene transcription. HMTs can transfer a methyl group onto lysine or arginine 
residue in a histone. Usually, methylation of amino acid residues of histones negatively 
regulates gene activation by blocking TF interaction with DNA (Berger, 2002, de la Cruz 
et al., 2005).  
 
1.6.4.2 Chromatin remodelling 
In some situations, histone modification is not sufficient for the TFs to bind the 
target promoter. Often, chromatin remodelling, an ATP-dependent process, is required to 
increase the accessibility of the target gene for transcription.  
Activators bind to their specific DNA sequences and recruit a chromatin 
remodelling complex that alters the chromatin structure. Chromatin remodelling systems 
act together with histone-modifying enzymes to assist TF binding to their cognate 
sequences. Chromatin complexes can make this change via sliding, transferring, or 
restructuring a nucleosome on the DNA (Figure 1.9) (Strachan and Read, 2004). 
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Figure 1.9: Chromatin remodelling and histone modifications are working 
together. 
A chromatin remodelling complex is recruited by DNA-binding protein 1 to alter 
nucleosome accessibility. Action of the DNA-binding proteins stimulate formation of 
a more accessible chromatin structure by recruiting HATs to the target DNA region. 
From (Watson, 2003).  
 
1.6.5 DNA methylation 
DNA methylation can regulate transcription in eukaryotic cells, especially in 
mammals. Methylation of cytosine residues in cytosine–guanine dinucleotides (CpGs), 
which are located around the promoter region, can cause transcriptional inhibition. This 
modification disturbs the interaction of transcription factors with the promoter region. In 
general, DNA methylation correlates with an inactive gene status, but switching off a 
gene completely requires further modifications. This is achieved by a combination of 
DNA methylation and nucleosomal alterations (Cedar and Bergman, 2009). 
Methylation patterns are heritable. During the replication process, methylated 
parental DNA strands are divided and passed onto daughter cells. Methylation of the 
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complementary new strand is completed by the maintenance methyltransferase which 
recognise the hemi-methylated pattern and methylates the CpG dinucleotide on the newly 
synthesized strand (Figure 1.10) (Alberts, 2004).  
 
 
Figure 1.10: Maintenance methyltransferase 
During DNA replication, the maintenance methyltransferase allows transfer of an existing 
DNA methylation pattern to a new DNA strand. From (Alberts, 2004). 
 
1.6.5.1 CpG islands  
In mammals, 70–80% of CpG dinucleotides are methylated across the whole 
genome, with the other non-methylated CpG dinucleotides concentrated in the gene 
promoter regions (Portela and Esteller, 2010). A region of 200 bp with at least 50% CpG 
content is considered a CpG island. CpG islands are commonly found as non-methylated 
regions in promoters of housekeeping genes and tissue-specific genes in differentiated 
cells. 
 
1.6.6 DNA methylation and transcription 
CpG methylation has a significant function in transcriptional control, chromosomal 
structure and organisation, and differentially expression of genes depending on their 
parent-of-origin, called genomic imprinting.(Robertson, 2002). Most promoter regions 
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have CpG-rich regulatory fragments, and some TF-binding sites contain CpG 
dinucleotides. 
In the promoter of an inactive gene, a DNA methyltransferase (DNMT) adds a 
methyl group to position 5 of the cytidine generating 5-methylcytosine. Specific proteins, 
which recognise a methylated cytosine residue, can bind methylated sequences. These 
proteins can then switch off a gene completely through the action of HDACs and HMTs 
(Figure 1.11) (Watson, 2003). 
DNA methylation in a promoter region can inhibit binding of the transcriptional 
initiation machinery or TFs in a number of ways. Firstly, methylation can inhibit TF 
binding (Tate and Bird, 1993). Secondly, some proteins specifically bind to methylated 
CpG residues and repress transcription by preventing TF binding to the target promoter 
region. For example, DNMTs can inhibit transcription via modifying histones. Studies 
have shown that DNMTs are associated with HDACs (Robertson, 2002).  
Methylated CpGs can also be recognised by methyl-CpG-binding-protein (MeCP2) 
which recruits HDACs (Nan et al., 1998). Also, the DNA-methyl-binding domain (MBD) 
proteins interact with methylated DNA, in the same way as MeCP2, and can recruit 
proteins to suppress transcription.  
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Figure 1.11: Collective effect of DNA methylation and histone modifications on the 
transcription  
This figure illustrates the switching-off of an active gene by changing its DNA 
methylation and histone modification status. (A) DNMTs catalyse methylation on target 
DNA CpG dinucleotides. (B) This change triggers histone deacetylation. (C) Finally, 
DNA becomes more compact and this compaction leads to transcriptional silencing of a 
gene.  
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1.7 Project aims 
The functional properties and physiological roles of B0AT1 in different organs have 
been extensively studied (Bröer et al., 2004). However, not many studies have attempted 
to describe the regulatory elements of the Slc6a19 gene. By bioinformatics analysis, 
Kikuchi et al. predicted a possible HNF1a-binding site on the Slc6a19 promoter at 
position –126 to –110. Except this study no single study has been focused on the B0AT1 
regulation so far. The aim of this project was to investigate the transcriptional regulation 
of the neutral amino acid transporter B0AT1 and to identify key control elements involved 
in its transcription. 
 
1.8 Research questions 
1. Does B0AT1 mRNA expression mirrors its protein expression reported previously? 
2. What are the regulatory elements in the promoter region of B0AT1? 
3. Why is B0AT1 not expressed in intestinal crypt cells? 
4. What transcription factors are involved in the positive regulation of B0AT1 expression 
in cells located in the intestinal villi? 
5. Does the nuclear chromatin status across the B0AT1 promoter differ between the crypt 
and the villus?  
6. Is DNA methylation involved in B0AT1 transcriptional silencing outside the villus 
region (e.g. cells in the crypts or liver cells)? 
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Chapter 2      Material and Methods 
 
2.1 Materials  
2.1.1 Solutions 
 
Table 2.1: Solutions used in this study 
Luria-Bertani (LB) medium Luria-Bertani (LB) agar 
Tryptone 10 g 
Yeast extract 5 g 
NaCl 10 g 
Add 1 L H2O, pH = 7.0 
Sterilized by autoclaving. 
 
Tryptone 10 g 
Yeast extract 5 g 
NaCl 10 g 
Agar 15 g 
Add 1 L H2O, pH = 7.0 
Sterilized by autoclaving. 
Super optimal broth (SOB) medium Hanks Buffer 
Tryptone 20g 
Yeast extract 5g 
NaCl 8.5 mM 
KCl 2.5 mM 
Add 1 L H2O, pH = 7.0 
Sterilized by autoclaving, then add 
MgCl2 10 mM 
MgSO4 10 mM 
For SOC (also add glucose 20 mM) 
CaCl2 1.26 mM 
KCl 5.4 mM 
KH2PO4 0.44 mM 
MgCl2 6H2O 0.5 mM 
MgSO4 7H2O 0.4 mM 
NaCl 136.6 mM 
HEPES 10 mM 
Na2HPO4 2.7 mM 
pH 7.4 
TB buffer Phosphate buffered saline (PBS, 10×) 
HEPES 10 mM, pH 6.7 
CaCl2 15 mM 
MnCl2 55 mM 
KCl 250 mM 
Sterilized by filtration through a 0.22-μm 
filter 
 
 
NaCl 1.37 M 
KCl 26.8 mM 
Na2HPO4 80.6 mM 
KH2PO4 14.7 mM 
pH 7.4, sterilize by autoclaving 
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TAE buffer (50×) Cracking buffer (for rapid screening, 
2×)  
Tris 2 M 
Na2EDTA 50 mM 
Glacial acetic acid 5.71 % 
pH 8.0 
Sucrose 0.2 g 
SDS 50 μL of 10% (w/v) SDS 
NaOH 40 μL 5M 
H2O top up to 1 ml 
Tris buffered saline (TBS, 10×) Marker mix (for rapid screening) 
Tris-HCl 0.5 M, pH 7.5 
NaCl 1.5 M 
Sterilized by autoclaving 
 
KCl 4 M 
Bromophenol blue 0.4% (w/v) 
 
Tris-borate-EDTA buffer (TBE, 10×)  
Tris 892 mM 
Boric acid 890 mM 
Na2EDTA  20 mM 
pH 8.0 
 
 
2.1.2 Reagents and commercial kits 
Opti-MEM®, DMEM/F-12, 0.25% trypsin–EDTA solution, 200 mM L-glutamine, 
Ultrapure™ 0.5 M EDTA, Ultrapure™ 10% SDS solution, heat inactivated foetal bovine 
serum (FBS) and 1× PBS buffer were purchased from Gibco® Life Technologies. 
Penicillin-streptomycin solution, DMEM, and oligonucleotides were obtained from 
Sigma-Aldrich®. RPMI 1640 medium with L-glutamine was purchased from PAA 
Laboratories. SimpleCHIP® Enzymatic Chromatin IP Kit was purchased from Cell 
Signaling Technology®. Power SYBR® Green PCR Master Mix, Supercoiled DNA ladder, 
SuperScript® III Reverse Transcriptase, T4 DNA ligase, Lipofectamine™ 2000 reagent, 
Lipofectamine® LTX, PureLink™ Quick Gel Extraction Kit, PureLink™ Quick Plasmid 
Miniprep Kit, Zero Blunt® TOPO® PCR Cloning Kit, and TOPO® XL PCR Cloning Kit 
were obtained from Life Technologies™. RNeasy Mini Kit, EpiTect® Bisulfite Kit, 
DNeasy® Blood & Tissue Kit, QIAquick® PCR Purification Kit, Rotor-Gene SYBR® 
green PCR Kit, and Thermus aquaticus (Taq) DNA polymerase were purchased from 
Qiagen. RNA 6000 Nano Labchip® Kit and QuikChange II Site-directed Mutagenesis Kit 
were purchased from Agilent. NucleoSpin® Plasmid purification Kit and NucleoBond 
Xtra Maxi EF were purchased from Macherey-Nagel. cOmplete, EDTA-free protease 
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inhibitor cocktail tablets were purchased from Roche. Phusion® high-fidelity DNA 
polymerase and T4 DNA Quick Ligation™ Kit were obtained from New England 
Biolabs® (NEB). Twenty-four-well cell culture plates were purchased from Iwaki. Dual-
Luciferase® Reporter Assay System was purchased from Promega. 
 
2.1.3 Antibodies 
Antibodies used in chromatin immunoprecipitation assay (ChIP) are listed in Table 
2.2. 
 
Table 2.2: Antibodies used in this study 
Antibody (anti-mouse) Source Supplier (catalogue no) 
Histone H3 (acetyl K27) Rabbit polyclonal antibody  Abcam (ab4729) 
Histone H3 (tri-methyl K4) Rabbit polyclonal antibody  Abcam (ab8580) 
SOX9 Rabbit polyclonal Abcam (ab3697) 
TATA-binding protein Mouse monoclonal Abcam (ab51841) 
HNF4a Mouse monoclonal Abcam (ab41898) 
IgG Rabbit polyclonal antibody Cell signaling (2729) 
Histone H3 Rabbit antibody Cell signaling (4620) 
HNF1a Goat polyclonal Santa Cruz (sc-6547X) 
 
2.1.4 Vectors 
The pcDNA 3.1 (+) vector was used for gene expression in mammalian cells (see 
Section 2.6.4). This vector contains a human cytomegalovirus (CMV) immediate–early 
promoter that achieves a high level of expression in a wide variety of cell lines. It contains 
the ampicillin- and neomycin resistance genes to facilitate selection in bacteria and cell 
lines, respectively. 
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pGL4.12[luc2CP] and pGL4.74[hRluc/TK] reporter vectors (Promega) were used 
in the dual luciferase assay (see Section 2.6). Promoter fragments were cloned into 
pGL4.12 vector to measure their activity. The pGL4.74 vector was used as an internal 
control in the dual luciferase assay. See Table 2.3 for sources and comparison of these 
vectors. Detailed maps of the plasmids generated in this study are illustrated in the 
Appendix 8.1.  
 
Table 2.3: Vectors used in this study 
Vector Features Source 
pcDNA3.1 (+)  CMV promoter for optimal 
expression in a wide range of 
mammalian cells 
 SV40 polyadenylation site upstream 
of the CMV promoter 
 Neomycin- and ampicillin-resistance 
genes 
Invitrogen 
pGL4.12[luc2CP]  Promoter-less 
 Firefly luciferase gene 
 Ampicillin-resistance gene 
Promega 
pGL4.74[hRluc/TK]  Thymidine kinase promoter 
 Renilla luciferase gene 
 Ampicillin-resistance gene 
Promega 
 
 
2.1.5 Animals 
Adult mice C57BL/6J (B6) mice were obtained from the Australian Phenomics 
Facility of The Australian National University (ANU) and housed under pathogen-free 
conditions. All experiments were approved by the ANU Animal Ethics and 
Experimentation Committee. 
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2.1.6 Antibiotics  
Ampicillin: A stock solution of ampicillin sodium salt was dissolved in distilled 
water (50 mg/mL) and stored at –20 °C. 
Penicillin-Streptomycin: This solution includes 10,000 IU of penicillin and 10 mg 
streptomycin per mL. The antibiotic aliquots were kept at 4 °C.  
Kanamycin (ICN Biomedicals): A stock solution of kanamycin monosulphate was 
dissolved in distilled water (20 mg/mL) and aliquots were stored at –20 °C.  
 
2.2 Bacterial experiments 
2.2.1 Bacterial strains 
Three strains of Escherichia coli (E. coli) were used as host bacteria for plasmid 
transformations (Table 2.4), namely the chemically competent DH5α, and 
electrocompetent XL-1 and strains. Aliquots of competent cells were stored at –80 °C. 
 
Table 2.4: Bacterial strains were used in this study 
Strain Genotype Source 
E. coli DH5α F–Φ80lacZΔM15 Δ(lacZYA-
argF) U169recA1 endA1 hsdR17 
(rk–, mk+) phoA supE44 λ– thi-1 
gyrA96 relA1 
Life Technologies 
E. coli DH10B F–mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80lacZΔM15 ΔlacX74 recA1 
endA1 araD139 Δ (ara, leu)7697 
galU galK λ- rpsL nupG 
/pMON14272/pMON7124 
NEB 
E. coli XL-1 Blue recA1 endA1 gyrA96 thi-1 hsdR17 
supE44 relA1 lac [F’ proAB 
lacIqZ ΔM15 tn10 tetr] 
Stratagene 
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Strain Genotype Source 
E. coli Top10 F–mcrA Δ(mrr-hsdRMS-mcrBC) 
Φ80lacZΔM15 ΔlacX74 recA1 
araD139 Δ(ara leu) 7697 galU 
galK rpsL (StrR) endA1 nupG 
Invitrogen 
 
2.2.2 Transformation of electrocompetent bacteria 
Plasmid DNA (2.5 μL) was added to electro-competent bacteria (E. coli XL-1 Blue) 
that were thawed on ice. The mixture was incubated on ice for 30 seconds and then 
transferred to a pre-chilled 0.2 cm electroporation cuvette (Astral). The cells were briefly 
exposed to a strong electrical field using a Bio-Rad Gene Pulser II (BioRad) set to 2.5 kV, 
200 Ω and 25 μF. SOC medium (0.5–1 mL) was added to the cuvette immediately after 
the pulse and the mixture was transferred to a 15 mL Falcon tube. The cells were then 
allowed to recover from the electroporation for 60 min by shaking at 220 rpm at 37 °C. 
The transformed cells were then plated onto LB-agar plates containing the 
appropriate antibiotic (100 μg/mL for ampicillin, 50 μg/mL for kanamycin) 
corresponding to the resistance gene present on the plasmid. The presence of the specific 
antibiotic in the medium ensured the growth of those cells that had taken up the plasmid. 
The plates were incubated overnight at 37 °C and visible colonies were further analysed 
(see Section 2.4.1.3). 
 
2.2.3 Transformation of chemically competent bacteria 
Aliquots (50 μL) of chemically competent bacteria (E. coli DH5α, DH10B or Top10) 
were thawed on ice and transferred into a pre-chilled 14 mL round bottom Falcon tube 
(BD Biosciences). One microliter of DNA was added to the bacteria. The tube was 
swirled and incubated on ice for 30 min. The transformation reaction was then placed in 
a 42 °C water bath for 45 seconds. The tube was immediately placed on ice for 2 min, 
after which 0.5 mL of SOC was added to the reaction. The bacteria were incubated at 37 
°C for 60 min by shaking at 220 rpm. A volume of 150-250 μL of the reaction was plated 
onto an LB-agar plate containing the appropriate antibiotic to select transformed colonies. 
The plate was incubated overnight at 37 °C. 
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2.2.4 Bacterial growth 
To culture transformed bacterial colonies, 10 mL of LB was placed in a 50 mL 
Falcon tube. The appropriate antibiotic was added to the LB at a final concentration of 
100 μg/mL or 50 μg/mL for Ampicillin or Kanamycin, respectively. A sterile toothpick 
was used to pick a single transformed colony and was placed into the Falcon tube. The 
cultures were grown overnight in a rotatory shaker at 220 rpm at 37 °C.  
 
2.3 Eukaryotic cell culture 
2.3.1 Cell lines and cell culture 
Cell lines used in this study were maintained in appropriate culture media (Table 
2.5) at 37 °C in a humidified atmosphere of 5% CO2 in an incubator. The cells were grown 
in 80-cm2 tissue-culture flasks (Nunc) and cell density and morphology was examined on 
a daily basis by light microscopy. When cells reached 85–90% confluence, the medium 
was removed and the cells were detached from the surface of the flask by addition of 10 
mL 0.25% trypsin–EDTA. After stopping trypsinization by adding media containing 10% 
FBS, the cells were transferred into a 50 mL falcon tube and collected by centrifugation 
at 1,500 rpm for 5 minutes. The pellet was resuspended with the relevant medium and 
centrifugation was repeated. After the supernatant was removed, the pellet was 
resuspended again in fresh medium and transferred into a new culture flask at a 1:20 ratio.  
 
Table 2.5: Cell lines used in this study 
Cell line Description Media 
HeLa Human cervix carcinoma cells DMEM/F12 + 2 mM Q  
+ 10% FBS 
Caco-2 Human epithelial colorectal  
adenocarcinoma cells 
DMEM/F12 +10% FBS  
+1% penicillin-streptomycin 
FRTC Rat thyroid cancer cells DMEM/F12 + 5% FBS 
HEK293 Human embryonic kidney cells RPMI + 2 mM Q+ 5% FBS 
HepG2 Human liver carcinoma cells RPMI + 10% FBS 
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2.3.2 Counting of cell numbers 
Cell suspensions were analysed and counted by using an automated cell counter 
(Scepter, Millipore). 
 
2.4 Isolation and manipulation of DNA 
2.4.1 DNA isolation 
2.4.1.1 DNA extraction from mouse tissues 
Isolation of DNA from C57BL/6J mice tissues was carried out using DNeasy Blood 
& Tissue Kit (Qiagen). The kidneys and intestine were used to isolate genomic DNA and 
its concentration was measured using a NanoDrop spectrophotometer (ThermoFisher 
Scientific). 
 
2.4.1.2 Plasmid DNA isolation 
Plasmids were isolated from overnight cultures using the NucleoSpin Plasmid Kit 
according to the manufacturer’s protocol. Plasmid preparations for transient transfection 
of cell lines (see Section 2.6.1) were prepared using the NucleoBond Xtra Maxi 
Endotoxin-free Kit. The quality of the isolated plasmid DNA was checked using 
spectrophotometry (see Section 2.8.2) and agarose gel electrophoresis (see Section 2.8.1). 
The isolated plasmids were stored at –20 °C.  
 
2.4.1.3 Rapid screening of transformed colonies 
Following the transformation of the plasmid of interest, ~15 colonies were picked 
using a sterile toothpick or a pipet tip and re-streaked onto LB-agar plates containing 
appropriate antibiotic(s). After incubation at 37 °C overnight, a single colony was 
transferred to an Eppendorf tube using a toothpick. Forty μL of 10 mM EDTA (pH 8.0) 
was added to the tube and the bacteria were resuspended by vortex mixing. Fifty μL of 
freshly prepared 2× cracking buffer was added to lyse the bacteria and the mixture was 
mixed by a vortex and incubated for 5 minutes at 23 °C. After adding 10 μL of Marker 
mix, the tube was incubated on ice for 10 min. The samples were centrifuged at 4 °C for 
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3 min at 15,000×g. Of the supernatant, 20 μL was loaded onto a 1% agarose gel adjacent 
to a supercoiled DNA ladder (Invitrogen). 
 
2.4.2 DNA experiments 
2.4.2.1 Restriction enzyme digestion 
Restriction digestion was used for cloning and linearization of plasmid DNA. 
Target DNA was typically digested for 2h by 10–20 U of a specific restriction enzyme in 
the recommended reaction buffer at the recommended temperature. The restriction 
enzymes were sourced from Invitrogen, NEB, or Takara Biotechnology.  
 
2.4.2.2 Gel elution 
Gel elution was used to clean PCR products, restriction enzyme digested DNA, and 
to separate the DNA fragments from unwanted vector impurities. Briefly, after 
electrophoresing the samples, the DNA fragment was cut out from the agarose gel using 
a scalpel and weighed. The DNA fragment was extracted from the isolated band using 
PureLink Quick Gel Extraction Kit. Spectrophotometry (see Section 2.8.2) was used to 
determine the concentration of the extracted DNA.  
 
2.4.2.3 DNA ligation 
To ligate DNA inserts into vectors, the T4 DNA Quick Ligation Kit was used. Ten 
μL 2× Quick Ligation Buffer and 1 μL of Quick T4 DNA ligase were added to a 1:3 molar 
ratio of vector to insert. The reaction mixture was incubated at 25 °C for 5 min after which 
the ligated DNA was precipitated by addition of 1 μL of yeast tRNA (5 µg/μL), 0.5 
volumes of 7.5 M ammonium acetate, and 2.5 volumes of 100% ice-cold ethanol. The 
contents were mixed by a vortex and incubated for 10 min at 23 °C. The DNA was 
pelleted by centrifugation for 20 min at 16,000×g and the supernatant was discarded. A 
volume of 250 μL 70% ice-cold ethanol was added and the mixture was spun for a further 
10 min at the same speed. The supernatant was discarded and the pellet was dried on the 
bench at 23 °C. The pellet was then dissolved in 5 μL of sterile water. A 2 μL aliquot of 
ligation product was later used to transform electro-component bacteria (see Section 
2.2.2). 
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2.4.2.4 Polymerase chain reaction (PCR) 
PCR reactions were performed using Taq DNA polymerase (Qiagen) according to 
the manufacturer’s instructions. Each reaction contained 2 units of the polymerase 
enzyme, 1 μL of 10 mM deoxynucleotide triphosphate (dNTP) mix, 100 ng of DNA 
template, 5 μL of 10× PCR buffer, and 0.5 μM of the forward primer and 0.5 μM of the 
reverse primer in a final volume of 50 μL in distilled water. PCR reactions were run in a 
96-well Veriti® thermal cycler (ABI) at the conditions shown in Table 2.6.  
 
Table 2.6: Conditions of a PCR cycling 
Process Temperature (°C) Time 
(min:sec) 
Number of 
repeats 
Denaturation 94 5:00 1 
Denaturation 94 0:30  
 
30 
Annealing 50–58 (depending on the 
melting temperature (Tm) of 
primers) 
0:30 
Extension 72 1:00 
Extension (Final) 72 10:00 1 
 
In order to obtain proofread products, the PCR reactions were performed using 
PfuUltra high fidelity DNA polymerase (Agilent) or Phusion high-fidelity DNA 
polymerases according to the manufacturers’ protocols. The products were separated on 
a 1% agarose gel (see Section 2.8.1). Thermal cycler conditions used in conjunction with 
PfuUltra and Phusion® high-fidelity DNA polymerases are listed in the Appendix 8.2.  
 
2.4.2.5 Site-directed mutagenesis 
QuikChange II Site Directed Mutagenesis Kit was used for this method. The entire 
plasmid was amplified by PCR using long primers (25–45 bp) with the desired mutation 
located in the centre of the primer (Table 2.7).  
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Table 2.7: Primer sequences used for site-directed mutagenesis 
Red text indicates inserted mutations. 
Mutation 
type 
Sequence 
HNF1a 
BS1(Mut1) 
5’TGGAGGGGGTGGCTTAGCTTCGGAGGCTGGGTGCCTCTGCAG3’ 
3’CTGCAGAGGCACCCAGCCTCCGAAGCTAAGCCACCCCCTCCA5’  
HNF1a 
BS2(Mut2) 
5’TGGGTGCCTCTGCAGATAAGGCAGGCCCAGTTCTGCAGGACGC3’ 
3’GCGTCCTGCAGAACTGGGCCTGCCTTATCTGCAGAGGCACCCA5’ 
HNF1a 
mutation 
(R131W)  
5’GCACAACATCCCCCAGTGGGAGGTGGTGGACACC3’ 
3’GGTGTCCACCACCTCCCACTGGGGGATGTTGTGC5’ 
HNF4a 
BS2(Mut2) 
5’GGGTTGAGGTGCTGACGGTTCTCTATAAAG3’ 
3’CTTTATAGAGAACCGTCAGCACCTCAACCC5’ 
HNF4a 
BS4(Mut3) 
5’GACAACAGAACACTCCACGTCCTGTGAATTC3’ 
3’GAATTCACAGGACGTGGAGTGTTCTGTTGTC5’ 
HNF4a 
BS5(Mut4) 
5’GTGAATTCTAGTCATGTCACGTGTGCCAAG3’ 
3’CTTGGCACACGTGACATGACTAGAATTCAC5’ 
SOX9-BS1 
Mut 
5’CAGTGTGTTTGGTTGACGGTCAGGCCCCTG3’ 
3’CAGGGGCCTGACCGTCAACCAAACACACTG5’ 
Sox9-Mut1 5’GCCTATGTCTGGGCCTTTGCAGGAGGAGGG3’ 
3’CCCTCCTCCTGCAAAGGCCCAGACATAGGC5’ 
Sox9-Mut2 5’CAACCACTTGCCCTGGGTCTGCCGAGCTGCC3’ 
3’GGCAGCTCGGCAGACCCAGGGCAAGTGGTTG5’ 
SOX9 
mutation  
(H65Y) 
5’GCTGCGCGTGCAGTACAAGAAAGACCACC3’ 
3’GGTGGTCTTTCTTGTACTGCACGCGCAGC5’ 
Spdef-mut 5’CAGGCCTTCAGCAGGATCTCCTGTCCGTG3’ 
3’CACGGACAGGAGATCCTGCTGAAGGCCTG5’ 
 
Template DNA (50 ng) was mixed with 5 μL of the provided 10× reaction buffer, 
125 ng of the sense primer, 125 ng of the antisense primer, and 1 μL of the dNTP mix. 
The final volume was adjusted to 50 μL using deionized water. One μL of PfuUltra high-
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fidelity DNA polymerase (2.5 U/μL) was added to the reaction before performing PCR 
amplification (Table 2.8). 
Table 2.8: PCR conditions for site-directed mutagenesis 
Process Temperature (°C) Time (min:sec) Number of repeats 
Denaturation 95 0:30 1 
Denaturation 95 0:30  
16–18 cycles Annealing 55 1:00/kb of 
plasmid 
Extension 68 4:00 1 
 
The amplified DNA was digested for 3 hours with DpnI (10 U/μL) at 37 °C to 
remove the template DNA. The DNA was then transformed into either chemically or 
electrocompetent E. coli. 
 
2.5 Bioinformatics analysis 
2.5.1 Alignment of promoter region 
To identify the promoter regions conserved among different species, the promoter 
sequences were analysed using the University of California, Santa Cruz (UCSC) Genome 
Browser (http://genome.ucsc.edu). Using this method, regions of ~2.5 kb upstream of 
mouse Slc6a19, Ace2, and Collectrin transcription start sites were examined. 
 
2.5.2 Prediction of transcription-factor-binding sites 
The MatInspector program (http://genomatix.de) is a web-based bioinformatics tool 
which predicts transcription-factor-binding sites based on similarity of the input sequence 
to a library of known motifs (Quandt et al., 1995). A 2.5 kb fragment of Slc6a19 promoter 
was analysed using this tool. 
 
2.6 Reporter gene assay 
The Dual-Luciferase® Reporter Assay system was used to identify effects of 
transcription factors on the mouse Slc6a19 promoter. To this end plasmid 
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pGL4.12[luc2CP] containing the target promoter region, was expressed alone or was co-
transfected with transcription factors of interest. 
 
2.6.1 Principle of dual reporter assay 
HEK293 cells were seeded out in 24 well plates at a density of 1×105 cells per well 
24 hours before transfection. Transfections were performed using the Lipofectamine LTX 
(Invitrogen) reagent, according to the manufacturer’s instructions.  
Briefly, 500 ng of different Slc6a19 promoter constructs in pGL4.12[luc2CP] 
vector (Figure 2.1), plus 100 ng of a transcription factor (TF) expressing vector (typically 
inserted into pcDNA3.1(+)), 5 ng of pGL4.74[hRluc/TK] control vector (Figure 2.1), and 
2 μL of Lipofectamine LTX were added to 100 μL Opti-MEM®. The DNA solution was 
mixed and incubated for 30 min at 23 °C. After incubation, the mixture was added to 
HEK293 cells in a 24-well plate and incubated at 37 °C for 24 h.  
 
 
 
Figure 2.1: pGL4.12[luc2CP] plasmid and pGL4.74[hRluc/TK] plasmid were used 
as reporter plasmids in the Dual-Luciferase® Reporter Assay system. 
pGL4.12 lacks a promoter sequence to start transcription of the Firefly Luciferase gene. 
Potential promoter sequences can be inserted upstream of the luciferase sequence. The 
Renilla luciferase, by contrast, is expressed constitutively from the Herpes Simplex 
thymidine kinase promoter (pGL4.74 vector). It serves as an internal control for the 
reporter gene assay system. 
 
After 24 h of incubation, the cell medium was removed and, cells washed once with 
PBS (pH 7.4). Cell layers were lysed in 100 μL Passive Lysis Buffer (Promega) for 20 
min at 23 °C using a shaker plate.  
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A 20 μL aliquot of the lysate was placed into a 1.5 mL Eppendorf tube containing 
100 μL Luciferase Assay Reagent (LARII) and after 10 seconds, luminescence activity 
of the Firefly luciferase was measured using a Turner TD-20/20 illuminometer. 
Subsequently, 100 μL of Stop and Glo reagents was injected into the same tube to stop 
the Firefly luminescence and activate the Renilla luciferase. The relative luciferase 
activity was quantified by normalising the Firefly luciferase activity relative to the Renilla 
luciferase activity of the pGL4.74 control plasmid. Each transfection and measurement 
of luciferase activity was performed in triplicates. 
 
2.6.2 Cloning of mouse Slc6a19 promoter 
Based on bioinformatic analysis, a 2.5 kb region upstream of the Slc6a19 
transcriptional start site was selected.  
A 2551 bp fragment of the promoter spanning from position –2494 to +57, was 
generated using a two-step nested PCR amplification procedure. Initially, a 3013 bp 
section (–2639 to +374) of the promoter was amplified by PCR (Table 2.9). Two μL of 
the first PCR was used as a template for the second PCR targeting the 2551-bp promoter 
region. Primer Slc6a19(–2494) included a KpnI restriction site and primer Slc6a19(+57) 
contained a BglII restriction site (Table 2.9). The final PCR product was purified and 
ligated (see Section 2.4.2.3) into a KpnI/BglII digested pGL4.12 vector. 
 
Table 2.9: Primers used for amplification of the Slc6a19 promoter 
Name Sequence 
Slc6a19(–2639) 5’ACCGGGTCATTTTTCTGCTCG3’ 
Slc6a19(+374) 3’TCCTGAGGAACATCCATCCAT5’ 
Slc6a19(–2494) KpnI 5’ATGGTACCTTAGAGAGCTGCCTC3’ 
Slc6a19(+57) BglII 3’GAAGATCTCGCTGGGCTGGGCCGGGC5’ 
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2.6.2.1 Preparing the truncated Slc6a19 constructs 
The truncated Slc6a19 promoter constructs were generated using the full promoter 
construct in pGL4.12 using inverse PCR. Selection of the truncation points was based on 
sequence conservation. The resulting fragment sizes are listed in Table 2.10. 
 
Table 2.10: Oligonucleotides used for the synthesis of B0AT1 promoter deletion 
constructs 
Promoter construct Oligonucleotide Insert size 
pSlc6a19(–2494/+57) 5’ATGGTACCTTAGAGAGCTGCCTC3’ 2551 bp 
pSlc6a19(–1703/+57) 5’ATCTCTCTTGGTCTCTGTCCC3’ 1760 bp 
pSlc6a19(–1380/+57) 5’CTAGTTTCCCAGTGTGTTTGG3’ 1437 bp 
pSlc6a19(–972/+57) 5’GAGAAAGGGGATAGGGTAACA3’ 1029 bp 
pSlc6a19(–437/+57) 5’CTTCAGCCACCTTTAGGAATA3’ 494 bp 
pSlc6a19(–201/+57) 5’GTGCCCAGGCCTTCAGCAGG3’ 258 bp 
pSlc6a19(–136/+57) 5’GGTGCCTCTGCAGATAAGG3’ 193 bp 
pSlc6a19(–108/+57) 5’GTTCTGCAGGACGCGCCCT3’ 165 bp 
pSlc6a19(–37/+57) 5’GGTTCTCTATAAAGAGCCG3’ 94 bp 
 
2.6.3 Cloning of the Ace2 and Collectrin promoter constructs  
The mouse Ace2 promoter sequence was amplified by nested PCR. Firstly, a 
fragment ranging from position –1602 to +254 was amplified. Subsequently, a shorter 
fragment from position –1509 to +170 was amplified by a nested PCR, using primers with 
incorporated XhoI and KpnI restriction sites (Table 2.11). The final product was digested 
using XhoI and KpnI, purified, and ligated into reporter vector pGL4.12. 
The mouse Collectrin promoter DNA was generated by nested PCR. In the first 
PCR step, a fragment ranging from position –2125 to +266 was amplified (Table 2.11). 
In the second step, a smaller fragment (–1903 to +76) was generated using a primer set 
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that contained restriction sites for KpnI and XhoI (Table 2.11). The final product was 
digested using KpnI and XhoI, purified, and ligated into the reporter vector pGL4.12. 
 
Table 2.11: Oligonucleotides used for the synthesis of Ace2 and Collectrin promoter 
constructs 
Promoter construct Oligonucleotide 
Ace2(–1602)F 5’CCGGGGTACTGCTTAGTTCA3’ 
Ace2(+254)R 3’ATTTTCCTCGGTGAGGGACT5’ 
Ace2 (–1509)XhoI 5’ATCTCGAGAGCTGACTGTGAGCATCCAC3’ 
Ace2 (+170)KpnI 3’TAGGTACCGCCAAGATCCCATCCACTGA5’ 
Collectrin(–2125)F  5’CTCCTTGCGTACCTGCTTTC3’ 
Collectrin (+266)R 3’TTTCAAGCCACATGTCCAAA5’ 
Collectrin(–1903)KpnI 5’ATGGTACCTGGTGGTGTTAGGTGTATT3’ 
Collectrin(+76)XhoI 3’TACTCGAGGCCGCAAACAGAAGACAAACT5’ 
 
2.6.4 Transcription factor constructs  
Transcription factor complementary DNAs (cDNAs) used in this study were either 
cloned in our lab or obtained commercially.  
The coding sequences of transcription factors HNF4a, SOX9, ATF4, PAX4, 
CREB3L3, GATA4, FOXA2 (HNF3b), NEUROG3, SMAD3, EGR1, and HNF1b were 
amplified on mouse intestinal cDNA by nested PCR. Initially, larger fragments were 
amplified using primers listed in Table 2.12. Subsequently, the coding sequence was 
amplified using the primers containing appropriate restriction sites. The final fragment 
was digested using the corresponding enzymes, purified, and ligated into mammalian 
expression vector pcDNA3.1(+). All transcription factor constructs were sequenced to 
confirm their identities (Biomolecular Resource Facility, John Curtin School of Medical 
Research (JCSMR), ANU). 
The mouse HNF1a cDNA was purchased from Thermo Scientific (Clone 
ID:30471380). The mouse Cdx2 (BC103516) was purchased from Open Biosystems and 
cloned into the pcDNA3.1(+) (Invitrogen). The mouse GFP–STAT3 (embedded into 
pEGFP-C3) and the human Flag–STAT3 (embedded into pXJ40-FLAG) expression 
plasmids were kindly provided by Marie Bogoyevitch (Bio21 Institute, Melbourne). 
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Table 2.12: Primers used for cloning of TFs 
Clone Sequence NCBI Ref. Seq. 
HNF4a  NM_008261.2 
mHNF4a-BamHI 5’TTGGATCCGGGAGAATGCGACTCTCTAAA3’  
mHNF4a-EcoRI 3’ATGAATTCAGCTTGCTAGATGGCTTCTTG5’  
SOX9  NM_011448.4 
mSox9s 5’TTGGATCCATGAATCTCCTGGACCC3’  
mSox9a 3’ATGAATTCTCAGGGTCTGGTGAGCTG5’  
mSox9-BamHI 5’TTGGATCCATGAATCTCCTGGACCCCTT3’  
mSox9-EcoRI 3’ATGAATTCTCAGGGTCTGGTGAGCTGTGT5’  
ATF4  NM_009716.2 
mAtf4-BamHI 5’TTGGATCCATGACCGAGATGAGCTTCCTG3’  
mAtf4-EcoRI 3’ATGAATTCTTACGGAACTCTCTTCTTCCC5’  
PAX4  NM_011038.1 
mPax4s 5’GCTCTCCGTTTTCAGTTTGC3’  
mPax4a 3’GAGGCCTCTTATGGCCAGTT5’  
mPax4-BamHI 5’TTGGATCCATGCAGCAGGACGGACT3’  
mPax4-EcoRI 3’ATGAATTCTTATGGCCAGTTTGAGC5’  
CREB3L3  NM_145365.3 
mCreb3l3s 5’AACATCCGGTGACGCTAGAC3’  
mCreb3l3a 3’GCCAGCCTGGTCTACAAGAG5’  
mCreb3l3-NotI 5’TTGCGGCCGCATGGATGGGGACATAGCG3’  
mCreb3l3-XbaI 3’ATTCTAGATCACAGCACCCCCAATGCA5’  
GATA4  NM_008092.3 
mGata4-EcoRI 5’TTGGATCCATGTACCAAAGCCTGGCCAT3’  
mGata4-BamHI 3’ATGAATTCTTACGCGGTGATTATGTCC5’  
FOXA2 
(HNF3b) 
 NM_010446.2 
mHnf3bs 5’CCCGGGACTTAACTGTAACG3’  
mHnf3ba 3’GGTGAGACTGCTCCCTTGAG5’  
mHNF3-EcoRI 5’TTGGATCCATGCTGGGAGCCGTGAAG3’  
mHNF3-BamHI 3’ATGAATTCTTAGGATGAGTTCATAATAGG5’  
NEUROG3  BC104327.2 
mNeurog3s 5’GGTGTGTGTGGGGGATACTC3’  
mNeurog3a 3’TGGAGCGAGAGTTTGATGTG5’  
mNeurog3-NotI 5’TTGCGGCCATGGCGCCTCATCCCTTGGA3’  
mNeurog3-XbaI 3’ATTCTAGATCACAAGAAGTCTGAGAACA5’  
SMAD3  NM_006754.6 
mSmad3s 5’GCGGAGACCCAAACTTTCTA3’  
mSmad3a 3’GAAACAGGCTGGTGCCTTAG5’  
mSmad3-EcoRI 5’TTGGATCCATGTCGTCCATCCTGCCCTT3’  
mSmad3-BamHI 3’ATGAATTCCTAAGACACACTGGAACAGC5’  
EGR1  NM_007913.5 
mEgr1s 5’CCACCCAACATCAGTTCTCC3’  
mEgr1a 3’GGCAGGGATGGTAAGTGAAA5’  
mEgr1-EcoRI 5’TTGGATCCATGGCAGCGGCCAAGGCCGA3’  
mEgr1-BamHI 3’ATGAATTCTTAGCAAATTTCAATTGTCCT5’  
HNF1b  NM_009330.2 
mHNF1bs 5’CCCTCAACCCCTTCTTTTTC3’  
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Clone Sequence NCBI Ref. Seq. 
mHNF1ba 3’GGGTTTCTCCCTTCTCGTTG5’  
mHNF1b-EcoRI 5’TTGGATCCATGGTGTCCAAGCTCACGT3’  
mHNF1b-BamHI 3’ATGAATTCACCAGGCTTGCAGTGG5’  
 
2.7 RNA Studies 
2.7.1 RNA extraction and quantitative PCR 
2.7.1.1 Isolation of epithelial cells along the intestinal crypt–villus axis 
Mouse intestinal tissue was isolated from an equal number of female and male mice 
(C57BL/6J (B6), 6 to 8 weeks old). To isolate cells populations from crypts and villi of 
mouse intestines, a fractionation method was used. This method used inversion of the 
intestinal lumen as described by Barnard et al. (1989) and optimized by Traber et al. 
(1991). 
Briefly, the small intestine was cut after the duodenum and before the ileocaecal 
valve and perfused with ice-cold PBS, pH 7.4, containing 1mM dithiothretiol (DTT). 
Subsequently, a 6-cm-long section of mouse jejunum was inverted onto a plastic rod. The 
plastic rod was inserted into a purpose made hole in the cap of a 12–mL, plastic, round-
bottom centrifuge tube, containing 10 mL citrate buffer (96 mM NaCl, 1.5 mM KCl, 27 
mM sodium citrate, 8 mM KH2PO4, and 5.6 mM Na2HPO4, pH 7.4). After sealing with 
Parafilm, the assembly was incubated on a rotatory shaker at 37 °C for 10 min. 
Subsequently, the citrate buffer was changed to 10 mL PBS (pH 7.4) containing 0.5 mM 
DTT, 1.5 mM EDTA, and 1 mg/mL bovine serum albumin at 37 °C. Rotary shaking was 
continued for 10–20 min until the solution turned opaque indicating detachment of cells 
from the intestinal lumen. The solution was removed and replaced by pre-warmed fresh 
solution until 5 to 7 fractions were collected. Cell viability was judged by Tryphan Blue 
exclusion (Strober, 2001). 
 
2.7.1.2 RNA extraction and microarray studies 
Total RNA was isolated using the RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s protocol. RNA quality was determined by using an RNA 6000 Nano 
LabChip® Kit on the Agilent Bioanalyzer 2100 (Agilent Technologies) platform 
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according to the manufacturer’s protocol. RNA samples with and RNA integrity number 
(RIN) of ≥8 were used in subsequent microarray analyses (Figure 2.2). 
 
 
Figure 2.2: Quality analysis of microarray samples 
The quality of the total RNA was examined using the Bionalyzer 2100 (Agilent). 
According to RIN values, the quality of the isolated cells from the crypt was slightly better 
than that from villus. In these electropherograms, the two peaks represent the 18s and 28s 
ribosomal RNA (rRNA). 
 
Global gene expression was analysed using an Agilent SurePrint G3 Mouse Exon 
Microarray kit at the Ramaciotti Center, University of New South Wales, Sydney.  
 
2.7.1.3 Complementary DNA synthesis 
cDNA was generated from extracted RNA using the SuperScript™ III Reverse 
Transcriptase enzyme (Invtirogen). The reaction was prepared by adding 1 μL of 
oligo(dT) primer (Invitrogen), 0.5 mM of dNTPs, and 8 μL of total RNA (concentration, 
250 ng/μL). The reaction was incubated at 65 °C for 5 min to denature RNA before being 
transferred onto ice for 1 minute. Subsequently, 4 μL of 5× First-Strand buffer, 1 μL of 
RIN:7.9 
RIN:9.2 
RIN:8.2 
RIN:9.7 
 
Villus  samples 
 
Crypt  samples 
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0.5 mM DTT, 1 μL RNAseOut (Invitrogen), 0.5 μL SuperScript™ III, and 3.5 μL of 
sterile distilled water was added. The resulting mixture was incubated for 60 min at 50 
°C. The reaction was stopped by heating at 85 °C for 5 min. 
 
2.7.1.4 Quantitative real-time RT-PCR (qRT-PCR) 
qRT-PCR was conducted using the Fast SYBR® Green master mix (Applied 
Biosystems) in conjunction with an Applied Biosystems 7900 instrument. The reaction 
mixture (10 μL) included 5 μL SYBR® Green master mix, 3 μL of sample cDNA (1:10 
dilution) and 1 μL of each primer (final concentration, 200 nM). The samples were 
pipetted into a 394-well plate. The PCR cycling parameters were 50 °C for 2 min, 
followed by 40 cycles of denaturation at 95 °C for 15 s and 60 °C for 1 min. All samples 
were analysed in duplicates. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
cDNA served as an internal control. GAPDH previously used as a single reference gene 
to compare the gene expression in the crypt-villus axis (Anderle et al., 2005). Primers 
were designed using the Primer3 program (http://frodo.wi.mit.edu/) to amplify fragments 
of 170–250 bp. The primers used for qRT-PCR are listed in Table 2.13. To validate the 
quality of the mRNA for microarray analysis, mRNA expression of six selected genes 
was quantified by qRT-PCR. 
 
Table 2.13: Primer sets used for RT-PCR and qRT-PCR amplifications 
Name Sequences 
Lgr5 5’TAAAGACGACGGCAACAGTG3’ 
3’GATTCGGATCAGCCAGCTAC5’ 
Slc6a19 5’CCGTCGTCTACGTGTATGGA3’ 
3’ACCCAGTTGGGGTATGGAAT5’ 
Hnf1a 5’TCACAGACACCAACCTCAGC3’ 
3’CCGTTGGAGTCGGAACTCT5’ 
Hnf4a 5’GCCAAGATTGACAACCTGCT3’ 
3’ATTCAGATCCCGAGCCACTT5’ 
Gata4 5’TCAAACCAGAAAACGGAAGC3’ 
3’GCCGGACACAGTACTGAATGT5’ 
Cdx2 5’GCAGTCCCTAGGAAGCCAAG3’ 
3’CTGCGGTTCTGAAACCAAAT5’ 
GAPDH 5’AACTTTGGCATTGTGGAAGG3’ 
3’CCCTGTTGCTGTAGCCGTAT5’ 
Sox9 5’TCAGATGCAGTGAGGAGCAC3’ 
3’CCAGCCACAGCAGTGAGTAA5’ 
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2.7.2 Microarray Analysis 
2.7.2.1 Bioinformatics analyses of microarray data 
Microarray data were analysed using the GeneSpring GX software (Agilent 
Technology). The GeneSpring software has tools for normalisation, statistical analyses, 
statistical interpretations, and quality control of gene expression data. Duplicate samples 
were prepared for each cell population. The normalisation step was performed as follows: 
individual probe sets were first filtered on expression between the 20th and 100th 
percentile in at least 2 out of 4 samples. After normalisation, the remaining probe sets 
were filtered for a more than three-fold change of expression. Unpaired T-tests, which 
were corrected with Bonferroni multiple testing, were applied on the differentially 
expressed genes. After normalisation and statistical analysis, 4464 probes were identified 
as differentially expressed genes. 
 
2.7.2.2 Gene Ontology (GO) Analysis 
Gene ontology (GO) is a bioinformatics tool designed to organise genes in different 
groups based on their attributes. To identify significantly enriched GO terms, 
differentially expressed genes from the microarray analysis were classified using 
GeneSpring GX software. GeneSpring GX program identified classes of genes based on 
p <0.01. Each significant set of genes was grouped into different categories, based on 
biological processes, molecular function, and cellular components according to the GO 
consortium database (http://www.geneontology.org). 
 
2.7.2.3 Pathway Analysis 
The GeneSpring program was also used for pathway analysis of the 4464 
differentially expressed genes. For a more selective pathway analysis a >10-fold change 
was set. The GeneSpring program uses the Kyoto Encyclopaedia of Gene and Genomes 
(KEGG) pathway database to identify significant pathways (p < 0.05). 
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2.8 Analysis of DNA and RNA 
2.8.1 Agarose gel electrophoresis 
DNA products were analysed using an agarose gel electrophoresis system. Briefly, 
the agarose gel (1%) was dissolved in the TAE buffer by boiling the mixture using 
microwave heating. After cooling the agarose to ~55 °C, it was poured into the 
electrophoresis apparatus containing a comb. Subsequently, the agarose was left to set 
and the gel was submersed in the TAE buffer, and the comb removed.  
Approximately 20 μL of DNA products were mixed with the 6× loading buffer 
(Invitrogen) and loaded onto the gel wells. The presence of 60% glycerol in the loading 
buffer helped to sink the sample to the bottom of the well. This included bromophenol 
blue which assisted in the visualisation of DNA migration. Either a 1-kb or a 100-bp DNA 
ladder (NEB) was loaded as marker to determine the electrophoresed band sizes.  
The electrophoresis tank (Bio-Rad) was run at 10 V/cm to separate DNA bands. 
The gel was stained with ethidium bromide solution (5 μL/mL) for 15 min before being 
photographed using a Gel-Doc UV system and an integrated imaging program (Vision-
Capture).  
  
2.8.2 Spectrophotometry 
Both DNA and RNA samples were quantified using a NanoDrop 
Spectrophotometer (NanoDrop Technologies) at a wavelength of 260 and 280 nm using 
deionized water as a control.  
 
2.8.3 DNA sequencing 
DNA sequencing was performed by the Biomolecular Resource Facility (BRF) at 
JCSMR, ANU. Sequencing was performed using the Big Dye Terminator sequencing kit 
(ABI) and the Applied Biosystems 3730XL DNA analyser.  
The sequencing reaction consisted of 2 μL of Big Dye Terminator (BDT), which 
included the polymerase enzyme and fluorescent nucleotides, 3 μL of a 5× BDT buffer 
(ABI), 3.2 pmol of the amplification primer (Table 2.14), 300 ng of template DNA, and 
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distilled water to adjust the final reaction volume to 20 μL. The contents of the reaction 
were mixed and placed in a 96 well Veriti thermal cycler (ABI). Cycling conditions are 
shown in Table 2.15. 
 
Table 2.14: Primers used for sequencing 
Name Sequence 
pcDNA3.1 Seq Antisense #10 3’CTGGCAACTAGAAGGCACAGT5’ 
pcDNA3.1 Seq Sense #6 5’GGCTAGCGTTTAAACTTAAGC3’ 
pcDNA3.1 Seq Antisense #7 3’TTAAACGGGCCCTCTAGACTC5’ 
pcDNA3.1 mHNF1a Seq Sense #8 5’GTCTACAACTGGTTTGCCAAC3’ 
pGL4.12 int100L #24 3’TGGTGGCTTTACCAACAGTA5’ 
 
Table 2.15: The Sequencing PCR conditions 
Process Temperature (°C) Time (min:sec) Number of repeats 
Denaturation 94 5:00 1 
Denaturation 94 0:10  
30 cycles Annealing 50 0:10 
Extension 60 4:00 
Extension (Final) 60 8:00 1 
 
To purify the reaction, 2 μL of 3 M sodium acetate (pH 5.2) and 50 μL of ethanol 
(ice cold) were added to the 20 μL of the PCR reaction. After incubating the mixture at 
23 °C for 15 min, it was spun at maximum speed for 20 min in a table top centrifuge. The 
supernatant was discarded, 250 μL of 70% ethanol was added, and the mixture spun for 
5 min at maximum speed. After discarding the supernatant, the reaction was dried at 23 
°C and delivered to the BRF for sequencing. 
 
2.8.4 DNA bisulphite sequencing 
Genomic DNA was isolated using DNeasy Blood & Tissue kit (Qiagen). Up to 200 
µg of isolated genomic DNA was treated with an EpiTect Bisulfite Kit (Qiagen) 
according to the manufacturer’s instructions. In this process, all unmethylated cytosine 
residues were converted to uracil nucleotides, whereas methylated cytosine residues (5-
methylcytosine) remained intact during the treatment. 
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The promoter region was amplified by nested PCR from bisulphite-treated template 
DNA. In the first round, a 1639 bp fragment starting from position –1380 to +259 was 
amplified, followed by another amplification of a fragment ranging from position –1131 
to +18. The PCR products were sequenced and analysed for the methylation status of all 
CpG dinucleotides in the selected region. Primers used to investigate CpG dinucleotides 
in the B0AT1 promoter region are listed in Table 2.16. MethPrimer 
(http://www.urogene.org/methprimer/index1.html) was used for selecting and designing 
these methylation primers. 
 
Table 2.16: Primers used in DNA methylation analysis 
metB0AT1(–1380) 5’TTAGTTTTTTAGTGTGTTTG3’ 
metB0AT1(+259) 3’AAAAATACTATAACTTCCAC5’ 
metB0AT1(–1131) 5’GAGGAAAAAGATAATAGAAT3’ 
metB0AT1(+18) 3’AACACAAACCTCACCATAATAATC5’ 
 
The amplification was performed using the Taq polymerase (Qiagen) in a 50 μL 
reaction volume for 35 cycles under the following conditions: 94 °C for 5 min, 94 °C for 
30 s, 50°C for 30 s, 72 °C for 1 min and a terminal extension at 72 °C for 5 min. A 50 μL 
aliquot of the amplification product was run on a 1% agarose gel, and gel elution was 
carried out using PureLink Quick Gel Extraction Kit (Invitrogen) according to the 
manufacturer’s protocol (see Section 2.4.2.2). The purified fragment of the correct 
product size was cloned using the Zero Blunt Topo XL cloning kit (Invitrogen). A small 
aliquot (2 μL) of the ligation reaction was transformed into chemically competent E. coli 
(TOP10 cells) (see Section 2.2.3). Ten colonies were grown overnight, plasmid was 
isolated and subjected to sequencing for confirmation of methylation status at the BRF. 
Methylation results were visualised by the BIQ Analyzer software (http://biq-
analyzer.bioinf.mpi-inf.mpg.de/). 
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2.9 Protein-DNA interaction 
2.9.1 Chromatin immunoprecipitation (ChIP) 
Chromatin immunoprecipitation (ChIP) was performed using the SimpleChip 
Enzymatic Chromatin IP Kit #9003 (Cell Signaling Technology) according to the 
manufacturer’s instructions. Freshly prepared tissue of mouse kidney cortex, liver, 
mucosa, or intestinal fractionations were used in the ChIP assay. Forty mg of each of the 
mouse tissues was cut into small pieces using a scalpel. The cut tissues were placed into 
the 15-mL falcon tubes with 1 mL ice cold PBS, pH 7.4, buffer containing the protease 
inhibitor cocktail (Cell Signaling Technology). Nuclear proteins were then cross-linked 
to the DNA by addition of freshly prepared formaldehyde (to a final concentration of 
1.5%), and the tubes were incubated on a rotator for 20 min at 23 °C. The cross-linking 
was stopped by addition of glycine to a final concentration of 125 mM followed by further 
incubation on a rotator for 5 min at 23 °C. The tissues were centrifuged at 4 °C for 5 min 
at 1,500 rpm, and washed with 1 mL ice-cold PBS (pH 7.4) containing protease inhibitors. 
The centrifugation and washing steps were repeated seven times for seven fractions. The 
tissues were treated with 20–25 strokes in a Potter homogeniser, followed by 
centrifugation at 4 °C for 5 min at 1500 rpm. Chromatin was digested to 150–900-bp 
nucleosomal fragments using Micrococcal Nuclease (Mnase; Cell Signaling Technology) 
for 20 min at 37 °C. The reaction was stopped by adding EDTA. For further transcription 
factor studies, the nuclear membrane was fragmented by 25 strokes using a Potter 
homogeniser. For histone protein studies, the membrane was disrupted using a Misonix 
S-4000 sonicator at 15- s intervals for 2 min at 4 °C. The lysates then were centrifuged at 
10000 rpm for 10 min at 4 °C to obtain the cross-linked chromatin in the supernatant. 
The chromatin samples were immunoprecipitated with specific antibodies (listed in 
Section 2.1.3) at 4 °C with overnight rotation. After immunoprecipitation (IP) with the 
indicated antibodies, the IP mixture was incubated with ChIP Grade Protein G Magnetic 
Beads (#9006; Cell Signaling Technology) at 4 °C for 2 h with rotation. The magnetic 
beads were then washed with low-salt and high-salt ChIP buffer (Cell Signaling 
Technology). Subsequently, crosslinking was reversed in elution buffer and proteins were 
digested by adding proteinase K at 65 °C for 2 h. The DNA was purified using a spin 
column provided in the kit. Purified DNA fragments were analysed further by quantitative 
PCR (qPCR) and PCR amplifications using specific primers (Table 2.17). 
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Table 2.17: ChIP primer sets used for B0AT1 promoter analysis 
P1 (–139/+11) 5’CTGGGTGCCTCTGCAGATAA3’ 
3’AAAGGGCAAGTGGTTGTGTC5’ 
P2 (–353/–136) 5’ATCAGTATCCTGCTGGTCTGT3’ 
3’CCAGCCTAACCAGCTAAGCC5’ 
P3 (–495/–281) 5’CTGGAAGAACCCAAGCCATA3’ 
3’GGAGGCATCTCCAGCAAATA5’ 
P4 (–501/–332) 5’CTGTGCCTGGAAGAACCCAA3’ 
3’TACAGACCAGCAGGATACTGA5’ 
P5a (–858/–674) 5’CATGCCCCACCTAAGTCCT3’ 
3’TACAGAGAAGCCAGCATGACA5’ 
P5 (–682/–502) 5’TGCTGGCTTCTCTGTATCTCCC3’ 
3’GCTCCGTGCTCTAAGTGTCC5’ 
P6 (–984/–812) 5’GGAGGGGAATTTGAGAAAGG3’ 
3’TGTTCGTTTCGTGCAAACAT5’ 
P7 (–1236/–976) 5’ATTTGGGCTTTAGGGGTGTT3’ 
3’CCCCTACATCATGTCCTTGG5’ 
P8 (–1368/–1255) 5’TCTCAGGGTCCTTCTTCACC3’ 
3’AACACCCCTAAAGCCCAAAT5’ 
 
2.10 Statistical analysis 
All results are expressed as mean ± SD. p < 0.05 was considered to be statistically 
significant. For statistical comparison Student's t-test was used. All statistical studies 
were performed using GraphPad Prism v.6 (GraphPad Software). 
  
  
69 
 
Chapter 3      Comparison of differentially expressed genes 
along the crypt–villus axis 
 
3.1 Introduction  
Each villus can be separated anatomically into two regions, namely crypt and villus 
tip. Enterocytes are continually dividing and differentiating, starting in intestinal crypts, 
and migrating along a villus, until they eventually slough off at the villus tip (Cosentino 
et al., 1996). The B0AT1 protein is expressed at the apical membrane of villus enterocytes 
but not in crypt cells. Previous studies also showed that B0AT1 mRNA is highly expressed 
at the villus tips, while absent in intestinal crypts (Bröer et al., 2004). The comparison of 
these two regions should provide insight about transcriptional regulation of the Slc6a19 
gene on the intestinal surfaces. 
Caco-2 cells are endowed with villi and have been used as a cellular model of 
intestinal enterocytes for transport and metabolic studies (Van Beers et al., 1995). Rodent 
IEC6 cells, by contrast, have been used as a model of crypt-like intestinal cells (Quaroni 
and Beaulieu, 1997, Quaroni and May, 1979, Trompette et al., 2004, Drago et al., 2006). 
Similarly, another progenitor-like cell model, the human intestinal epithelial cell line 
(HIEC), was used to study intestinal cell differentiation (Benoit et al., 2010, Escaffit et 
al., 2006). 
As an alternative to cell lines, cell fractionation methods have been developed 
(Traber et al., 1991) and widely used to examine the function, proliferation or 
differentiation of intestinal epithelial cells along the crypt–villus axis. Alternatively, laser 
micro-dissection has been used to examine and characterise mouse or human intestinal 
epithelial cells (Anderle et al., 2005, Stappenbeck et al., 2003, Crosnier et al., 2006). 
Initially, Olsen et al. (2004) established an online database of crypt–villus gene 
expression patterns in the mammalian intestine. The mammalian crypt–villus axis has 
also been studied by microarray analyses by a number of groups with different study 
objectives (Anderle et al., 2005, Mariadason et al., 2005, George et al., 2008). These 
studies have shown that genes associated with DNA synthesis are expressed in the crypt, 
whereas genes related to digestion and absorption of nutrients present in differentiated 
enterocytes of the villus. 
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3.2 Results 
3.2.1 Validation of the crypt–villus cell fractionation 
Using a rotatory shaking mechanism, cells were detached in different fractions (see 
Section 2.7.1.1). Initial fractions were enriched in enterocytes released from the tip, and 
later fractions were enriched in cells derived from the crypt. 
Cell enrichment in fractions was assessed by qRT-PCR (see Section 2.7.1.4). For 
instance, fractions 1 and 2 contained high levels of Slc6a19 mRNA, while it was barely 
detectable in fraction 7 (Figure 3.1). Lgr5 (leucine-rich repeat containing G-protein 
coupled receptor 5), a crypt stem cell marker, showed an opposite trend and was highly 
enriched in fraction 7. 
Accordingly, RNA from fraction 2 (villus) and 7 (crypt) were selected for 
microarray analyses. RNA samples were hybridised to Agilent arrays using 39,430 probe 
sets. 
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F1 
F2 
F3 
F4 
F5 
F6 
F7 
A B 
C 
Figure 3.1: Schematic presentation of the crypt–villus structure and expression profiles of Slc6a19 and Lgr5 
Blue horizontal lines visualise fractionation (A). Expression profile of villus marker (Slc6a19) along the crypt–villus axis (B). 
Expression profile of crypt marker (Lgr5) along the crypt–villus axis (C). 
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3.2.1.1 Validation of microarray data 
The microarray data were validated through qRT-PCR of six selected genes (Figure 
3.2). A high level of correlation was found between qRT-PCR and microarray results (R 
= 0.9146).  
 
A 
 
 Fold difference (Crypt vs Villus) 
Gene name Microarray qRT-PCR 
Lgr5 +49.21 +115.69 
Slc6a19 –18.36 –7.59 
Hnf1a +2.83 +4.11 
Hnf4a +3.42 +5.41 
Gata4 +3.39 +4.98 
Cdx2 +4.18 +3.23 
 
 
B 
 
Figure 3.2: Confirmation of the microarray results by qRT-PCR 
(A) Expression levels of selected genes as measured by microarray and qRT-PCR. 
(B) Correlation between microarrays and qRT-PCR. 
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3.2.1.2 Gene ontology (GO) analysis 
Gene ontology analysis was performed to identify genes that perform villus-specific 
or crypt-specific functions (see Section 2.7.2.2). More than 3000 differentially expressed 
genes were identified. Of these, 1,854 genes were up-regulated and 2,610 genes were 
down-regulated along crypt–villus axis. 
Robustly expressed genes were categorised based on their involvement in 
biological processes, molecular functions, or cellular structures/organelles according to 
the GO consortium database (http://www.geneontology.org). In agreement with the roles 
of mature enterocytes in nutrient and ion absorption, transport-associated genes were 
highly enriched in the villus tip. A summary of the results is shown in Table 3.1. A 
detailed graph of gene ontology terms enriched in the villus is shown in Appendix 8.3. 
 
Table 3.1: List of gene ontology (GO) categories significantly up-regulated in cells 
of the villus tip 
 “Total genes in GO class” stands for the number of genes included in a GO category. 
“Number of genes” stands for the actual number of genes that were up-regulated in the 
category. P <0.05 indicates statistical significance. 
 
GO category Total genes 
in GO class 
Up-
regulated 
genes 
P-value 
 
 
Biological process/organic substance transport 392 44 <0.01 
Biological process/Na+ transport 145 23 <0.01 
Biological process/carboxylic acid transport 179 24 <0.01 
Biological process/nitrogen compound 
transport 
147 21 <0.01 
Biological process/lipoprotein transport 12 5 <0.01 
Cellular component/brush border 61 13 <0.01 
Molecular function/symporter activity 114 20 <0.01 
Molecular function/solute–sodium symporter 
activity 
47 12 <0.01 
Molecular function/cofactor transporter 
activity 
11 5 <0.01 
Molecular function/carboxylic acid 
transmembrane transporter activity 
95 14 <0.01 
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Genes that were up-regulated in crypt cells were mostly associated with cell 
proliferation. This result is shown in Table 3.2. A more detailed graph showing gene 
ontology terms enriched in the crypt is shown in Appendix 8.4. 
 
Table 3.2: List of gene ontology (GO) categories significantly up-regulated in crypt 
cells 
“Total genes in GO class” stands for the number of genes included in a GO category. 
“Number of genes” stands for the actual number of genes that were up-regulated in the 
category. P <0.05 indicates statistical significance. 
 
GO category Total genes 
in GO class 
Up-
regulated 
genes 
P-value 
 
 
Biological process/M phase of mitotic cell 
cycle 
216 63 <0.01 
Biological process/cell cycle 787 115 <0.01 
Biological process/chromosome segregation 105 30 <0.01 
Biological process/DNA replication 152 25 <0.01 
Biological process/DNA repair 291 33 <0.01 
Cellular component/chromosome 498 61 <0.01 
Cellular component/microtubules 627 68 <0.01 
Cellular component/nuclear part 1745 120 <0.01 
Molecular function/microtubule motor activity 44 10 <0.01 
 
3.2.1.3 Pathway analysis 
The GeneSpring program was used to categorize genes according to the Kyoto 
Encyclopaedia of Gene and Genomes (KEGG) (Kanehisa and Goto, 2000) (see Section 
2.7.2.3). 
In addition to genes involved in digestion and absorption, cell adhesion and 
cytoskeleton-associated pathways were significantly up-regulated in the villus 
compartment. This is consistent with a role of adherence and tight junctions between 
enterocytes functioning as an epithelial barrier (Champe et al., 2005). Furthermore, the 
brush border on the surface of differentiated enterocytes requires an elaborate cytoskeletal 
network to support the microvillus structure (Mooseker, 1985).  
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Digested dietary lipids, including cholesterol, free fatty acids, and 
monoacylglycerol, are absorbed by fully differentiated enterocytes and distributed to the 
body via chylomicrons (Shiau, 1987). Chylomicrons, which contain triacylglycerol, 
cholesterol, and phospholipids, are assembled in the endoplasmic reticulum of 
enterocytes and secreted into the lymphatic system which transports them to the blood 
(Champe et al., 2005). Accordingly, it is not surprising that expression of genes associated 
with lipid uptake and lipid biosynthesis was found to be up-regulated in villus cells. Also, 
genes associated with the peroxisome proliferator-activated receptors (PPAR) signalling 
pathway, which mediate chylomicron formation and lipid metabolism (Braissant et al., 
1996), were highly expressed in the villus compartment. 
Pathway analyses revealed that genes associated with immune functions, including 
T cell and B cell receptor signalling pathways, chemokine signalling pathways, 
interleukin signalling pathways, were highly enriched in villus. A summary of these 
pathways is shown in Table 3.3. In contrast to earlier studies, genes related to pathways 
associated with immune cell signalling were enriched in the villus. This is consistent with 
the fact that the differentiated epithelium harbors lymphocytes which are important for 
host defence against potential pathogens (Ferguson, 1977).  
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Table 3.3: Overrepresented KEGG pathways in the villus 
“Pathway entities” refers to the number of genes corresponding to the KEGG pathways. 
“Matched entities” is the number of the significantly expressed genes in a pathway. The 
P-value indicates statistical significance. 
 
Pathway 
 
Pathway 
entities 
Matched 
entities 
P-Value 
T cell receptor signalling pathway 133 62 <0.001 
Regulation of actin cytoskeleton 151 54 <0.001 
B cell receptor signalling pathway 156 54 <0.001 
Chemokine signalling pathway 193 60 <0.001 
PPAR signalling pathway 87 32 <0.001 
Calcium regulation in the cardiac cell 150 48 <0.001 
Integrin mediated cell adhesion 100 35 <0.001 
Focal adhesion 191 53 <0.001 
Insulin signalling 159 47 <0.001 
Glycolysis and gluconeogenesis 48 21 <0.001 
IL-2 signalling pathway 76 27 <0.001 
IL-5 signalling pathway 69 24 <0.001 
IL-4 signalling pathway 61 22 <0.001 
Myometrial relaxation and contraction 157 43 <0.001 
EGF1 signalling pathway 176 46 <0.001 
Statin pathway 20 10 <0.001 
Triacylglyceride synthesis 23 11 <0.001 
G protein signalling pathways 91 27 <0.001 
Kennedy pathway 14 8 <0.001 
IL-6 signalling pathway 99 28 <0.001 
Nuclear receptors in lipid metabolism 30 12 <0.001 
Eicosanoid synthesis 19 9 <0.001 
Selenium metabolism 31 10 <0.001 
Adipogenesis 133 34 0.001 
Purine metabolism 7 5 0.001 
IL-3 signalling pathway 100 27 0.001 
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Similar to GO analysis, KEGG pathway analysis of crypt cells confirmed 
enrichment of mRNAs involved in cell proliferation, including those involved in DNA 
replication and cell cycle. A summary of the analysis is shown in Table 3.4.  
As outlined in Section 1.3.1.1, Wnt signalling is important for regulation of stem 
cell populations in the crypt and maturation of Paneth cell. The microarray analysis 
confirmed that Wnt signalling pathway was up-regulated in the crypt tissue.  
 
Table 3.4: KEGG pathways enriched in the crypt  
“Pathway entities” refers to the number of genes corresponding to the KEGG pathways. 
“Matched entities” is the number of the significantly expressed genes in a pathway. The 
P-value indicates statistical significance. 
Pathway Pathway 
entities 
Matched 
entities 
P-Value 
Ribosomal proteins 80 73 <0.001 
DNA replication 41 34 <0.001 
Cell cycle 88 49 <0.001 
G1-to-S cell-cycle control 62 40 <0.001 
Translation factors 51 26 <0.001 
Purine metabolism 178 54 <0.001 
mRNA processing 551 194 <0.001 
miRNA regulation of DNA damage 
response 
91 29 <0.001 
Eukaryotic transcription initiation 41 21 <0.001 
Homologous recombination 13 10 <0.001 
TNFα NF-κB signalling 184 50 <0.001 
Mismatch repair 9 8 <0.001 
One carbon metabolism 29 13 <0.001 
Nucleotide metabolism 19 9 <0.001 
Mitochondrial gene expression 19 9 <0.001 
TGF-β receptor signalling pathway 150 35 <0.001 
Non-homologous end joining 8 5 0.001 
Oestrogen signalling 74 19 0.003 
Histone modifications 5 3 0.01 
Wnt signalling pathway 109 22 0.03 
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3.2.1.4 Transcription factors 
To determine which TFs could potentially regulate Slc6a19 gene expression, 
microarray data for all TFs was separately analysed. TFs were classified into three groups, 
namely those that showed a more than 3-fold difference (up or down) between expression 
in the villus tip and crypts and those that were expressed with little change in expression. 
A total of 428 TFs showed significant expression along the crypt–villus axis. Among 
these, 73 TFs had higher expression in the tip and 68 TFs had higher expression in the 
crypts. Whilst 287 TFs were evenly expressed along the entire axis (Figure 3.3). A 
complete list of expressed TFs is presented in Table 8.6. A possible regulatory role of 
these TFs in transportation of nutrients along the crypt–villus axis was analysed further. 
 
 
Figure 3.3: Proportion of TFs along the crypt–villus axis 
Distribution of total 428 TF genes along the crypt–villus axis based on their expression 
profiles, each criteria p < 0.05. 
 
 
 
 
Villus FC>3 
(73 TFs)
Crypt FC>3 
(68 TFs)
Crypt-villus 
FC<3 
(287 TFs)
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3.3 Discussion 
In this chapter, I investigated the genome-wide expression patterns of different 
genes using RNA derived from cells at the villus tip and cells from the crypts.  
As shown in previous studies, B0AT1 expression is higher at the villus tip than in 
the crypt region. To further analyse these two different regions, a modified version of a 
fractionation method developed by Traber et al. (Traber et al., 1991) was used. This 
method uses mechanical force (flushing of inverted intestine) to isolate intestinal 
epithelial cells from the crypts through villus tips. The method was employed 
successfully, as demonstrated by a significant enrichment of Slc6a19 mRNA in villus tip 
fractions and of the well-known intestinal stem cell marker Lgr5 in crypt fractions. Some 
limitations of the crypt–villus fractionation technique were observed. For instance, the 
technique appears to underrepresent cells derived from the very bottom of the crypt. 
Therefore, genes expressed in the crypt region may not be highly enriched in these 
fractions i.e. crypt genes such as Cdx2 and Tcf4 were found to be evenly expressed along 
the crypt–villus axis (Table 8.6). 
 
3.3.1 Pathway and GO analysis 
To gain insight into the biological processes underlying the expression of a specific 
set of genes at the villus tip, GO and KEGG pathway analyses were applied to the 
microarray data. These analyses confirmed that crypt and villus epithelial cells express 
entirely separate sets of genes. 
In mature enterocytes at the villus tip, many genes were expressed that are involved 
in nutrient and ion absorption. Accordingly, GO categories associated with transporter-
related genes were identified. This observation is consistent with earlier studies indicating 
that most genes associated with nutrient absorption were overrepresented in differentiated 
enterocytes (Mariadason, Nicholas et al. 2005, George, Wehkamp et al. 2008). A previous 
study also demonstrated that genes associated with lipid synthesis were up-regulated 
during crypt to villus differentiation (Stegmann, Hansen et al. 2006), which was 
confirmed by our microarray analyses. 
In the crypt compartment, GO and KEGG analyses, identified genes that are 
involved in DNA replication. It has been reported that DNA synthesis quickly shuts down 
during crypt to villus transition (Stegmann et al., 2006). It has also been shown that genes 
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related to the Wnt signalling pathways were highly expressed in crypt cells (Stegmann, 
Hansen et al. 2006, Sabates-Bellver, Van der Flier et al. 2007). Our analysis confirms 
these previous reports. 
 
3.4 Summary 
In summary, these results showed significant alterations in expression of genes 
related to TFs and signalling pathways during the crypt–villus differentiation. More 
importantly, the analysis provides us with TF candidates that may control villus-specific 
regulation of the B0AT1 transporter in mouse intestine. Our results further showed that 
the fractionation method successfully isolated crypt–villus cell populations. 
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Chapter 4      Transcriptional regulation of Slc6a19 gene along 
the crypt–villus axis 
 
4.1 Introduction 
Finger-like protrusions, called villi, expand the intestinal epithelial surface area. 
Crypts are located at the base between villi. The crypt–villus axis is an important 
structural feature of the intestinal surface. Intestinal stem cells reside at the bottom of the 
crypts. Mature intestinal cells localise along the crypt–villus axis. Continuous division of 
stem cells generates new cells, which differentiate into absorptive enterocytes or secretory 
cells (see Section 1.2.1) while migrating up towards the villus tip. Intestinal secretory 
cells are categorised as enteroendocrine cells, goblet cells, Paneth cells and tuft cells 
(Barker and Clevers, 2007). 
Previously, it was shown that B0AT1 is highly expressed on the apical membrane 
of intestinal enterocytes (Bröer et al., 2004). While the functional properties of the protein 
have been extensively characterized and its physiological role in different organs has been 
elucidated, the transcriptional regulation underlying its localised expression has not been 
investigated. TFs play key roles in controlling cell differentiation along the crypt–villus 
axis (Figure 4.1). Some of the TFs that are involved in intestinal cell differentiation are 
summarised in the following paragraphs. 
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Figure 4.1: Distribution of differentiated intestinal cells along the crypt–villus axis 
Transcription factors depicted in boxes control cell-type-specific gene expression 
required for cell differentiation; from (Gerbe et al., 2011). 
 
4.1.1.1 Hepatocyte nuclear factors 
The transcription factors HNF1a (see Section 1.3.2.3) and HNF4a (see Section 
1.3.2.4) are necessary for hepatocyte development, but they are also expressed in the 
kidney, intestine and pancreas (Sladek et al., 1990, Pontoglio et al., 1996). In the kidney 
both TFs are exclusively expressed in the proximal tubules (Pontoglio et al., 1996). 
HNF1a and HNF4a are highly expressed in the crypts and villi, and are important for 
crypt formation (Sauvaget et al., 2002). HNF1a has a dimerization domain, a DNA-
binding domain and a transactivation domain (Chouard et al., 1990). Another important 
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hepatocyte nuclear factor is HNF1b, which controls terminal cell differentiation of stems 
cells into mature enterocytes (D'Angelo et al., 2010). 
4.1.1.2 SPDEF 
SPDEF is a member of the Ets (E26 transformation-specific) family of TFs and is 
expressed in cells residing in crypts. SPDEF is particularly important for maturation of 
intestinal goblet and Paneth cells (Figure 4.1) (Gregorieff et al., 2009). 
4.1.1.3 SOX9 
In the intestine, SOX9 (see Section 1.3.2.1) is expressed in the progenitor cells 
located in the crypts. SOX9 is required for differentiation of stem cells into Paneth cells 
and goblet cells (Figure 4.1) (Bastide et al., 2007). As mentioned in Section 1.3.2.2, 
SOX9 is crucial for β-catenin/Wnt interaction, which is essential for crypt–villus 
formation (Sato et al., 2009). SOX9 is known to inhibit Cdx2 and Muc2 genes in the 
crypts; both proteins are expressed in the villus where SOX9 is not expressed (Blache et 
al., 2004). 
4.1.1.4 NEUROG3 
Neurogenin 3 (NEUROG3) is required for enteroendocrine cell development in the 
gastrointestinal tract and the pancreas (Figure 4.1) (Wang et al., 2006). 
4.1.1.5 FOXA2 
Forkhead box protein a2 (FOXA2) belongs to the forkhead class of DNA-binding 
proteins and is widely expressed in mouse intestinal crypts (Besnard et al., 2004). Foxa2 
can activate Muc2, which encodes mucin secreted by the goblet cells. Foxa2 is important 
for regulation of goblet cell differentiation (Ye and Kaestner, 2009). 
4.1.1.6 CDX2 
CDX2 contains a homeobox domain that is required for the development and 
differentiation of the intestine (Lorentz et al., 1997). Sucrase–isomaltase (SI) was one of 
the first genes the expression of which along the crypt–villus axis was characterized in 
detail. These studies suggested that HNF1a and CDX2 are regulating gene activation 
(Traber, 1990). Similarly, HNF1a and CDX2 also regulate the lactase-phlorizin hydrolase 
(LPH) gene transcription in the intestine (Mitchelmore et al., 2000). 
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4.1.1.7 GATA4 
GATA4 is a member of the zinc-finger family of TFs. GATA4 and HNF1a are 
necessary for expression of epithelial genes involved in nutrient absorption (Bosse et al., 
2007). Together with CDX2, these TFs regulate many of the enterocyte-specific genes in 
the mammals (Benoit et al., 2010). 
 
4.2 Results  
4.2.1 Prediction of putative nuclear receptor response elements in the Slc6a19 
promoter 
To identify relevant TFs and their binding sites on the Slc6a19 (GenBank® 
accession number NM_028878) promoter, the UCSC Genome Browser 
(www.genome.ucsc.edu) was used (see Section 2.5.1). Fifteen different species were 
examined. Bioinformatic analysis revealed that a region located between –1960 and +57 
of the TSS was conserved to some extent (Figure 4.2.A). Furthermore, another region 
close to the TSS was highly conserved (–228 to +57) among the different species (Figure 
4.2.B). Therefore, in our studies, we targeted a 2.5 kb fragment of this region of the 
promoter sequence.  
The proximal promoter of the mouse Slc6a19 gene, as judged by conservation of 
the sequence across mammalian species, was relatively short, i.e. 228 bp. It is a typical 
class II promoter where the TSS is preceded by a TATA-binding motif (Weaver, 2012) 
at position –23 to –28 and a reasonably conserved transcription factor IIB recognition 
motif (position –39 to –46), comprising the binding sites for general TFs and for 
polymerase II (Weaver, 2012). The TSS CCACTT is similar to the mammalian consensus 
initiator sequence (Weaver, 2012). 
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A 
 
B 
 
Figure 4.2: Promoter sequence alignment of Slc6a19 
The UCSC Genome Browser was used for sequence alignment. The alignments include Slc6a19 sequences from 15 species spanning position –2494 to 
+57 (A) and at higher resolution position –352 to +57 (B). Black domains indicate conserved regions when compared to the rat sequence. 
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Subsequently, the MatInspector program was used to identify TF candidates that 
potentially bind to this region. The MatInspector program found 227 different TF-binding 
sites in a 2.5 kb region upstream of the Slc6a19 TSS. Candidates (see Section 3.2.1.4) 
with robust microarray expression along the crypt–villus axis (Table 4.1) were analysed 
further. 
 
Table 4.1: Expression of candidate TFs in crypts or villi 
TFs with robust expression in either crypts or villi are shown. GATA4, HNF1b and PAX4 
are listed because they have been previously implicated in enterocyte maturation but do 
not have predicted promoter binding sites. A matrix number of 1.00 indicates an exact 
match with the TF consensus binding site, whereas 0.75 is considered a possible binding 
site for a TF. Revised location indicates results from mutagenesis data (shown below). 
The ratio of mRNA abundance along the crypt–villus axis was determined by microarray 
analysis. BS# was used to discriminate multiple binding sites. 
 
TFs Position Strand Matrix 
Revised 
Location Effect 
Ratio 
Villus/Crypt 
(Microarray) 
ATF4 –1212/–1204 – 0.99  0 0.90 
CDX2 –36/–18 – 0.92  0 0.52 
CDX2 –1212/–1194 – 0.87  0 0.52 
CDX2 –1833/–1815 + 0.86  0 0.52 
CREB3L3 –89/–69 + 0.95  0 8.80 
EGR1 –167/–151 + 0.89  0 0.11 
EGR1 –2112/–2096 + 0.86  0 0.11 
FOXA2 –305/–289 – 0.99  0 0.32 
FOXA2 –835/–819 – 0.99  0 0.32 
GATA4 – – –  0 0.91 
HNF1a–BS1 –126/–110 – 0.81 –126/–110 ++ 0.96 
HNF1a–BS2  –153/–137 + 0.89  0 0.96 
HNF1a–BS3 –1205/–1189 – 0.90  0 0.96 
HNF1b – – – – – – 
HNF4a–BS1 –239/–215 – 0.85 –41/–38 +++ 1.10 
HNF4a–BS2 –1368/–1344 + 0.93  0 1.10 
HNF4a–BS3 –1701/–1677 + 0.88  0 1.10 
NEUROG3 –2352/–2340 + 0.96  0 0.18 
NEUROG3 –2474/–2462 + 0.98  0 0.18 
PAX4 – – –  0 0.36 
SMAD3 –228/–218 + 0.99  0 0.66 
SMAD3 –2016/–2006 + 0.99  0 0.66 
SOX9–BS1 –47/–23 + 0.77 –218/–215 0/– (on 
HNF 
activated 
promoter) 
0.05 
SOX9–BS2 –1150/–1126 + 0.967  0 0.05 
SPDEF –27/–7 + 0.86 –195/–192 ++ 0.71 
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TFs Position Strand Matrix 
Revised 
Location Effect 
Ratio 
Villus/Crypt 
(Microarray) 
STAT3 –301/–283 + 0.77  0 10.6 
STAT3 –303/–285 – 0.76  0 10.6 
STAT3 –504/–486 – 0.97  0 10.6 
STAT3 –718/–700 + 0.95  0 10.6 
STAT3 –1044/–1026 – 0.959  0 10.6 
 
4.2.2 Analysis of possible TF candidates 
Twelve different TFs (Table 4.1) were identified as putative candidates regulating 
Slc6a19 transcription. Their functional regulatory effects on the Slc6a19 promoter 
activity were tested by luciferase reporter assays (see Section 2.6). GATA4, HNF1b and 
PAX4 were included because they have previously been identified as enterocyte 
differentiation regulators. 
HEK293 cells were co-transfected with the full-length Slc6a19 promoter pGL4(–
2494/+57) (see Section 2.6.2) and each of the predicted TFs separately, namely ATF4, 
CDX2, CREB3L3, EGR1, FOXA2, GATA4, HNF1a, HNF1b, HNF4a, NEUROG3, 
PAX4, SMAD3, SOX9, SPDEF, or STAT3 (Figure 4.3). 
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Figure 4.3: Effects of the different TFs on the Slc6a19 promoter activity 
HEK293 cells were co-transfected with three different plasmids. (i) Firefly luciferase 
inserted into pSlc6a19(–2494 to +57) (ii) Renilla luciferase in the control vector (iii) one 
of the following constructs: pcDNA3.1 carrier vector alone (blue bar), or pcDNA3.1 
expressing ATF4, CDX2, CREB3l3, EGR1, FOXA2, GATA4, HNF1a, HNF1b, HNF4a, 
NEUROG3, PAX4, SMAD3, SOX9, or SPDEF.  Twenty-four hours after transfection, 
luciferase activity was measured. Relative luciferase activity was determined by 
normalising the Firefly luciferase activity to the control Renilla luciferase activity. 
Transfections were repeated at least three times using triplicate samples. The data are 
means ± SD of triplicate experiments. (** p < 0.01). 
 
STAT3 is unique it has to be activated after co-transfection. When not activated, 
STAT3 is located in the cytoplasm (Kishimoto, 1993); however, after phosphorylation, it 
translocates into the nucleus. STAT3 phosphorylation can be triggered by interleukin-6 
(IL-6), a pro-inflammatory cytokine (Zhong et al., 1994). Two different constructs were 
used to express STAT3, namely, mouse STAT3–GFP and human STAT3, both inserted 
in a mammalian expression vector. Luciferase assays were hence performed after co-
transfection of STAT3 and treatment with IL-6 (20 ng/mL).  
Except for HNF1a, HNF4a, and SPDEF, none of the other candidates (Table 4.1) 
significantly activated the Slc6a19 promoter (Figure 4.3 and Figure 4.4).  
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Figure 4.4: Characterization of STAT3-mediated transcriptional activation by 
reporter gene assays 
HEK293 cells were co-transfected with three different plasmids. (i) Firefly luciferase 
inserted into pSlc6a19(–1703/+57) (ii) Renilla luciferase in the control vector (iii) one of 
the following constructs: mouse STAT3-GFP or human STAT3 empty pcDNA3.1 
expression vector. Cells were treated with IL-6 to activate STAT3. Twenty-four hours 
after transfection, luciferase activity was measured. Relative luciferase activity was 
determined by normalising the Firefly luciferase activity to the control Renilla luciferase 
activity. Transfections were repeated at least three times using triplicate samples. The 
data are means ± SD of triplicate experiments. 
 
4.2.3 HNF1a can activate the Slc6a19 promoter  
HNF1a is important for the differentiation of stem cells into epithelial cells in the 
intestine (D'Angelo et al., 2010). The MatInspector program predicted three different 
binding sites for HNF1a in the proximal region of the Slc6a19 promoter (Figure 4.5). 
These putative binding sites were located at positions; –111 to –114 (HNF1-BS1), –144 
to –147 (HNF1-BS2), and –1205 to –1189 (HNF1-BS3). To validate these binding sites, 
the Slc6a19 promoter deletion constructs were co-transfected with HNF1a expression 
vectors into HEK293 cells. Seven different deletion constructs were used: pSlc6a19(–
2494/+57), pSlc6a19(–1703/+57), pSlc6a19(–1380/+57), pSlc6a19(–972/+57), 
pSlc6a19(–437/+57), pSlc6a19(–136/+57), or pSlc6a19(–37/+57). 
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Figure 4.5: Locations of HNF1a-binding sites on the mouse Slc6a19 promoter 
Predicted HNF1a-binding sites are underlined and core binding sites indicated in red 
colour. The TATA box is marked by a box. The arrow indicates the TSS, designated as 
+1.  
 
Figure 4.6 shows that except for the shortest construct pSlc6a19 (–37/+57), HNF1a 
coexpression caused a three to fivefold higher activity than the background activity 
measured in the absence of HNF1a. Even a construct comprising just 136 bp upstream of 
the TSS was fully active in the presence of HNF1a. This suggests that an HNF1a-binding 
site is located between positions –136 to –37 bp on the Slc6a19 promoter. 
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Figure 4.6: Identification of the Slc6a19 promoter regions responsive to the HNF1a 
TF using luciferase reporter experiments in vitro 
HEK293 cells were co-transfected with vectors expressing the Firefly luciferase 
downstream of the Slc6a19 promoter deletion constructs and with the Renilla luciferase 
as control. HNF1a expression vector (red bars) or empty pcDNA3.1 expression vector 
(blue bars) was co-expressed to activate transcription or serve as control, respectively. 
The following promoter deletion constructs were used: pSlc6a19(–2494/+57), 
pSlc6a19(–1703/+57), pSlc6a19(–1380/+57), pSlc6a19(–972/+57), pSlc6a19(–437/+57), 
pSlc6a19(–136/+57), or pSlc6a19(–37/+57). Twenty-four hours after transfection, 
luciferase activity was measured. Relative luciferase activity was determined by 
normalising the Firefly luciferase activity to the control Renilla luciferase activity. P 
values indicate the significance derived from three experiments, each using triplicate 
transfections. The data are means ± SD of triplicate experiments. Significant increases of 
promoter activity due to co-transfection of HNF1a are indicated by asterisks (** p < 0.01).  
 
To further examine the putative HNF1a-binding sites, we mutated the sites 
identified by the MatInspector program. Site-directed mutagenesis (see Section 2.4.2.5) 
was used to mutate two predicted HNF1a-binding sites in the pSlc6a19(–136/+57) and 
pSlc6a19(–437/+57) promoter constructs. Mutation of the HNF1a-BS1 at (–111/–114) 
(Hnf1a-Mut1) diminished activity compared with the activity of the corresponding wild-
type promoter. The second mutation, HNF1-BS2 at (–144/–147) (HNF1a-Mut2), did not 
affect luciferase activity when co-transfected with HNF1a (Figure 4.7). The in vitro 
studies showed that the binding site at position –111 to –114 was responsible for 
expression of Slc6a19 in the presence by HNF1a. No evidence was found for 
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MatInspector program predicted binding sites (Table 4.1) at positions–153 to –137 
(HNF1-BS2) or –1205 to –1189 (HNF1a-BS3). 
 
 
Figure 4.7: Detection of HNF1a-binding sites using mutated constructs 
HEK293 cells were co-transfected with vectors expressing the Firefly luciferase 
downstream of the Slc6a19 promoter constructs and with the Renilla luciferase as control. 
HNF1a expression vector (red bars) or empty pcDNA3.1 expression vector (blue bars) 
was co-expressed to activate transcription or serve as control, respectively. The following 
promoter constructs were used: pSlc6a19(–1380/+57), pSlc6a19(–972/+57), pSlc6a19(–
437/+57), pSlc6a19(–136/+57), pSlc6a19(–437/+57)Mut2, pSlc6a19(–437/+57)Mut1, 
pSlc6a19(–136/+57)Mut1, or pSlc6a19(–37/+57). Twenty-four hours after transfection, 
luciferase activity was measured. Relative luciferase activity was determined by 
normalising the Firefly luciferase activity to the control Renilla luciferase activity. P 
values indicate the significance derived from three experiments, each using triplicate 
transfections. The data are means ± SD of triplicate experiments. Significant increases of 
promoter activity due to co-transfection of HNF1a are indicated by asterisks (* p < 0.05; 
** p < 0.01). 
 
To determine whether HNF1a could bind to the Slc6a19 promoter within living 
cells, chromatin immunoprecipitation (ChIP) assay was used. The ChIP assay was 
performed using chromatin fragments isolated from intestinal enterocytes (see Section 
2.9.1) and an antibody against HNF1a. Real-time PCR was subsequently performed to 
generate amplicons of 100-200 bp spanning the Slc6a19 promoter from position –1368 
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to +11. ChIP analysis revealed that the promoter region from –139 to +11 could bind to 
HNF1a (Figure 4.8). This result was consistent with the luciferase assay, which indicated 
the presence of an HNF1a-binding site at position –111 to –114. An additional binding 
site for HNF1a was detected between –984 and –812; this site could not be observed by 
the reporter gene assays. 
 
 
Figure 4.8: HNF1a directly binds to the Slc6a19 promoter 
ChIP assay was performed to identify proteins cross-linked to chromatin extracted from 
the mouse small intestinal epithelium. The chromatin was immunoprecipitated using an 
antibody against HNF1a. After DNA purification, the precipitated DNA was quantified 
by qPCR using primer sets specific for –139/+11, –353/–136, –495/–281, –501/–332, –
682/–502, –984/–812, –1236/–976, or –1368/–1255 regions. The lower part of the graph 
shows the location of primer pairs used in the real-time PCR. The upper part of the graph 
indicates that ChIP signals relative to the input signal. 
 
4.2.4 HNF4a activates the Slc6a19 promoter  
Our initial promoter experiment indicated that HNF4a is another activator of the 
Slc6a19 promoter (Figure 4.3). HNF4a was highly expressed along the crypt–villus axis 
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(Figure 4.18). Three HNF4a-binding sites were predicted using the MatInspector 
program at positions –239 to –215 (HNF4a-BS1), –1368 to –1344 (HNF4a-BS2), and –
1701 to –1677 (HNF4a-BS3). According to HNF4a consensus binding site (CAAAGT) 
(Wallerman et al., 2009), three additional binding sites were predicted by visual 
inspection at locations –1108 to –1105 (HNF4a-BS4), –1088 to –1085 (HNF4a-BS5), and 
–38 to –41 (HNF4a-BS6) (Figure 4.9). To confirm the possible binding sites in vitro, 
HNF4a was co-expressed with truncated Slc6a19 promoter constructs: pSlc6a19(–
2494/+57), pSlc6a19(–1703/+57), pSlc6a19(–1380/+57), pSlc6a19(–972/+57), 
pSlc6a19(–437/+57), pSlc6a19(–136/+57), or pSlc6a19(–37/+57). 
 
 
Figure 4.9: Location of putative HNF4a-binding sites on the Slc6a19 promoter 
Predicted binding sites for HNF4a are indicated on the Slc6a19 promoter sequence. The 
TATA box is highlighted by a box. The arrow indicates the TSS designated as +1. 
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Co-expression of HNF4a activated the promoter about 20-fold in the longest 
construct pSlc6a19(–2494/+57) (Figure 4.10). This activation dropped to fourfold in 
construct pSlc6a19(–972/+57). The smallest construct did not show any significant 
promoter activity. These results suggested the presence of at least two HNF4a-binding 
sites. 
 
 
Figure 4.10: HNF4a induces luciferase expression driven by the Slc6a19 promoter 
in vitro 
HEK293 cells were co-transfected with vectors expressing the Firefly luciferase 
downstream of the Slc6a19 promoter constructs and with the Renilla luciferase as control. 
HNF4a expression vector (red bars) or empty pcDNA3.1 expression vector (blue bars) 
was co-transfected to activate transcription or serve as control, respectively. The 
following promoter constructs were used: pSlc6a19(–2494/+57), pSlc6a19(–1703/+57), 
pSlc6a19(–1380/+57), pSlc6a19(–972/+57), pSlc6a19(–437/+57), pSlc6a19(–136/+57), 
or pSlc6a19(–37/+57). Twenty-four hours after transfection, luciferase activity was 
measured. Relative luciferase activity was determined by normalising the Firefly 
luciferase activity to the control Renilla luciferase activity. P values indicate the 
significance derived from three experiments, each using triplicate transfections. The data 
are means ± SD of triplicate experiments. Significant increases of the promoter activity 
due to co-transfection with HNF4a are indicated by asterisks (* p < 0.05; ** p < 0.01). 
N.S designates non-significant results. 
 
Functional expression analysis did not show a significant activity difference 
between the pSlc6a19(–1703/+57) and the pSlc6a19(–1380/+57) deletion constructs. 
Similarly, luciferase activity did not show any significant decrease when we deleted the 
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region spanning –437 to –136. Therefore, we concluded that the predicted HNF4a-BS3 
and HNF4a-BS1 sites were inactive in the in vitro assay system. Consequently, HNF4a-
BS2 is most likely the actual binding site of HNF4a. In addition, the results suggested 
that there should be another binding site located between –136 and –37, which was not 
identified by the MatInspector program. 
To determine the potential HNF4a-binding regions, we mutated their corresponding 
binding sites in the pSlc6a19(–1380/+57) and the pSlc6a19(–972/+57) reporter constructs 
(Figure 4.11). This included the atypical HNF4a-binding site between –136 and –37 
(HNF4a-BS6), which were accidentally discovered while searching for putative SOX9-
binding sites (Figure 4.19) on the Slc6a19 promoter.  
Figure 4.11: Determination of HNF4a-binding sites using mutated constructs 
HEK293 cells were co-transfected with vectors expressing the Firefly luciferase 
downstream of the Slc6a19 promoter constructs and with the Renilla luciferase as control. 
HNF4a expression vector (red bars) or empty pcDNA3.1 expression vector (blue bars) 
was co-expressed to activate transcription or serve as control, respectively. The following 
promoter constructs were used: pSlc6a19(–1380/+57), pSlc6a19(–1380/+57)Mut1, 
pSlc6a19(–1380/+57)Mut2, pSlc6a19(–1380/+57)Mut1,2, pSlc6a19(–972/+57), 
pSlc6a19(–972/+57)Mut1, pSlc6a19(–136/+57), or pSlc6a19(–37/+57). Twenty-four 
hours after transfection, luciferase activity was measured. Relative luciferase activity was 
determined by normalising the Firefly luciferase activity to the control Renilla luciferase 
activity. P values indicate the significance derived from three experiments, each using 
triplicate transfections. The data are means ± SD of triplicate experiments. Significant 
increases of promoter activity due to co-transfection of HNF4a are indicated by asterisks 
(* p < 0.05; ** p < 0.01). N.S designates non-significant results. 
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Mutation of the HNF4a-BS6 binding site on the shorter construct pSlc6a19(–
972/+57), completely suppressed HNF4a-induced activation of the Slc6a19 promoter. A 
very short promoter deleted upstream of position –37, did not induce luciferase activity. 
However, mutating the predicted HNF4a-binding site, HNF4a-BS2, on pSlc6a19(–
1380/+57) did not reduce the reporter gene activity (Figure 4.11).  
When we deleted the region from –1380 to –972, the luciferase activity was 
significantly reduced (Figure 4.11). Furthermore, reducing the distance between both 
HNF4a-binding sites increased reporter gene activity, suggesting that both sites were 
functional (Figure 4.12). These suggest the presence of another functional binding site 
for HNF4a between –1380 to –972. 
 
 
Figure 4.12: Reducing the distance between HNF4a-binding sites enhances in vitro 
luciferase expression driven by the Slc6a19 promoter 
HEK293 cells were co-transfected with vectors expressing the Firefly luciferase 
downstream of the Slc6a19 promoter constructs and with the Renilla luciferase as control. 
HNF4a expression vector (red bars) or empty pcDNA3.1 expression vector (blue bars) 
was co-transfected to activate transcription or serve as control, respectively. The 
following promoter constructs were used: pSlc6a19(–2494/+57), pSlc6a19(–972/+57), or 
pSlc6a19(–2494/+57)[–812/–136]. Twenty-four hours after transfection, luciferase 
activity was measured. Relative luciferase activity was determined by normalising the 
Firefly luciferase activity to the control Renilla luciferase activity. The experiment was 
performed three times, each using triplicate transfections. The data are means ± SD of 
triplicate experiments. Significant increases of promoter activity due to co-transfection of 
HNF4a are indicated by asterisks (* p < 0.05; ** p < 0.01). 
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As a result, we predicted and mutated two further putative sites, namely HNF4a-
BS4(–1105/–1108) and HNF4a-BS5(–1085/–1088) (Figure 4.9), and prepared more 
targeted deletion constructs to identify the second HNF4a-binding site. The deletion 
constructs showed a significant drop in reporter gene activity between –1226 to –1078. 
However, mutating HNF4a-BS4 and HNF4a-BS5 (HNF4a-Mut3 and HNF4-Mut4) did 
not reduce the luciferase activity (Figure 4.13). 
 
 
Figure 4.13: Detection of the second putative HNF4a-binding site using mutated 
constructs 
HEK293 cells were co-transfected with vectors expressing the Firefly luciferase 
downstream of the Slc6a19 promoter constructs and with the Renilla luciferase as control. 
HNF4a expression vector (red bars) or empty pcDNA3.1 expression vector (blue bars) 
was co-expressed to activate transcription or serve as control, respectively. The following 
promoter constructs were used: pSlc6a19(–1380/+57), pSlc6a19(–1316/+57), pSlc6a19(–
1226/+57), pSlc6a19(–1078/+57), pSlc6a19(–1380/+57)Mut4, pSlc6a19(–
1380/+57)Mut3, pSlc6a19(–972/+57), pSlc6a19(–136/+57), or pSlc6a19(–37/+57). 
Twenty-four hours after transfection, luciferase activity was measured. Relative 
luciferase activity was determined by normalising the Firefly luciferase activity to the 
control Renilla luciferase activity. Transfections were repeated at least three times using 
triplicate samples. The data are means ± SD of triplicate experiments. Significant 
increases of the promoter activity due to co-transfection of HNF4 are indicated by 
asterisks. (* p < 0.05; ** p < 0.01)  
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To verify whether HNF4a binds to the putative binding sites on the Slc6a19 
promoter in intact tissue, ChIP assays were performed. Cross-linked chromatin, isolated 
from scraped mouse intestinal mucosa, was used for ChIP assays. The intestinal 
enterocyte chromatin was immunoprecipitated using an antibody against HNF4a. 
Immunoprecipitated DNA was analysed by real-time PCR amplification generating 
amplicons of 100-250bp spanning position –1368 to +11 of the Slc6a19 promoter, as 
shown in Figure 4.14. ChIP analysis of this DNA fragment showed that the two primer 
sets covering the region –353 to +11 showed the strongest signal for HNF4a-binding 
(Figure 4.14). This result confirmed the putative HNF4a-binding site at position –38 to 
–41, but failed to confirm any other strong binding site between –1226 and –1078.  
 
Figure 4.14: HNF4a directly binds to the Slc6a19 promoter 
ChIP assay was performed on cross-linked chromatin isolated from the mouse small 
intestine epithelium. Chromatin was immunoprecipitated using an antibody against 
HNF4a. After purification, the precipitated DNA was quantified by qPCR using primer 
sets specific for –139/+11, –353/–136, –495/–281, –501/–332, –682/–502, –984/–812, –
1236/–976, or –1368/–1255 regions. The lower part of the graph shows the corresponding 
location of primer pairs used in the real-time PCR. The upper part of the graph presents 
that the ChIP signal relative to the input signal. 
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4.2.5 Synergistic effects of HNF1a and HNF4a co-transfection on the Slc6a19 
promoter activity 
It has previously been reported that HNF1a and HNF4a can act synergistically to 
transcriptionally activate human α1-antitrypsin (α1-AT), UDP glucuronosyltransferase 1 
family-polypeptide A9 (UGT1A9), and dihydrodiol dehydrogenase (DD4) (Eeckhoute et 
al., 2004, Ozeki et al., 2001, Hu and Perlmutter, 1999).  
To determine whether HNF1a and HNF4a could also synergistically activate the 
Slc6a19 promoter, both TFs were co-expressed in HEK293 cells (Figure 4.15). The 
experiment showed that co-expression of HNF1a and HNF4a did not increase the 
luciferase activity more than HNF4a-induced promoter activity alone.  
Another study suggested synergistic action between HNF1a and Cdx2 at the 
lactase-phlorizin hydrolase (LPH) promoter (Mitchelmore et al., 2000). However, co-
expression of HNF1a and Cdx2 using our Slc6a19 reporter gene constructs did not 
significantly increase the luciferase activity compared to HNF1a-induced activity alone 
(Figure 4.15). CDX2 alone could not activate Slc6a19 transcription (Figure 4.3).  
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Figure 4.15: The combinatorial effect of CDX2 and HNF TFs on the Slc6a19 
promoter activity 
HEK293 cells were co-transfected with vectors expressing the Firefly luciferase 
downstream of the promoter construct pSlc6a19(–2494/+57), together with various TFs 
and with the Renilla luciferase as control. The following combinations were used: HNF1a 
expression vector, HNF1a plus CDX2, HNF4a, HNF1a plus HNF4a, or empty pcDNA3.1 
expression vector (blue bar). Twenty-four hours after transfection, the luciferase activity 
was measured. Relative luciferase activity was determined by normalising the Firefly 
luciferase activity to the control Renilla luciferase activity. Transfections were repeated 
at least three times using triplicate samples. The data are means ± SD of triplicate 
experiments. 
 
4.2.6 SPDEF can activate Slc6a19 transcription in vitro  
According to the microarray data, SPDEF was highly expressed in the intestinal 
villus (Figure 4.18) and could therefore be a candidate TF to activate the Slc6a19 
promoter. Furthermore, the MatInspector program predicted that the Slc6a19 promoter 
contains a putative SPDEF-binding site located between –27 bp to –7 bp (SPDEF-BS1) 
(Figure 4.16).  
Luciferase assays, however, indicated that SPDEF-induced reporter gene activity 
dropped to background activity when deletions passed beyond position –201 (Figure 
4.17). No further loss could be detected in the smallest construct pGL4(–136/+57), which 
contained the predicted SPDEF-binding region. The pGL4(–136/+57) construct also 
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could not be activated by co-expression of SPDEF, suggesting that the potential binding 
site was likely located upstream of the predicted site. 
The consensus binding site for mouse SPDEF has previously been confirmed (Wei 
et al., 2010) to be the sequence CCGGAT. A similar site (CAGGAT) was identified in 
the Slc6a19 promoter at position –183 to –180 (SPDEF-BS2) (Figure 4.16).  
 
 
Figure 4.16: Predicted binding sites for the mouse SPDEF 
Two putative SPDEF-binding sites are shown in red letters. Both sites were mutated to 
test their relevance. 
 
Luciferase activity was measured to investigate the two putative SPDEF-binding 
sites. The assays showed a sevenfold and sixfold increase in activity of the pSlc6a19(–
437/+57) and pSlc6a19(–201/+57) promoter constructs, respectively, when SPDEF was 
co-expressed (Figure 4.17). Slc6a19 promoter activity was abolished by mutation of the 
second proposed SPDEF-BS2 binding site. Accordingly, a deletion upstream of position 
–136 bp abolished the effect of SPDEF on Slc6a19 promoter activity. This experiment 
demonstrates that SPDEF, similar to HNF1a and HNF4a is sufficient to activate the 
Slc6a19 promoter in the HEK293 cells. 
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Figure 4.17: SPDEF induces in vitro luciferase activity driven by the Slc6a19 
promoter 
HEK293 cells were co-transfected with vectors expressing the Firefly luciferase 
downstream of the Slc6a19 promoter constructs and with the Renilla luciferase as control. 
SPDEF expression vector (red bars) or empty pcDNA3.1 expression vector (blue bars) 
was co-transfected to activate transcription or serve as control, respectively. The 
following promoter constructs were used: pSlc6a19(–437/+57), pSlc6a19(–201/+57), 
pSlc6a19(–201/+57)[mutated], or pSlc6a19(–136/+57). Twenty-four hours after 
transfection, the luciferase activity was measured. Relative luciferase activity was 
determined by normalising the Firefly luciferase activity to the control Renilla luciferase 
activity. P values indicate the significance derived from three experiments, each using 
triplicate transfections. The data are means ± SD of triplicate experiments. Significant 
increases of promoter activity due to co-transfection of SPDEF are indicated by asterisks 
(* p < 0.05; ** p < 0.01).  
 
4.2.7 Identification of possible repressor(s) along the crypt–villus axis 
The in vitro and in vivo experiments indicated that SPDEF, HNF1a and HNF4a 
strongly activated B0AT1 transcription in the mouse intestine. qPCR was used to confirm 
the relative expression of TFs in the villus and the crypt as determined by microarray for 
some of the most prominent TFs (Table 4.1). Fractionation experiments followed by 
qPCR showed robust transcript levels of HNF1a and HNF4a along the crypt-villus axis 
(Figure 4.18A). HNF1a and HNF4a expression was high in the crypt region, but marked 
expression remained in villus cells. 
All TF candidates tested thus far had higher levels of expression in crypts as 
ascertained by qPCR and microarray analysis (Table 4.1). Thus, Slc6a19 mRNA 
expression in the villus cells could not be explained by a corresponding expression of 
SPDEF, HNF1a, or HNF4a.  
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Genome-wide analyses showed that 68 TFs had robust expression in the intestine 
and were expressed at significantly higher levels (ratio > 3) in the villus than in the crypt 
(Table 8.6). Of these, only STAT3 and CREB3L3 have putative binding sites on the 
Slc6a19 promoter. However, co-transfection of STAT3 and CREB3L3 failed to activate 
reporter gene expression (Figure 4.3). Consequently, we hypothesized that other TF(s) 
might supress Slc6a19 expression in the crypts. 
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A  
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Figure 4.18: Expression profiles of putative TFs in the villus and crypt as determined 
by qPCR and microarray studies 
(A) Expression levels of Hnf1a, Hnf4a and Sox9 are shown in consecutive fractions 
derived from mouse small intestine (F1 villus tip – F7 crypts). (B) Microarray results 
showing expression levels in crypt and villus fractions. 
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4.2.8 Analysis of SOX9-binding on Slc6a19 promoter  
The TF Sox9 was particularly lowly expressed in the villus compared to crypt 
fractions (Figure 4.18.A). Microarray results confirmed expression patterns similar to 
those obtained by qPCR analyses (Figure 4.18.B). Moreover, it was markedly expressed 
in hepatic and pancreatic tissues (Mori-Akiyama et al., 2007, Kanai and Koopman, 1999), 
which do not express Slc6a19 similarly to intestinal crypts. 
The pGL4(–2494/+57) promoter construct contains two predicted SOX9-binding 
sites at positions between –37 and –34 (SOX9-BS1), and between –1150 and –1126 
(SOX9-BS2) (Figure 4.19). To elucidate the effects of SOX9 on the regulation of Slc6a19 
promoter activity, SOX9 was co-expressed in HEK293 cells.  
 
 
Figure 4.19: Predicted binding sites for SOX9 on the mouse Slc6a19 promoter 
The two predicted SOX9-binding sites on the Slc6a19 proximal promoter region are 
indicated in red. The predicted TATA box and TSS (+1) are also shown. 
 
Luciferase reporter assays showed that SOX9 did not activate Slc6a19 transcription 
(Figure 4.3). However, when this TF was co-transfected with either HNF1a (Figure 4.20) 
or HNF4a (Figure 4.21), it strongly inhibited the promoter activity as long as the 
predicted SOX9-binding site BS1 was included in the tested construct.  
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Figure 4.20: SOX9 inhibits in vitro luciferase activity induced by HNF1a 
HEK293 cells were co-transfected with vectors expressing the Firefly luciferase 
downstream of the Slc6a19 promoter constructs, with the Renilla luciferase as control. 
HNF1a expression vector (purple bars) or empty pcDNA3.1 expression vector (red bars) 
was co-expressed to activate transcription or serve as control, respectively. In a separate 
experiment, SOX9 was expressed together with HNF1a (orange bars). The following 
promoter constructs were used: pSlc6a19(–1380/+57), pSlc6a19(–972/+57), pSlc6a19(–
437/+57), pSlc6a19(–136/+57), or pSlc6a19(–37/+57). Twenty-four hours after 
transfection, luciferase activity was measured. Relative luciferase activity was 
determined by normalising the Firefly luciferase activity to the control Renilla luciferase 
activity. P values indicate the significance derived from three experiments, each using 
triplicate transfections. The data are means ± SD of triplicate experiments. Significant 
changes in promoter activity due to co-transfection of SOX9 are indicated by asterisks (* 
p < 0.05; ** p < 0.01). N.S designates non-significant results. 
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Figure 4.21: SOX9 inhibits luciferase expression activated by HNF4a in vitro 
HEK293 cells were co-transfected with vectors expressing the Firefly luciferase 
downstream of the Slc6a19 promoter constructs and with the Renilla luciferase as control. 
HNF4a expression vector (purple bars) or empty pcDNA3.1 expression vector (blue bars) 
was co-expressed to activate transcription or serve as control, respectively. In a separate 
experiment, SOX9 was co-expressed with HNF4a (green bars). The following promoter 
constructs were used: pSlc6a19(–1380/+57), pSlc6a19(–972/+57), pSlc6a19(–437/+57), 
pSlc6a19(–136/+57), or pSlc6a19(–37/+57). Twenty-four hours after transfection, 
luciferase activity was measured. Relative luciferase activity was calculated by 
normalising the Firefly luciferase activity relative to the control Renilla luciferase activity. 
Transfections were repeated at least three times using triplicate samples. The data are 
means ± SD of triplicate experiments. Significant changes of the promoter activity due to 
co-transfection of SOX9 are indicated by asterisks (* p < 0.05; ** p < 0.01). N.S 
designates non-significant results. 
 
We were unable to analyse mutation of SOX9-binding site SOX9-BS1 (–37 to –34), 
because the proposed SOX9-BS1 binding site overlaps with the HNF4a-binding site 
(Figure 4.22); mutation of this site also abolishes activation by HNF4a. As shown in 
Figure 4.20 and Figure 4.21, deletion of the SOX9-BS2 region (–1150 to –1126) did not 
abolish the inhibitory effect of SOX9 on Slc6a19 promoter constructs –972/+57, –
437/+57, and –136/+57, respectively. 
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Figure 4.22: Investigation of the putative SOX9-binding site using wild-type and 
mutated pSlc6a19(–972/+57) constructs 
HEK293 cells were co-transfected with Renilla luciferase as control and with vectors 
expressing the Firefly luciferase downstream of the promoter construct pSlc6a19(–
972/+57) or the same construct with mutated SOX9-BS1. In addition different 
transcription factors were co-expressed. The following constructs were used: HNF1a 
expression vector (orange bars), HNF4a (green bars), HNF1a plus SOX9 (grey bars), or 
empty pcDNA3.1 expression vector (red bars). Twenty-four hours after transfection, the 
luciferase activity was measured. Relative luciferase activity was determined by 
normalising the Firefly luciferase activity to the control Renilla luciferase activity. 
Transfections were repeated at least three times using triplicate samples. The data are 
means ± SD of triplicate experiments. (* p < 0.05; ** p < 0.01). 
 
To further validate the reporter gene results, SOX9-binding to the Slc6a19 promoter 
was tested in isolated mouse intestinal cells by ChIP assay using cross-linked mouse 
intestinal chromatin. Chromatin fragments were immunoprecipitated using a polyclonal 
antibody against SOX9 and the Slc6a19 promoter was detected by real-time PCR 
generating amplicons of 150-200 bp spanning the promoter region from position –1368 
to +11.  
These experiments (Figure 4.23) suggested that the SOX9 binding site was located 
between position –353 to –136 confirming findings by luciferase assays. The precise 
location, however, could not be determined. 
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Figure 4.23: SOX9 directly binds to the Slc6a19 promoter 
ChIP assay was used to identify SOX9-binding sites on cross-linked chromatin isolated 
from mouse small intestinal epithelium. The chromatin was immunoprecipitated using an 
antibody against SOX9. After purification, the precipitated DNA was quantified by qPCR 
using primer sets specific for –139/+11, –353/–136, –495/–281, –501/–332, –682/–502, 
–984/–812, –1236/–976, or –1368/–1255. The lower part of the graph shows the location 
of primer pairs used in the real-time PCR. The upper part of the graph shows the ChIP 
signal relative to the input signal. 
 
SOX9 has been shown to recognise an ACAA motif to regulate transcription 
(Harley et al., 1994) (Figure 4.24.A). Further inspection of the proximal promoter 
revealed possible binding sites at positions +10/+13 (SOX9-BS3) and –218/–215 (SOX9-
BS4) (Figure 4.24.B).  
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Figure 4.24: Predicted binding sites for SOX9 
(A) Weblogo presentation of the SOX9 consensus sequence. (B) Location of predicted 
SOX9-binding on the Slc6a19 promoter.  
 
To check whether these binding sites could be targeted by SOX9, site-directed 
mutagenesis was performed. SOX9-BS3 mutation did not change the effect of SOX9 on 
luciferase activity. However, mutation of the SOX9-BS4 site increased the overall 
promoter activity and partially abrogated the effect of SOX9 regardless of whether 
transcription was driven by HNF1a or HNF4a (Figure 4.25). 
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Figure 4.25: Investigation of the SOX9-binding sites using mutated constructs. 
HEK293 cells were co-transfected with vectors expressing the Firefly luciferase 
downstream of the promoter constructs, together with various transcription factors and 
with the Renilla luciferase as control. The following constructs were used: pSlc6a19(–
437/+57), SOX9-BS3 mutated pSlc6a19(–437/+57), SOX9-BS4 mutated pSlc6a19(–
437/+57), together with HNF1a expression vector (orange bars), HNF1a plus SOX9 (grey 
bars), HNF4a (green bars), HNF4a plus SOX9 (red bars), or empty pcDNA3.1 expression 
vector (black bars). The Renilla luciferase was used as control vector. Twenty-four hours 
after transfection, the luciferase activity was measured. Relative luciferase activity was 
determined by normalising the Firefly luciferase activity to the control Renilla luciferase 
activity. Transfections were repeated at least three times using triplicate samples. The 
data are means ± SD of triplicate experiments. (* p < 0.05; ** p < 0.01). 
 
Mutation of SOX9-BS4 did not completely abolish the inhibitory effect of SOX9, 
suggesting that this TF may affect transcription indirectly, for instance by binding to other 
TFs. To test whether the SOX9 effect required direct binding to the promoter region, the 
SOX9 DNA-binding domain was mutated. To this end, a well-known SOX9 mutation, 
H65Y, was chosen (McDowall et al., 1999), which affects its target sequence binding. 
The experiments indicated that the inhibitory effect of SOX9 was weakened but not 
completely abolished (Figure 4.26). This suggested that SOX9 may inhibit transcription 
through interaction with the promoter region and through protein-protein interaction with 
other TFs, such as HNF1a and HNF4a. 
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Figure 4.26: The effect of SOX9(H65Y) on the pSlc6a19(–437/+57) 
HEK293 cells were co-transfected with vectors expressing the Firefly luciferase 
downstream of the promoter construct pSlc6a19(–437/+57), together with different TFs 
and with the Renilla luciferase as control. The following combinations were used: HNF4a 
expression vector, HNF4a plus SOX9, HNF4a plus SOX9(H65Y), HNF1a, HNF1a plus 
SOX9, HNF1a plus SOX9(H65Y), or empty pcDNA3.1 expression vector (red bar). 
Twenty-four hours after transfection, luciferase activity was measured. Relative 
luciferase activity was determined by normalising the Firefly luciferase activity to the 
control Renilla luciferase activity. P values indicate the significance derived from three 
experiments, each using triplicate transfections. The data are means ± SD of triplicate 
experiments. Significant changes of the promoter activity due to co-transfection of 
HNF1a and HNF4a are indicated by asterisks (* p < 0.05; ** p < 0.01).  
 
To further investigate whether some of the SOX9 effects are independent of DNA-
binding, SOX9(H65Y) was co-transfected with a promoter containing a mutated SOX9-
binding site 4 which completely abolished the inhibitory effect of SOX9 (Figure 4.27). 
This result suggested that SOX9 can act both as a sequence-specific transcription factor 
and as an inhibitory cofactor. In summary SOX9 acts as powerful inhibitor of HNF4a and 
HNF1a-driven Slc6a19 expression. 
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Figure 4.27: The combinatorial effects of SOX9(H65Y) and SOX9-binding-site 
mutation on pSlc6a19(–437/+57) 
HEK293 cells were co-transfected with vectors expressing the Firefly luciferase 
downstream of promoter construct SOX9-BS4 mut/pSlc6a19(–437/+57), together with 
different TFs and with the Renilla luciferase as control. The combinations used were: 
HNF1a expression vector, HNF1a plus SOX9, HNF1a plus SOX9(H65Y), HNF4a, 
HNF4a plus SOX9, HNF4a plus SOX9(H65Y), or empty pcDNA3.1 expression vector 
(red bar). Twenty-four hours after transfection, luciferase activity was measured. Relative 
luciferase activity was determined by normalising the Firefly luciferase activity to the 
control Renilla luciferase activity. P values indicate statistical significance derived from 
three experiments, each using triplicate transfections. The data are means ± SD of 
triplicate experiments. Significant changes of promoter activity due to co-transfection of 
HNF4a and HNF1a are indicated by asterisks (* p < 0.05; ** p < 0.01).  
 
4.2.9 Analysis of mouse Collectrin and Ace2 promoters 
To explain regulatory mechanisms driving ACE2 (Ace2) and TMEM27 (Collectrin) 
co-expression (see Section 1.4.3) with B0AT1 in kidney and intestine, we analysed their 
promoter regions. To determine the length and position of the Ace2 and Collectrin 
promoters and to determine highly conserved regions, bioinformatics was used to analyse 
promoter regions of the genes encoding Collectrin (NM_020626) and Ace2 (NM_027286) 
upstream of their corresponding TSSs. As a result, a sequence 1450 kb upstream of the 
Ace2 TSS (Figure 4.28.A) and another sequence 1800 bp upstream of the Collectrin TSS 
(Figure 4.28.B) were chosen.  
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Figure 4.28: Sequence alignment of promoters of Collectrin and Ace2 from different species 
Alignments were generated using the UCSC Genome Browser. Black domains indicate conserved regions in different species. Regions 1.5 kb 
upstream of the Ace2 TSS (A) and 2 kb upstream of the Collectrin TSS (B) were analysed. 
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The distributions of putative TF-binding sites on the Collectrin and Ace2 
promoters were examined by the MatInspector program. Possible binding sites for 
HNF1a, HNF1b and HNF4a, but not SOX9, were found on the Collectrin promoter 
(Table 8.4). The Ace2 promoter had binding sites for HNF1a and HNF4a, but not HNF1b 
or SOX9 (Table 8.5). 
To test whether the Tmem27 and Ace2 promoters were controlled by similar 
regulatory elements as the Slc6a19 promoter, a region 2 kb upstream of the Tmem27 TSS 
and another 1.5 kb upstream of the Ace2 TSS were inserted separately into the pGL4.12 
firefly luciferase reporter plasmid (see Section 2.6.3). Subsequently, HEK293 cells were 
co-transfected with reporter gene constructs and TFs previously identified to regulate the 
Slc6a19 promoter (Figure 4.29).  
Similar to Slc6a19, Tmem27 and Ace2 promoters were markedly transactivated 
by HNF1a and HNF1b transcription factors and these effects were suppressed by SOX9. 
However, HNF4a, did not activate Tmem27 and Ace2 promoters. While HNF1b did not 
affect the Slc6a19 promoter. Despite these differences Slc6a19 and Ace2 are co-expressed 
in enterocytes (Kowalczuk et al., 2008), confirming the synergistic action of HNF1a and 
HNF4a in the intestinal epithelium (Shih et al., 2001).
  
117 
 
A  Collectrin 
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Figure 4.29 Effects of the different TFs on Collectrin and Ace2 promoters 
HEK293 cell were co-transfected with the Firefly luciferase inserted in (A) 
pCollectrin(–1903/+76) and (B) pAce2(–1509/+170) together with the Renilla 
luciferase vector as control. In addition, the following constructs were co-transfected 
separately: empty pcDNA3.1 (black bar), or pcDNA3.1 expressing HNF1a, HNF1a 
plus SOX9, HNF4a, HNF1b, SPDEF, CDX2, ATF4, PAX4, GATA4, CREB3L3, 
EGR1, FOXA2, NEUROG3, or SMAD3. Twenty-four hours after transfection, the 
luciferase activity was measured. Relative luciferase activity was determined by 
normalising the Firefly luciferase activity to the control Renilla luciferase activity. 
Transfections were repeated at least three times using triplicate samples. The data are 
means ± SD of triplicate experiments. (* p < 0.05; ** p < 0.01). 
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4.2.10 Effects of HNF1a mutation on Ace 2 or Tmem27 promoter activities 
One hundred and ninety-three different HNF1a mutations have been described in 
MODY patients (Ellard and Colclough, 2006). The HNF1a(R131W) mutation is the most 
common cause of type 3 MODY disorder. The R131W mutation is located in the DNA-
binding domain of HNF1a; this mutation abrogates HNF1a-binding to its target sequence 
(Chi et al., 2002). When we co-transfected this HNF1a variant with Ace2 and Tmem27 
promoters (Figure 4.30), transcriptional activation was largely abolished. While co-
expression with the Slc6a19 promoter reduced activation by about 50%. 
 
 
Figure 4.30: The effect of HNF1a(R131W) on Slc6a19, Ace2 and Tmem27 promoters. 
HEK293 cells were co-transfected with the Firefly luciferase inserted in pSlc6a19(–
1380/+57), pCollectrin(–1903/+76), or pAce2(–1509/+170) together with the Renilla 
luciferase vector as control. In addition, the following constructs were co-transfected: 
empty pcDNA3.1 (blue bars), and pcDNA3.1 expressing HNF1a (red bars) or 
HNF1a(R131W). Twenty-four hours after transfection, luciferase activity was measured. 
Relative luciferase activity was determined by normalising the Firefly luciferase activity 
to the control Renilla luciferase activity. P values indicate the significance derived from 
three experiments, each using triplicate transfections. The data are means ± SD of 
triplicate experiments. (* p < 0.05; ** p < 0.01). 
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4.3 Discussion 
Previously, Slc6a19 was shown to be highly expressed in intestinal enterocytes 
and epithelial cells of the kidney proximal tubule (Bröer et al., 2004). While the transport 
activity of B0AT1 and its physiological roles in different organs have been described in 
some detail, the transcriptional regulation underlying its localised expression has not been 
investigated. In this chapter, I have examined the transcriptional regulation of the Slc6a19 
gene in detail. 
 
4.3.1 Novel Hepatocyte Nuclear Factor response elements on the Slc6a19 promoter 
Hepatocyte Nuclear Factors are necessary for hepatocyte development. However, 
these TFs are not only expressed in the liver, but they are also expressed in the kidney 
and intestine. Accordingly, HNF1a and HNF4a have been shown to be important 
regulators of differentiation in intestinal epithelial cells (Pontoglio et al., 1996, Sladek et 
al., 1990). 
Kikuchi et al. (2010) used bioinformatics and epigenetic analyses to investigate 
the regulation of amino acid transporters’ genes in kidney (Kikuchi, Yagi et al. 2010). 
The bioinformatics analysis showed an HNF1a-binding site at position –111 to –114. The 
study also showed possible HNF1a-binding sites on all major amino acid transporter 
genes. To our knowledge, this was the first and only report suggesting HNF1a-binding 
motifs in the Slc6a19 promoter region. In agreement with that study, our in vitro analysis 
confirmed that HNF1a binds to the Slc6a19 promoter at this predicted murine promoter 
site. Additionally, our ChIP analysis using mouse intestinal chromatin verified that 
HNF1a binds the promoter region, in vivo. As shown in human patients with MODY 
disorder, HNF1a and HNF4a are also critical for glucose metabolism (Fajans et al., 2001). 
We replicated an HNF1a mutation, which causes MODY disorder, and co-transfected this 
mutated form of the TF with the Slc6a19 promoter, but it did not completely abolish 
transcriptional activation.  
To our knowledge, no other studies have investigated the regulatory function of 
HNF4a on the Slc6a19 gene in the mammals. With similar methodology, an HNF4a-
binding site was confirmed by in vitro and in vivo studies. This is the first study showing 
that HNF4a can regulate Slc6a19 gene in the mammalian intestine. As discussed earlier 
(see Section 1.3.2.3), HNF1a-knockout mice suffer from renal Fanconi syndrome, which 
  
120 
 
is characterised by diabetes, glycosuria and aminoaciduria (Pontoglio et al., 1996). Recent 
clinical studies have shown that an R76W mutation in HNF4a causes Fanconi syndrome 
due to dysfunction of the renal tubules (Hamilton et al., 2013, Numakura et al., 2015). 
This new finding indicates that not only HNF1a, but also HNF4a, is necessary for proper 
functioning of the renal proximal tubules. In accordance with the above studies, our 
results suggest that HNF4a together with HNF1a controls Slc6a19 expression along the 
renal proximal tubules.  
Some studies have shown that a number of intestinal genes are regulated by 
combinatorial action of HNFs, GATA TFs and CDX2 (Boudreau et al., 2002, Coskun et 
al., 2010, Maher et al., 2006). In contrast, our luciferase experiments testing different 
combinations of these TFs did not show any synergistic regulatory effect on the Slc6a19 
promoter. 
 
4.3.2 Negative effect of SOX9 on the Slc6a19 activation 
SOX9 is a well-known TF involved in transcriptional activation of genes (Bell et 
al., 1997, Bastide et al., 2007). Several studies have shown that SOX9 drives stem cell 
differentiation into mature enterocytes. Yet some genes can be negatively regulated by 
SOX9 in the crypt, including Cdx2 and Muc2 which are crucial for enterocyte maturation 
(Blache et al., 2004).  
CDX2 positively regulates intestinal TFs such as Cdx1, Hnf1a and Hnf4a, which 
control gene expression in villus cells (Gao et al., 2009, Heath, 2010). Therefore, reduced 
SOX9 expression could allow CDX2 expression in the villus cells; thus, activating 
Slc6a19 expression indirectly. However, we revealed that CDX2 expression in crypt cells 
is higher than in mature enterocytes; therefore, SOX9 is unlikely to indirectly activate 
Slc6a19 expression via CDX2. Instead, while HNF1a and HNF4a activated the Slc6a19 
promoter, their action was directly inhibited by SOX9. SOX9 has direct and indirect 
effects on the expression of its target genes. It has been shown that SOX9 negatively 
regulates the B-catenin/Tcf4 pathway indirectly via cyclin D1 and c-Myc (Bastide, 
Darido et al. 2007). A recent study showed that genes involved in chondrocyte maturation 
are regulated by SOX9 either directly or indirectly (Ohba et al., 2015). 
Our data further revealed a SPDEF consensus binding site on the Slc6a19 
promoter. Since SPDEF is expressed only in goblet and Paneth cells (Gregorieff et al., 
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2009, Noah et al., 2010) it could cause expression of Slc6a19 in these cells. However, 
SOX9 has a similar expression pattern, to SPDEF and is also expressed in Paneth cells 
(Mori-Akiyama et al., 2007). SOX9 down-regulation causes a significant decrease in the 
number of goblet cells (Bastide et al., 2007). Therefore, a possible activating effect of 
SPDEF could be supressed by SOX9 in Paneth and goblet cells. Further analysis should 
include in vivo studies to investigate SOX9 and SPDEF interaction, on the Slc6a19 
promoter of goblet and Paneth cells separately. 
 
4.3.3 Ace2 and Collectrin 
HNF1B was previously shown to transcriptionally regulate Tmem27 expression 
in the pancreatic β-cell and in kidney (Zhang et al., 2007). HNF1b is a member of the 
same TF family as HNF1a and they share almost 90% homology at their corresponding 
DNA-binding domains (Tronche and Yaniv, 1992). HNF1B is expressed in epithelial 
cells along the whole nephron (Zhang et al., 2007). Our microarray results, however, did 
not reveal any significant expression of the Hnf1b mRNA in the crypt–villus fractions. In 
vitro luciferase assays confirmed that Ace2 and Tmem27 transcriptions were positively 
regulated by HNF1b co-transfection. However, no significant activation of the Slc6a19 
promoter by HNF1b was observed. These results indicating that despite co-expression of 
these trafficking proteins with B0AT1, their transcriptions are controlled by different 
regulatory elements in the intestine and kidney.  
Although Slc6a19 and Ace2 are in part trans-activated by different regulatory 
elements, B0AT1 is co-expressed with the trafficking proteins in the intestine and kidney. 
These results may point to yet unknown TF(s), which help to coordinate the observed 
overlapping expression patterns” 
 
4.3.4 Summary 
The results from this study demonstrate a possible mechanism of the 
transcriptional regulation of the Slc6a19 gene in the crypt–villus axis. In vitro and in vivo 
analyses revealed that HNF1a, HNF4a and SOX9 bind and orchestrate regulation of 
Slc6a19 promoter in the mouse intestine. 
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Chapter 5      Methylation and histone modification of Slc6a19 
promoter in mouse intestine, liver and kidney 
 
5.1 Introduction   
In living cells, DNA is compacted as chromatin. The chromatin structure is an 
important regulator of the interaction of transcriptional factors with target regulatory 
DNA regions (Heintzman et al., 2007). Especially in differentiating cells, chromatin 
changes have been shown to play a central role in the regulation of transcription 
(Schübeler et al., 2004). Modifications on histone tails such as, methylation, acetylation 
and phosphorylation can affect transcriptional regulation (Figure 5.1). 
 
 
Figure 5.1 Possible positions of histone tail modification 
Locations and types of well-known histone modifications are shown in the figure. 
Numbers under each amino acid residue represent location of a modification. A = 
acetylation, P = phosphorylation, U = ubiquitination, M = methylation. From (Portela and 
Esteller, 2010). 
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Acetylation of histone H3 tails is generally accompanied by transcriptional 
activation (Allfrey et al., 1964). For instance, acetylation of histone H3 tail at lysine 27 
(H3K27ac) has been shown to correlate with transcription activation (Heintzman et al., 
2007). However, methylation of H3 residues and its effect depend on the position. For 
example, methylation of the H3K36 histone tails (H3K36me3) leads to repression of 
transcription (Azuara et al., 2006). While, tri-methylation of the H3 histone tails at lysine 
4 (H3K4me3) causes gene activation (Santos-Rosa et al., 2002). 
DNA methylation and histone modification together play a critical role in the 
regulation of transcriptional activity. Recent studies suggest a close relationship between 
these two epigenetic modifications. As an example, DNA methylation can guide histone 
modifications, and vice versa histone modifications can affect the methylation status 
(Hayashi, Nagae et al. 2007). However, the mechanisms underlying these interactions are 
not well understood. 
 
5.1.1 DNA methylation 
DNA-methyltransferases (DNMT) are responsible for the transfer of the methyl 
group to cytosine nucleotides. Four major methyltransferases have been identified so far 
(DNMT1, DNMT3a, DNMT3b and DNMT3L) (Okano et al., 1999). 
DNMT3a and DNMT3b are vital for embryonic development and de novo 
methylation in mammals (Chen et al., 2003). As a result, these enzymes need to access 
non-methylated CpG regions. Some histone modifications and specific DNA sequences 
can potentially initiate de novo methylation via recruitment of DNMT3a and DNMT3b 
(Klose and Bird, 2006). 
DNMT3L lacks methyltransferase activity alone, but it has a stimulatory effect on 
the methylase activity of DNMT3a and DNMT3b (Suetake et al., 2004). DNMT3L is 
crucial for maternal imprinting at the gametogenesis stage (Bourc'his et al., 2001). 
DNMT1 (maintenance methyltransferase) is the most common methyltransferases 
and the main enzyme for maintaining methylation during cell division (Richardson and 
Yung, 1999). DNMT1 has a high affinity for hemimethylated DNA strands during the S-
phase of mitosis, thereby, transferring the methylation pattern to the newly synthesised 
DNA strand (Figure 5.2).  
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While methylation is well understood, demethylation remains to be fully 
described. During vertebrate development, DNA is globally demethylated during two 
stages of embryonic development. First, demethylation happens during germ cell 
development. Second, demethylation happens after fertilisation and implantation of an 
embryo. During the replication process, failing of DNMT1 function causes passive 
demethylation (Razin and Riggs, 1980). Active demethylation, by contrast, occurs during 
DNA repair processes by specific enzymes, such as Gadd45 (Barreto et al., 2007). 
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Figure 5.2. DNA methylation and demethylation  
After global DNA demethylation, de novo methylation is re-established by DNMT3A 
and DNMT3B. Following cell division, this methylation pattern is preserved by 
DNMT1. Inhibition of DNMT1 during replication causes loss of methylation on the 
new DNA strand, this is called passive demethylation. Whereas, removal of methyl 
groups by enzymatic reaction is called active demethylation. From (Wu and Zhang, 
2010). 
 
5.1.2 DNase I hypersensitive sites 
Deoxyribonuclease I (DNase I) is an endonuclease that catalyses cleavage of 
unprotected DNA. In the chromatin context, nucleosome-free DNA is more sensitive to 
fragmentation by DNase I; these regions are called DNase I hypersensitive sites. An 
average DNase I sensitive region is around 100 to 200 bp long and is a nucleosome-free 
DNA fragment (Figure 5.3). This region, most of the time, contains transcriptional 
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regulators. Accordingly, searching for DNase I hypersensitive sites on genomic material 
is crucial to determine regulatory elements of transcription.  
 
 
Figure 5.3 DNase I hypersensitive site in the chromatin context.  
An example of a DNA fragment, showing DNase I hypersensitive sites (red arrows) 
around TSS (blue arrow) and promoter region, and protected areas of sequence. From 
(Bell et al., 2011). 
 
5.2 Results 
5.2.1 Analysis of H3K27ac and H3K4me3 histone modification associated with the 
5' flanking region of Slc6a19 promoter 
To examine whether histone modifications are associated with the Slc6a19 gene 
expression, ChIP assays were performed using two antibodies, one against acetylated 
histone H3 at residue K27 and the other against methylated histone H3 at residue K4. 
H3K27ac is typically associated with gene activation (Heintzman et al., 2009). To 
verify whether H3K27ac is found in the vicinity of the Slc6a19 promoter, ChIP was 
performed using cross-linked chromatin isolated from intestinal villus and crypt 
enterocytes using the fractionation protocol (see Section 2.7.1.1). The intestinal fractions 
and liver were immunoprecipitated using an antibody against H3K27ac. 
Immunoprecipitated DNA was analysed by real-time PCR generating amplicons of 150-
200 bp spanning the Slc6a19 promoter region from position –858 to +11. ChIP 
experiments demonstrated that acetylation of lysine 27 of histone H3 (H3K27ac) was 
significantly enriched in chromatin from villus tips compared to crypt and liver chromatin 
(Figure 5.4). 
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Figure 5.4 H3K27ac histone modification of the Slc6a19 promoter region in liver 
and intestine 
A H3K27ac-specific antibody was used in the ChIP assay. The genomic DNA was 
isolated from mouse villus and crypt cells, and from liver tissue. Data are given in percent 
signal relative to a real-time PCR reaction on input DNA. Primer pairs span the following 
promoter regions: –139/+11, –501/–332, –682/–502 and –858/–674. The data are means 
± SD of triplicate experiments. 
 
H3K4me3 is known to be associated with open chromatin regions (Santos-Rosa 
et al., 2002). ChIP assays were used to test whether H3K4me3 was bound to the promoter 
regions within living cells. The ChIP assay was performed using the chromatin isolated 
from intestinal fractionation, and from liver tissue. The enterocytes chromatin was 
immunoprecipitated using an H3K4me3 antibody. Real-time PCR was used to determine 
the localisation of the modified histones along the Slc6a19 promoter. ChIP indicated that 
H3K4me3 was significantly enriched in the intestine and more than that in the liver 
(Figure 5.5). 
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Figure 5.5 H3K4me3 histone modification of the Slc6a19 promoter region in liver 
tissue and crypt–villus fractions 
An H3K4me3-specific antibody was used in the ChIP assay. The Genomic DNA was 
isolated from mouse intestinal fractions and liver tissues. Data are given in percent 
signal relative to a real-time PCR reaction on input DNA. Primer pairs span the 
following promoter regions: –139/+11, –501/–332, –682/–502, –858/–674. The data 
are means ± SD of triplicate experiments. 
 
5.2.2 Modifications of H3K4m3 and H3K36m3 in the N-terminus of histone H3  
The ENCODE project (Rosenbloom et al., 2010) was completed by a worldwide 
consortium. The aim was to identify regulatory regions of the human genome in tissues 
and in more than 100 different cell lines. In addition to our ChIP experiments, the 
Encyclopedia of DNA Elements (ENCODE) database on the UCSC webpage 
(http://genome.ucsc.edu) was used to identify positioning of other histone modifications 
along the Slc6a19 gene.  
The ENCODE data indicated that the histone modification H3K4me3 was highly 
enriched over the promoter in kidney and small intestine, allowing binding of polymerase 
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II. Additionally, trimethylation of Lys36 in histone H3 (H3K36me3) was present over all 
exons confirming that the gene was actively transcribed. These two elements were absent 
in other tissues (Figure 5.6). 
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Figure 5.6. Histone modifications and polymerase II binding to the Slc6a19 promoter 
The ENCODE database was used to extract the distribution of histone modifications H3K4me3, H3K36me3, and RNA 
polymerase II binding along the mouse Slc6a19 gene in different tissues. The Slc6a19 gene shows active histone status and 
polymerase II binding in the small intestine and kidney but not in the liver.  
  
131 
 
5.2.3 DNase I hypersensitive sites on the Slc6a19 promoter 
To localise possible TF-binding sites on the Slc6a19 gene, DNase I hypersensitive 
sites were identified using ENCODE data. Two sensitive regions were identified in the 
mouse Slc6a19 promoter (Figure 5.7). The first hypersensitive fragment was located 
from +75 to –220, consistent with the core promoter region. The second hypersensitive 
region was located between position –1000 to –1200. The results suggested that the liver 
chromatin around the Slc6a19 promoter region was more condensed than the kidney 
chromatin. This explains RNA polymerase may bind to DNA in the extended chromatin 
of kidney. ENCODE data does not supply any information about DNase I hypersensitive 
status of the small intestine in the mouse. 
 
 
Figure 5.7 DNase I hypersensitive sites on the mouse the Slc6a19 promoter  
The histogram shows that two separate DNase I sensitive regions located around 1 kb 
upstream of the Slc6a19 promoter in the kidney chromatin. In liver chromatin, no DNase 
I sensitive regions were identified in the same region. 
 
5.2.4 DNA methylation profile of the Slc6a19 promoter in mouse 
In addition to showing the effects of histone modifications on the transcriptional 
activity, we also analysed the methylation status changes of the promoter in different 
tissues. Analysis of a region 1200 bp upstream of the Slc6a19 TSS revealed 20 CpG 
dinucleotides (Figure 5.8). Ten CpGs were located between (–171 to +56), which covers 
binding sites for transcription factor SOX9, HNF1a, HNF4a and the TATA-binding 
protein. However, no CpG island was detected by UCSC Genome Browser 
(http://genome.ucsc.edu).  
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Figure 5.8. CpG dinucleotides positions in the mouse Slc6a19 promoter 
Locations of 20 CpG sites in the 1.2 kb upstream of the Slc6a19 promoter was examined. 
The CpG dinucleotides (bold letters), putative TF-binding positions and TSS are indicated 
on the promoter. 
 
To examine DNA methylation effects on the Slc6a19 promoter, liver and kidney 
tissues were isolated from B6 mice as described in Section 2.8.4. Following DNA 
isolation, the methylation status of the target region was analysed using the bisulphite 
sequencing method. As shown in Figure 5.9, almost all CpG sites in the 5'-flanking 
sequence of the Slc6a19 gene were methylated in both tissues.  
CTTGCCCTTTGGCTGC AGCTGCC AGTGTGCCAGGCC GCCCAGCCCAG ACCACCATGGTG
GCCCAGGTGCTTGGGTTGAGGTGCCAAAGGTTCTCTATAAAGAGC GAGCTCCTGGACACAACCA
GCCTCTGCAGATAAGGCATTAACAGTTCTGCAGGA CCCTGAGGATCTGCTGA CCTCCTTT
TGCCCAGGCCTTCAGCAGGATCTCCTGTC TGAATGGAGGGGGTGGCTTAGCTGGTTAGGCTGGGT
AGTGGTCTGAACTGTCCCCCTCCA CCCAACCCTGGCCTATGTCTGGGTTTGTGCAGGAGGAGGGG
GTACAGGACATCAACAGACACCATCTATTTGATCTATTTGCTGGAGATGCCTCCCTTTCTCCTGAGG
ACTTTGTGTGAGCAGCAATTAGGGAACAGGGCTTCAGCCACCTTTAGGAATAATGGTGTTGTTCAGC
TTCCTATGGGTGAAACAGATTTCTGGGAGCTCCAATAGTCTAGGGAGAATCAGTATCCTGCTGGTCT
CAGAGGT TC AGGGACACTTAGAGCA GAGCTGTGCCTGGAAGAACCCAAGCCATACTGTGGC
GTCTCCTCACCCCTTAAGTGCTCCCTGGAAGAACAAATACTACAGGGAGCTAGAAGCTGGGGGTAGC
GTATCTCCCATCTGGTCACTCTGCCAGTGGCAAGACTTCATCAT TAGCTGCCTGGCATTGGCACA
GTAAGGCCCTTTACCCCAGCCTTTCCTGGCAAC GTGGCCCTCCCTGATGTCATGCTGGCTTCTCT
CAGAACAGAGGGCATGCCCCACCTAAGTCCTACCCTGCAATGTTTGCA AAA AACACTATCTCT
GAAGCTCAGGATAGTTCCCAGGGGTAGGGAGTCATGGGGTAGGCAGGAGAGGCAGAGGGGAAGGGCT
GTTTCTGGTCTTAGTTTAGACATAACCCTTGGTAGCCTTTTCTTGGACTTCTAGCTT AAGGCTGA
AGGCTGGACCAAGGTAGGTGGGAGGGGAATTTGAGAAAGGGGATAGGGTAACATCCTTGGCCCTTGA
AGGACATGATGTAGGGGAGGTTGGGTCAGTAGAGTCCAGGAAGGGCCCCCTGGAGAGCTGACCCTTG
AAAGGAAGAGGAAAAAGACAACAGAACACTAAAAGTCCTGTGAATTCTAGGAAGGTCA TGTGCCA
ATAAATAACCAGAGACAGAATTTAAAAAGTGTATCTATCATCATTTAAAAAAGAGAGAGCACAATGA
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Figure 5.9 Methylation status of the Slc6a19 promoter in the liver and kidney 
Genomic material was isolated from the mouse kidney and liver. The methylation pattern 
of each tissue was analysed by bisulphite conversion and sequencing methods. Twenty 
different CpG locations (closed circle, methylated; open circle, unmethylated) and TF-
binding sites (TATA, SOX9, HNF1a and HNF4a) are indicated. 
 
To investigate the methylation status of the Slc6a19 promoter during cell 
differentiation along the crypt–villus axis, the fractionation method was used. Only three 
of the fractions were analysed, namely F1 (villus), F4 (crypt/villus), and F5 (crypt) 
(Figure 5.10). Notably, DNA methylation around the core promoter region, spanning 
from +56 to –171, gradually decreased from crypt–villus cell fractions. 
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Figure 5.10 Methylation status of the Slc6a19 promoter region in the intestine 
Genomic material was isolated from three different intestinal cell fractions. The 
methylation pattern of each fraction was analysed by the bisulphite conversion method. 
CpG locations (closed circle, methylated; open circle, unmethylated) and TF-binding sites 
(TATA, SOX9, HNF1a and HNF4a) are indicated.  
 
 
5.3 Discussion 
Chromatin changes during transcription are controlled by histone modification 
and DNA methylation (Schubeler et al., 2004). Histone modifications are one of the major 
epigenetic mechanisms that alter gene expression. Generally, promoter regions of active 
genes have hyperacetylated histones and non-methylated CpG dinucleotides (Vaissière et 
al., 2008). 
ChIP assays were performed to determine histone modification profiles of the 
Slc6a19 promoter sequence. The results revealed that there was a significant difference 
in H3K27ac levels between crypt and villus. Acetylated histone H3K27 was highly 
enriched in the Slc6a19 promoter in villus enterocytes. Similarly, the sucrase-isomaltase 
gene (SI) was shown to be regulated by histone acetylation in the crypt–villus axis 
(Suzuki et al., 2008). Acetylation of histone H3 (lysine 9 and 14) was found to be highly 
associated with active SI gene expression in the villus.  
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The general transcription factor TFIID can directly interact with H3K4me3 (van 
Ingen et al., 2008). Therefore, enrichment of H3K4me3 in a promoter region is crucial 
for initiating transcription. Studies in different species have showed that H3 acetylation 
occurs before H3K4 methylation (Rice and Allis, 2001). In contrast to this finding, our 
ChIP assay indicated that in crypts before histone acetylation started, H3K4me3 was 
highly enriched at the promoter. How histone modification affect one another is still 
debated (Maltby et al., 2012).  
The ENCODE database results also supported expression of the Slc6a19 gene in 
intestine and kidney. H3K4me3 levels were significantly higher in the intestine and 
kidney. Another modification H3K36me3, which is similarly found over active 
promoters, confirmed that the gene is actively transcribed in the intestine and kidney. 
However, molecular mechanisms underlying activation of genes by H3K27ac and 
H3K4me3 are still unclear.  
In addition to histone modification, methylation of cytosine residues in genomic 
DNA is an important epigenetic factor that can contribute to gene silencing (Hayashi et 
al., 2007). Our findings indicated that DNA methylation was consistent with expression 
in the intestine, showing a highly methylated proximal promoter in the crypt, but complete 
demethylation in villus fractions. This result was contrary to a previous study (Kikuchi et 
al., 2010) showing differential methylation at position 1080 upstream of the TSS in 
intestinal cells. Our bisulphite sequencing data, by contrast, demonstrate differential 
methylation at the core promoter of the Slc6a19 gene, which is <300 bp long and where 
binding of TFs and RNA polymerase II occurs. 
Surprisingly, no significant difference was found between DNA methylation 
patterns in liver and kidney. The Slc6a19 promoter was highly methylated in both tissues. 
One possible reason explaining the unexpected hypermethylation in the kidney is the 
fraction of Slc6a19 expressed in the epithelial cells of the proximal tubules compared to 
other kidney cells. The methylation pattern of the Slc6a19 core promoter region is likely 
to contribute to gene activation along the crypt–villus axis. The mechanism of DNA 
demethylation during enterocyte differentiation from crypt to villus remains to be 
determined. It could involve passive demethylation during cell mitosis in the crypt region 
or could be mediated by active demethylation. 
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5.4 Summary 
In this chapter, I investigated whether histone modification and DNA methylation 
contribute to specific expression of the B0AT1 protein in intestine and kidney. I defined 
histone marks and DNA methylation patterns of the Slc6a19 promoter along the crypt–
villus axis and in kidney cells. The results showed that coordination of histone 
acetylation–methylation activities with CpG dinucleotide methylation plays important 
roles in the differential expression of the gene. 
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Chapter 6      General discussion 
 
The crypt–villus structure has interested many researchers because it is an ideal 
model for conveniently studying rapid differentiation of intestinal cells. As such, 
undifferentiated cells are located in the crypt which has been described as a perfect model 
for studying of stem cell niches (Clevers, 2013). After completing differentiation in the 
upper third of the crypt, cells gradually move up towards the villus tips. Explicit interplays 
between TFs and epigenetic regulatory mechanisms together control intestinal cells 
maintenance and differentiation. The Slc6a19 is a perfect model for studying intestinal 
gene differentiation because it is only expressed in differentiated enterocytes in the crypt–
villus axis. 
 
6.1 Links between DNA methylation and transcription 
Interactions between HNF1a and HNF4a have been well studied. The HNF1a 
promoter region includes conserved DNA-binding sites for HNF4a, and vice versa (Odom 
et al., 2004). Thus, HNF1a or HNF4a increase each other’s transcription. These two TFs 
play important roles in the regulation of Slc6a19 and some transporter genes. For example, 
HNF1a and HNF4a function as an important regulator controlling expression of many 
epithelial transporters (Kikuchi et al., 2010, Desvergne et al., 2006). In the kidney, HNF1a 
is expressed only in the proximal tubules (Pontoglio et al., 1996). This expression pattern 
mirrors that of the organic anion transporter 1 (OAT1) in mouse or human kidney. OAT1 
is highly expressed in the renal proximal tubules. Oat1 expression in renal proximal 
tubules is regulated by HNF1a and HNF4a (Maher et al., 2006). However, in extrarenal 
tissues, DNA methylation of the transporter promoter regions inhibits gene expression. 
Further, demethylated DNA in the promoter region of Oat1 is crucial for kidney-specific 
expression (Kikuchi et al., 2007). Thus, HNF1a, HNF4a and DNA methylation act in 
concert to control organic anion transporters in a tissue-specific manner in the mouse or 
human kidney.  
DNA methylation was long considered as a stable epigenetic mark. Inactivation 
of the X chromosome by DNA methylation during embryonic development was one of 
the first findings proving that DNA methylation was a dynamic epigenetic factor 
regulating gene expression (Mohandas et al., 1981). Moreover, genome-wide DNA 
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methylation studies have shown that DNA methylation is modified during the 
differentiation processes at relevant gene promoters (Ziller et al., 2013, Feldmann et al., 
2013).  
The DNA methylation status around the Slc6a19 core promoter region decrease 
during differentiation. The methylated Slc6a19 promoter in the crypt cells becomes fully 
demethylated after three to four cell divisions (Radtke and Clevers, 2005). Similarly, 
hormone-sensitive promoters and neuron-specific gene promoters have been found to 
undergo rapid demethylation (Ma et al., 2009b, Métivier et al., 2008). DNA 
demethylation could occur by two different mechanisms; first by lack of DNMT1 activity 
during mitosis, and second active demethylation by the DNA excision repair machinery 
(Ma et al., 2009a).We suggest that both mechanisms may be involved in the 
demethylation processes along the crypt–villus axis. Thus, DNMT1 is highly expressed 
in the crypt region while its expression decreases towards the villus. Ablation of DNMT1 
in the intestine leads to expansion of crypts (Sheaffer et al., 2014). This finding indicates 
that DNA methylation is crucial in balancing cell proliferation and differentiation along 
crypt–villus axis. 
Other reports have also demonstrated that many important intestinal TFs are 
controlled by epigenetic modifications. For example, DNA methylation analyses showed 
that the Lgr5 promoter was demethylated along the crypt–villus axis. Lgr5 is an intestinal 
stem cell marker. Lgr5 transcription is regulated by H3K4me3 modification, which are 
active in the crypts but repressed in the villi (Vincent et al., 2015). DNA methylation 
studies have also shown that complete DNA demethylation of SOX9 promoter occurs in 
the crypts, whereas it becomes gradually methylated in the villus cells except for goblet 
cells where SOX9 is highly expressed (Vincent et al., 2015). SOX9 expression has also 
been shown to be mainly regulated by the histone modification H3K4me2 in the cartilage 
tissues (Zhang et al., 2015).  
CDX2 is one of the major transcription factors that controls cell differentiation in 
the intestine. Its expression is necessary for activation of other essential intestinal TFs 
such as, HNF4, HNF1a and CDX1. Epigenetic studies have revealed that CDX2 
interplays between TFs and epigenetic modifications. CDX2 regulates histone 
modifications by triggering the formation of an active chromatin enhancer, H3K4me3 
(Verzi et al., 2013). DNA Methylation status of the Hnf1a promoter in the liver, kidney 
and brain was investigated previously (Kikuchi et al., 2010). It was reported that except 
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in the brain, the Hnf1a promoter was hypomethylated in the liver and kidney where the 
gene was highly expressed. All these studies revealed that TFs which are essential 
regulators of transporter gens were also controlled by epigenetic factors. 
 
6.2 The current model 
Taken together, my studies propose a model (Figure 6.1) for the regulation of 
Slc6a19 transcription along the crypt–villus axis. Hypermethylated CpG dinucleotides 
and deacetylated histone molecules cause condense chromatin state in the crypt and liver 
(Figure 6.1.A). DNA methylation affects expression of target genes by two mechanisms. 
First, methylated DNA directly interferes with TFs binding and prevents gene expression. 
Second, methylated cytosine residues can be recognised by methyl-CpG-binding domain 
(MBD) proteins which attracts chromatin remodelers to change nucleosome occupancy 
of TFs which in turn causes transcriptional inhibition (Salozhin et al., 2005). The 
inhibition mechanism of MBD proteins is not well understood. Studies showed that 
MBDs can interact with histone deactylases, which leads to a more condense chromatin 
status (Ballestar and Wolffe, 2001). Except position –243 other CpG residues were 
completely methylated in the core promoter region. Additionally, we located TF binding 
sites for HNF1a, HNF4a and SOX9 within a 250 bp region upstream of the TSS. We 
found eight differentially methylated CpG dinucleotides within the same region. DNA 
methylation at position –243 does coincide with the SOX9 binding site. This may allow 
direct SOX9 binding at the predicted position and lead to Slc6a19 silencing in the crypts. 
Thus, SOX9-induced inhibition, hypermethylated DNA and deactylated histones around 
the core promoter region may lead to more condensed chromatin structures, which can 
inhibit the transcriptional machinery and silence the gene in the crypt and the liver. 
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Figure 6.1 Working model for regulation of the Slc6a19 along crypt–villus axis 
The Slc6a19 promoter region in the crypt and liver tissues showing condensed chromatin 
conformation (A), due to methylated CpG dinucleotides and deacetylated histone 
molecules. By contrast, demethylation of CpG dinucleotides and histone acetylation (on 
the Slc6a19 promoter) allows binding of HNF1a and HNF4a TFs to activate gene 
expression in the villus (B). Differentially methylated CpG locations (red circle, 
methylated; white circle, unmethylated), acetylated histones and TFs (SOX9, HNF1a and 
HNF4a) are indicated. 
 
During differentiation, demethylation of DNA and histone acetylation within the 
Slc6a19 promoter lead open chromatin state in the villus (Figure 6.1.B). We speculated 
that an active DNA demethylation mechanism could involve in the Slc6a19 activation. 
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Our study discovered that the marker H3K4me3 for active histones was already enriched 
within the hypermethylated promoter sequences. Methylation of CpG residues can 
change histone modifications and nucleosome distribution around the targeted promoter 
regions (Cedar and Bergman, 2009). Inhibitor of growth protein 1 (Ing1), which is a tumor 
suppressor gene and expressed in the intestine and epidermis (Pena et al., 2008), 
recognises and binds to H3K4me3 chromatin if this modification is enriched at 
methylated DNA regions. Binding of Ing1 to a methylated H3K4 recruits Gadd45a, which 
is a crucial player for active DNA demethylation, and triggers DNA excision repair 
mechanisms for DNA demethylation (Schäfer et al., 2013). Therefore, H3K4me3 histone 
modification may trigger active DNA demethylation during early differentiation phases. 
In addition to active demethylation, passive DNA demethylation may occur by lack of 
DNMT1 after mitosis. Furthermore, histones in the promoter receive acetylated H3K27 
tails, thus increasing accessibility of the promoter region for transcriptional regulatory 
elements in the villus.  
 
6.3 Limitations and future studies 
There are some limitations to my study. We have conducted many fractionation 
experiments to use in ChIP, microarray and bisulphite sequencing assays. An alternative 
method could have been laser microdissection. However, instead of using laser 
microdissection, we had to use fractionation experiments to obtain sufficient amounts of 
DNA, and to keep fractionated samples consistent among different experiments. 
Furthermore, because of inherent limitations in the crypt–villus fractionation technique, 
our crypt fractions may not have included the cells from the very bottom of the crypt. 
Fractions may have also been contaminated with villus cells, but the crypt fractions were 
still highly enriched with undifferentiated cells originating from the crypt differentiation 
niches. The limitations of fractionation assays may have been compensated by studies 
using cell lines models of intestinal enterocytes. Caco-2, T84 and HT29 cells are 
resembling mature enterocytes and have been used as a cellular model of enterocytes for 
transport studies (Bolte et al., 1997). Ablating positive and negative regulating TF genes 
in these cell lines may help to support the TF effects. 
Despite many attempts, we could not achieve a successful ChIP assay to 
immunoprecipitate TFs from fractionated intestinal cells likely due to insufficient binding 
of the antibodies used. This missing experiment would have further clarified the TFs’ 
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roles in the crypt–villus cells’ differentiation. Also, further investigations should focus on 
genome-wide DNA methylation and histone modification studies along the crypt–villus 
axis to shed light on the crosstalk between genetic and epigenetic changes during 
intestinal differentiation. 
 
6.4 Summary 
In my PhD project, I investigated the mechanism of Slc6a19 transcriptional 
regulation by genetic and epigenetic mechanisms. The histone modification and DNA 
methylation status in the Slc6a19 core promoter region might be key reasons for lack of 
gene transcription in the crypt and in the liver tissue. Also, this thesis proved that multiple 
modifications act in combination to regulate Slc6a19 transcription dynamically along the 
crypt–villus axis. 
In conclusion, this study contributes to our understanding of the transcriptional 
regulation of intestinal genes and intestinal cell differentiation. However, there is still 
intense debate on hierarchy of interactions between genetic and epigenetic factors driving 
histone modifications, regulating gene expression or repression. Although researchers 
have made remarkable contributions to the understanding of relationships between TFs 
and histone modifications, it is still unclear in which order epigenetic modifications 
change during intestinal cell differentiation. 
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Chapter 8      Appendix 
 
8.1 Plasmids 
 
 
Figure 8.1: A plasmid map of the pGL4, the basic luciferase reporter vector, 
detailing key constructs and restriction enzyme sites 
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Figure 8.2: A plasmid map of the pGL4, the basic luciferase reporter vector, 
detailing key constructs and restriction enzyme sites 
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Figure 8.3: A plasmid map of the pcDNA3.1 
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8.2 Thermal cycler conditions 
 
Table 8.1: Cycling conditions for the PfuUltra enzyme 
Process Temperature (°C) Time (min:sec) Number of 
repeats 
Denaturation 95 5:00 – 
Denaturation 95 0:30  
30 Annealing 50–58 (depending 
on Tm of primers) 
0:30 
Extension 72 6:00 
Extension (Final) 72 10:00 – 
 
Table 8.2: Cycling condition for the Phusion® high-fidelity enzyme 
Process Temperature (°C) Time (min:sec) Number of 
repeats 
Denaturation 98 0:30 – 
Denaturation 98 0:10  
30 Annealing 50–58 (depending 
on Tm of primers) 
0:30 
Extension 72 2:00 
Extension (Final) 72 5:00 – 
 
Table 8.3: Cycling condition for ChIP PCR 
Process Temperature (°C) Time (min:sec) Number of 
repeats 
Denaturation 94 5:00 – 
Denaturation 94 0:30  
35–40 Annealing 50–58 (depending 
on Tm of primers) 
0:30 
Extension 72 1:00 
Extension (Final) 72 5:00 – 
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8.3 Gene ontology terms enriched in the villus (significant changes in 
expression of genes between crypt and villus) 
 
Biological Process/ Organic Substance Transport 
 
 
Adjusted p value : 9.146E-5 
p value : 8.728E-8 
Total genes in GO class : 392 
Genes in input list in GO class : 44 
Biological Process/Na+ Transport 
 
 
Adjusted p value : 2.626E-4 
p value : 2.94E-7 
Total genes in GO class : 145 
Genes in input list in GO class : 23 
  
Biological Process/ Organic Acid Transport 
 
 
Adjusted p value : 0.003 
p value : 4.44E-6 
Total genes in GO class : 181 
Genes in input list in GO class : 24 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biological Process/ Nitrogen Compound Tr. 
 
 
Adjusted p value : 0.003 
p value : 5.341E-6 
Total genes in GO class : 147 
Genes in input list in GO class : 21 
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Biological Process/ Lipoprotein Transport 
 
 
Adjusted p value : 0.049 
p value : 1.358E-4 
Total genes in GO class : 12 
Genes in input list in GO class : 5 
 
Cellular Component/ Brush Border 
 
 
Adjusted p value : 0.002 
p value : 4.03E-6 
Total genes in GO class : 61 
Genes in input list in GO class : 13 
Biological Process/Carboxylic Acid Transport 
 
 
Adjusted p value : 0.002 
p value : 3.65E-6 
Total genes in GO class : 179 
Genes in input list in GO class : 24 
Molecular Function/ Symporter Activity 
 
 
Adjusted p value : 2.883E-4 
p value : 3.281E-7 
Total genes in GO class : 114 
Genes in input list in GO class : 20 
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Molecular Function/ Cofactor Transporter 
Activity 
 
 
Adjusted p value : 0.035 
p value : 8.24E-5 
Total genes in GO class : 11 
Genes in input list in GO class : 5 
Molecular Function/ Carboxylic Acid 
Transmembrane Transporter Activity 
 
 
Adjusted p value : 0.049 
p value : 1.363E-4 
Total genes in GO class : 95 
Genes in input list in GO class : 14 
 
 
Molecular Function/ Solute: Sodium Symporter 
Activity 
 
 
Adjusted p value : 8.926E-4 
p value : 1.229E-6 
Total genes in GO class : 47 
Genes in input list in GO class : 12 
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8.4 Gene ontology terms enriched in the crypt (significant changes of 
genes between crypt and villus) 
 
Biological Process/ M phase of mitotic cell 
cycle 
 
 
Adjusted p value : 3.434E-28 
p value : 9.526E-33 
Total genes in GO class : 216 
Genes in input list in GO class : 63 
 
Biological Process/ Cell cycle 
 
 
 
Adjusted p value : 4.478E-24 
p value : 5.753E-28 
Total genes in GO class : 787 
Genes in input list in GO class : 115 
 
Biological Process/ DNA Replication 
 
Adjusted p value : 4.658E-5 
p value : 4.36E-8 
Total genes in GO class : 152 
Genes in input list in GO class : 25 
 
 
Biological Process/ DNA Repair
 
Adjusted p value : 0.002 
p value : 2.801E-6 
Total genes in GO class : 291 
Genes in input list in GO class : 33 
 
  
164 
 
Molecular Function/ Microtubule Motor 
Activity 
 
Adjusted p value : 0.013 
p value : 2.881E-5 
Total genes in GO class : 44 
Genes in input list in GO class : 10 
 
Cellular Component/ Microtubule Cytoskeleton 
 
 
Adjusted p value : 2.157E-7 
p value : 1.188E-10 
Total genes in GO class : 627 
Genes in input list in GO class : 68 
 
Cellular Component/ Nuclear Part 
 
 
Adjusted p value : 0.007 
p value : 1.405E-5 
Total genes in GO class : 1745 
Genes in input list in GO class : 120 
 
 
Cellular Component/ Chromosome 
 
 
Adjusted p value : 2.443E-11 
p value : 7.62E-15 
Total genes in GO class : 498 
Genes in input list in GO class : 67 
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Biological Process/ Chromosome Segregation 
 
 
Adjusted p value : 1.805E-12 
p value : 5.3E-16 
Total genes in GO class : 105 
Genes in input list in GO class : 30 
 
 
 
Table 8.4: Predicted TF-binding sites in the Collectrin promoter.  
A matrix number of 1.00 indicates an exact match with the binding site consensus 
sequence. Position and the core binding site of the TFs are indicated.  
TFs Position Strand Matrix Sequence 
HNF1b  –706/–690 – 0.866 taacaATTTatcaagcg 
 –711/–695 + 0.797 gataaATTGttactgat 
HNF1a –56/–40 + 0.948 tccaaattattaATTGc 
 –58/–42 – 0.910 ccgcaattaataATTTg 
 –77/–61 – 0.849 gcataATTGggttgact 
 –84/–68 – 0.836 gatacctgcataATTGg 
 –235/–219 – 0.889 atcgaATTGgtttgttg 
 –299/–283 + 0.858 gtccgATTGgttagact 
 –401/–385 – 0.931 taacaATTGgttggttg 
 –406/–390 + 0.882 aaccaATTGttaagggt 
 –408/–392 – 0.865 caacccttaacaATTGg 
 –431/–415 – 0.857 ctcaaATTGgatcggta 
 –659/–643 – 0.928 gttgaATTGatttactg 
HNF4a –284/–260 + 0.839 aaccgtattagAAACacggg
aaagt 
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Table 8.5: Predicted TF-binding sites in the Ace2 promoter.  
A matrix number of 1.00 indicates an exact match of the binding site consensus sequence. 
Position and the core binding site of the TFs are indicated. 
TFs Position Strand Matrix Sequence 
HNF1a –189/–
173 
– 0.919 cagtaATTGctcaagt 
 –196/–
180 
– 0.802 gaaaaagcagtaATTGc 
 –213/–
197 
– 0.853 agacaATTGtagaataa 
 –218/–
202 
+ 0.894 ctacaATTGtctgccca 
 –462/–
446 
+ 0.860 ttaaaATTGctttggag 
 –770/–
754 
+ 0.829 aatttatttttaATTTt 
 –814/–
798 
+ 0.824 tagctgtctttgATTGg 
 –1222/–
1206 
+ 0.845 agcttATTGatagaatt 
HNF4a –234/–
210 
– 0.778 cgctttattcTAAAcctgggcagac 
 –681/–
657 
+ 0.920 atgactgcttgAAACtttaccaaag 
 –1377/–
1353 
– 0.770 tggccaaatcAAAAcctggacatt 
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Table 8.6: List of TFs which were significantly expressed along crypt–villus axis (p 
< 0.05) 
 
TFs expressed in the villus (Fold change >3) 
 
1. Etv2 
2. Pou2f2 
3. Hoxb13 
4. Prrx2 
5. Hsf5 
6. Vax1 
7. Prrx1 
8. Gcm2 
9. Mafb 
10. Epas1 
11. Stat3 
12. Creb3l2 
13. Creb3l3 
14. Tbx3 
15. Stat4 
16. Tcf7l2 
17. Max 
18. Fosl2 
19. Mta3 
20. Nlrc5 
21. Nfatc2 
22. Crebl2 
23. Foxo6 
24. Elk3 
25. Trp63 
26. Pax3 
27. Spib 
28. Zfp423 
29. Lhx6 
30. Barx2 
31. Crebl2 
32. Ikzf1 
33. Tcf7l2 
34. Pura 
35. Maf 
36. Epas1 
37. Dlx3 
38. Pura 
39. Maf 
40. Cebpe 
41. Hmbox1 
42. Msx2 
43. Obfc1 
44. Foxi1 
45. Edf1 
46. Bach1 
47. Erf 
48. Fosl2 
49. Fli1 
50. Hnf4g 
51. Prdm1 
52. Klf4 
53. Edf1 
54. Pax8 
55. Foxo3 
56. Pbx1 
57. Lhx9 
58. Uncx 
59. Esr2 
60. Srebf1 
61. Elk3 
62. Tef 
63. Bcl6 
64. Alx4 
65. Pif1 
66. Sox13 
67. Ets1 
68. Nkx6-1 
 
 
TFs expressed in the crypt (Fold change >3) 
 
1. Ascl2 
2. Atf7 
3. Esrrg 
4. Uhrf1 
5. Myc 
6. Nr2e3 
7. Top2a 
8. Nr5a2 
9. Esrrg 
10. Nkx3-2 
11. Sox9 
12. Tcfap4 
13. Foxm1 
14. Ehf 
15. Zfp711 
16. Pitx1 
17. Ncl 
18. Klf2 
19. Nr4a1 
20. Ncl 
21. Sox4 
22. Ehf 
23. Egr1 
24. E2f1 
25. Dnmt1 
26. Msx3 
27. Msh2 
28. Foxp3 
29. Mcm2 
30. Tgif1 
31. Hes1 
32. Irx3 
33. Six5 
34. Hdac2 
35. Mlh3 
36. Nr5a2 
37. Sox4 
38. Zc3h8 
39. Bcl11b 
40. Bcl11b 
41. Orc2 
42. Hoxb7 
43. Pbx1 
44. Dnmt3b 
45. Sox4 
46. Pbx1 
47. Fosb 
48. Lass4 
49. Terf1 
50. Hsf1 
51. Meis1 
52. Trim28 
53. Lonp1 
54. Thrb 
55. Nme1 
56. Nme1 
57. Nfyb 
58. Rfc1 
59. Nkx2-2 
60. Foxa2 
61. Etv6 
62. Terf2 
63. Foxk1 
64. Hnrnpk 
65. Osr2 
66. Hnrnpd 
67. Srf 
68. Trp53bp1 
69. Tsn 
70. Ybx1 
71. Hnrnpab 
72. Foxa2 
73. Hnrnpk 
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TFs evenly expressed in the crypt–villus axis (Fold change <3) 
 
1. Elf2 
2. Nfyb 
3. E2f5 
4. Mta3 
5. Elf3 
6. Zfp105 
7. Isl1 
8. Hnrnpk 
9. Fos 
10. Pura 
11. Zfp238 
12. Nr2c1 
13. Crebzf 
14. Creb5 
15. Zhx3 
16. Bptf 
17. Tcf3 
18. Usf2 
19. Hnrnpa2b1 
20. Hnrnpab 
21. Vax2 
22. Med1 
23. Ctcf 
24. Obfc1 
25. Atf5 
26. Ppara 
27. Cebpb 
28. Crebzf 
29. Cdx2 
30. Pbx2 
31. Ppara 
32. Creb3l4 
33. Lrwd1 
34. Drap1 
35. Foxp1 
36. Pole4 
37. Pole3 
38. Thap1 
39. Erf 
40. Pbx3 
41. Xbp1 
42. Cdx1 
43. Cebpa 
44. Pot1a 
45. Atf1 
46. Cebpd 
47. Pax4 
48. Tcf3 
49. Tgif2 
50. Nr5a1 
51. Spdef 
52. Ybx1 
53. Med1 
54. Elk3 
55. Crebzf 
56. Nfyb 
57. Srf 
58. Obfc1 
59. Gatad1 
60. Mecp2 
61. Junb 
62. Foxd4 
63. Hnrnpa2b1 
64. Lhx1 
65. Mbd2 
66. Lass6 
67. Nfyc 
68. Adnp2 
69. Ncor2 
70. Sp1 
71. Hopx 
72. Nr4a2 
73. Creb1 
74. Dnmt3b 
75. Chrac1 
76. Msh3 
77. Med1 
78. Nr1d1 
79. Foxp1 
80. Trim24 
81. Stat5b 
82. Foxa1 
83. Lass5 
84. Ets2 
85. Batf3 
86. Nfkb1 
87. Zfp191 
88. Arx 
89. Atf3 
90. Rxrb 
91. Cxxc1 
92. Safb 
93. Mta3 
94. Foxa3 
95. Orc4 
96. Nme1 
97. Isx 
98. Foxp4 
99. Smg6 
100. Mta1 
101. Gata4 
102. Nfkb1 
103. Thap1 
104. Xrcc5 
105. Lbx2 
106. Pbx3 
107. Nr2f2 
108. Dr1 
109. Thrb 
110. Orc4 
111. Usf2 
112. Pou2f1 
113. Nfe2l2 
114. Nfyc 
115. Stat5b 
116. Foxp4 
117. Mta2 
118. Srebf2 
119. Atf6b 
120. Meis3 
121. Foxp1 
122. Hnf1a 
123. Thra 
124. Etv5 
125. Ybx1 
126. Nfil3 
127. Zhx1 
128. Terf2 
129. Vsx1 
130. Hnf1b 
131. Creb3l1 
132. Rest 
133. Foxk2 
134. Pitx2 
135. Tsnax 
136. Stat5a 
137. Zfp191 
138. Jund 
139. Prdm16 
140. Hopx 
141. Dnmt3a 
142. Nr1h4 
143. Tinf2 
144. Zfp110 
145. Terf2 
146. Rbpj 
147. Fosl1 
148. Atf1 
149. Nr4a2 
150. Homez 
151. Vdr 
152. Trim24 
153. Ncor1 
154. Nr2c1 
155. Mbd2 
156. Hoxb3 
157. Cebpg 
158. Batf 
159. Pparg 
160. Batf2 
161. Nr1h2 
162. Purb 
163. Ep300 
164. Foxl2 
165. Ahr 
166. Gzf1 
167. Alx3 
168. Crem 
169. Cux1 
170. Stat6 
171. Nr1h3 
172. Meis2 
173. Irx4 
174. Neurod1 
175. Ncor2 
176. Hhex 
177. Crem 
178. Dbp 
179. Sox1 
180. Rela 
181. Barhl1 
182. Foxj3 
183. Nfe2l1 
184. Lonp2 
185. Msx1 
186. Nr3c1 
187. Fev 
188. Rxra 
189. Atoh1 
190. Mafg 
191. Jdp2 
192. Zglp1 
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193. Tinf2 
194. Cux1 
195. Thra 
196. Mef2d 
197. Ppard 
198. Sox1 
199. Nr1h3 
200. Dnmt3b 
201. Onecut2 
202. Ppara 
203. Elf1 
204. Ddit3 
205. Zfp148 
206. Atf2 
207. Nr2c2 
208. Maff 
209. Rarg 
210. Jun 
211. Etv3 
212. Foxl2 
213. Foxs1 
214. Arnt 
215. Rorc 
216. Foxf1a 
217. Pou2f1 
218. Nanog 
219. Elf1 
220. Mef2a 
221. Lass2 
222. Usf1 
223. Pitx3 
224. Mef2d 
225. Kdm6b 
226. Mafg 
227. Meis3 
228. Nr3c1 
229. Nr1i2 
230. Pou3f1 
231. Lbx1 
232. Foxn3 
233. Tshz1 
234. Nfatc2 
235. Mef2a 
236. Ncor1 
237. Tcf4 
238. Hnf4a 
239. Arnt 
240. Hoxa4 
241. Nr2c2 
242. Lmx1a 
243. Rara 
244. Stat6 
245. Ncor1 
246. Evx2 
247. Zhx3 
248. Ppard 
249. Notch1 
250. Dbp 
251. Creb3 
252. Atf2 
253. Pdx1 
254. Tcf7l2 
255. Pou5f2 
256. Trp73 
257. Zfp281 
258. Gatad1 
259. Rara 
260. Foxo1 
261. Nr1d2 
262. Esrra 
263. Etv1 
264. Gata6 
265. Pura 
266. Mafg 
267. Rxra 
268. Mafk 
269. Tlr9 
270. Ets1 
271. Irf1 
272. Epas1 
273. Nkx2-2 
274. Foxo1 
275. Pura 
276. Srebf2 
277. Mafg 
278. Pole3 
279. Mafa 
280. Hsf2 
281. Atf2 
282. Dlx6 
283. Rxrg 
284. Zgpat 
285. Nr2f6 
286. Mef2d 
287. Nr1d2 
 
